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The zygote and blastomeres of cleavage stage mouse embryos have the capacity to 
differentiate to the embryonic and both extra-embryonic lineages and are considered 
functionally totipotent. Until now, it has not been possible to establish stable cell lines that 
resemble these totipotent-like cells. In this work, I hypothesised that by modulating signalling 
pathways known to be important in early embryonic development it may be possible to 
capture in vitro a self-renewing state that possessed features of pre-implantation blastomeres. 
I succeeded in formulating a novel hypothesis driven cell culture medium which allowed the 
establishment of a stem cell state that possessed expanded differentiation potential to the 
embryonic and both extra-embryonic lineages in vitro and in vivo. These cells were isolated 
directly from in vitro culture of mouse pre-implantation embryos or single cell blastomeres, 
reprogrammed from somatic cells or converted from mouse ES cells. With these cells, I 
generated single cell chimeras which demonstrated extensive contribution to all lineages in 
the developing organism providing additional evidence that this chemical medium maintained 
a homogenous stem cell population. I demonstrated that the transcriptome of these cells was 
enriched with an early pre-implantation blastomere signature, distinct from other rare 
published totipotent-like cells. Finally, I demonstrated that the same chemical formulation 
permitted the establishment in vitro of a human stem cell state that possessed expanded 
differentiation potential to the embryonic and extra-embryonic lineage in vitro. My work has 
shown for the first time that through chemical modulation of pathways implicated to be 
involved in pre-implantation development, a novel homogenous stem cell state that possesses 
a pre-implantation transcriptional signature and expanded differentiation potential to both the 
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embryonic and extra-embryonic lineage can be established and maintained in vitro in both 
mouse and human, suggesting a possible interspecies conservation of the signalling networks 
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CHAPTER 1  
1 INTRODUCTION 
 
1.1 Summary and aims 
The overarching aim of the work described in this PhD thesis was to investigate if stable, 
homogenous, ‘totipotent-like’ stem cell cultures could be established in vitro.  To this end, I 
developed a novel chemically defined media which targeted key signalling pathways known 
to be important in the development of the pre-implantation mouse embryo. Using this media, I 
succeeded in capturing a unique stem cell state that I subsequently extensively characterized 
for the presence of expanded differentiation potential to the embryonic and both extra-
embryonic lineages. In the second half of this thesis, I investigated whether there was inter-
species conservation of this stem cell state by using the human as a model system. This 
introductory chapter provides background information concerning these projects and is split 
into two sections. In the first section, I provide a general overview of totipotency and discuss 
pre-implantation development in the mouse with specific focus on the regulation of the first 
and second specialization events. In the second part, I review the current available knowledge 
on human pre-implantation development and consider the notion that the pathways implicated 







1.2 Development and fate restriction 
Development is a process of progressive fate restriction. A conceptual framework to visualise 
this process is provided in Waddington’s epigenetic landscape. In this model, development is 
conceptualized as a ball descending down the face of a mountain. During its descent, the 
undulations and variations in the landscape limit the number of paths the ball can ultimately 
take. Furthermore, the gradient of descent and surface irregularities prevent the ball from 
either re-ascending (reprogramming) or moving laterally (trans-differentiating) under normal 
conditions. In this metaphor, the ball sitting at the top of the mountain, prior to descent, has 
unbridled potential and may be referred to as being totipotent. Totipotency refers to a cell that 
is capable of developing into a complete organism. 
 
In mammalian systems, embryonic development begins once the sperm and egg fuse to 
produce the fertilized zygote. Prior to fertilization, the mouse oocyte is arrested in the 
metaphase of meiosis II. Following fertilization, the cell completes meiosis resulting in the 
formation of a one-cell embryo containing haploid paternal and maternal pronuclei. The 
zygote subsequently goes through a series of early cleavage divisions producing multiple 
equi-potent blastomeres. At the eight-cell stage, the embryo undergoes the process of 
compaction where individual blastomeres adopt a more flattened morphology secondary to 
increased intercellular adhesion and development of tight junctions. This process is essential 
for subsequent development of the three major lineages; the epiblast, trophoblast and 
primitive endoderm (Morgani and Brickman, 2014; Cockburn and Rossant, 2010; Czechanski 
et al., 2014)  (Figure 1.1). When we discuss the pre-implantation embryo, the choice of terms 
we use to describe the developmental potential of a particular embryonic stage is important. In 
the pre-implantation embryo, totipotency is reserved for the zygote and two-cell stage embryo 
both of which can support the development of a complete organism from a single starting cell 
(Tarkowski, 1959). In contrast, from the two-cell stage until approximately the 32-cell stage, 
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each blastomere has the capacity to forms all cell types of the developing organism in the 
presence of additional carrier blastomeres but, is not capable of forming the entire organism 







Blastomeres isolated from four and eight-cell stage mouse embryos that were injected into 
empty zonae and transferred to the oviduct of pseudopregnant female mice were capable of 
inducing decidual formation; however, no live embryo was obtained (Rossant, 1976). The 
conclusion was that experimental failure did not reflect a lack of totipotency per se, but rather 
could be explained by an insufficient number of cells being present at cavitation preventing 
normal development form progressing. It is argued; therefore, that we should use the term 
“plenipotent” to refer to these cells that possess expanded potential but lack all the features to 
be defined as truly totipotent (Condic, 2014). 
 
The above experiments demonstrated that blastomeres from the four-cell stage onwards had 
plenipotent potential; however, did the likelihood of identifying this plenipotent potential 
decrease with later cleavage divisions as would be expected from Waddington’s model?  
Horseradish peroxidase injection (HRP) was traditionally used to track cell lineages in 
Xenopus embryos (Hirose and Jacobson, 1979). HRP can also be used as a lineage marker in 
mouse embryos as it can diffuse through the cytoplasm allowing all daughter cells to be 
marked and it does not exit through gap junctions which increases the specificity of the 
staining (Lo and Gilua, 1979). HRP was injected into single blastomeres at the two-cell, four-
cell, 16-cell and morula-stage and embryos were then allowed to develop until the blastocyst 
stage. It was observed that single injected blastomeres contributed to both the ICM and the 
trophectoderm but the probability of observing this contribution pattern decreased at later 
embryonic stages with > 50% of the outer cells injected at the 16-cell and late morula stages 
contributing to trophectoderm only in keeping with the notion of temporal developmental fate 
restriction (Balakier and Pedersen, 1982). Importantly, this loss of plenipotent potential refers 
to the quantitative reduction in the likelihood of observed plenipotency rather than a reduction 
in the plenipotent capacity of a random cell as embryo splitting experiments have shown 
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plasticity in developmental potential as late as the 32-cell stage embryo (Rossant, 1976; 
Tarkowski et al., 2010). 
 
1.3 Transcriptional and epigenetic dynamics during pre-implantation 
development 
Much of our knowledge concerning pre-implantation development come from studies on the 
mouse due to the ease associated with its use. Analysis of global gene expression during 
mouse pre-implantation development has identified three characteristic events which 
correspond with the morphological and functional changes that are identified in the pre-
implantation embryo. Initially, following degradation of maternal RNA, which is 90% 
complete by the two-cell stage and which comprises the first characteristic event, there are 
two waves of de novo zygotic transcription. The first wave corresponds to zygotic gene 
activation (ZGA), also referred to as embryonic gene activation (EGA). Correct initiation of 
this process is critically dependent on maternal RNAs (Hamatani et al., 2004).  
 
In eutherian mammals, including mouse, the onset of ZGA at the two-cell stage coincides 
with a major epigenetic event necessary for normal development, the onset of X-chromosome 
inactivation (XCI).  In mouse, initial XCI is imprinted with preferential inactivation of the 
paternal X-chromosome which will subsequently remain silenced throughout pre-implantation 
development. The paternal X-chromosome will become re-activated in the inner cell mass and 
will subsequently undergo random XCI during somatic differentiation of the epiblast 
mediating dosage compensation of gene expression levels between the sexes (Lyon, 1961; 
Mak et al., 2004). The initial imprinted paternal XCI will persist in descendants of the extra-
embryonic lineage (Huynh and Lee, 2003; Takagi and Sasaki, 1975). 
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Beyond XCI, the pre-implantation embryo undergoes extensive epigenetic remodelling and 
removal of epigenetic signatures from the maternal and paternal genomes through active and 
passive DNA demethylation (Mayer et al., 2000, Oswald et al., 2000, Rougier et al., 1998). 
Active DNA demethylation is mediated by Tet3 dioxygenase-dependent oxidation of 5-
methylcytosine (5mC) (Gu et al., 2011). Passive demethylation occurs secondary to 5mC 
dilution from the subsequent cleavage divisions due to DNA replication (Rougier et al., 
1998). The ultimate goal of this widespread demethylation is the production of a completely 
hypomethylated genome in the epiblast which is unbiased in its somatic differentiation 
potential (Dean et al., 2001). Consistent with this stepwise remodelling of the pre-
implantation epigenome, the spatiotemporal timeline of pre-implantation development can be 
reconstructed using the global expression kinetics of chromatin modifiers alone (Burton et al., 
2013). 
 
The second wave of de novo zygotic transcription which is referred to as mid-preimplantation 
gene activation (MGA) immediately precedes the first lineage specification event (Hamatani 
et al., 2004). 
 
1.4 The first lineage specification 
After the 4th or 5th cleavage division corresponding to the 16 – 32 cell stage embryo, the 
morula undergoes a process of compaction and segregation into the developing inner cell 
mass and trophectoderm. Many theories have been proposed to explain this process; however, 
the exact mechanism remains elusive. 
1.4.1 Hypotheses to explain the first lineage specification 
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Over the years as our knowledge of mouse pre-implantation development has improved, the 
working models to explain the first cell fate specification have undergone continual 
refinement. Originally, the ‘early asymmetry model’ was suggested which proposed that fate 
determination i.e.: trophectoderm versus inner cell mass was decided as early as the zygote 
where spatial positioning relative to the dorsal or ventral cytoplasm would dictate future 
developmental potential (Gardner, 1996). This mechanism of fate determination exists in non-
mammalian species; therefore, it was plausible to consider that such a mechanism may exist 
in mammals. However, embryo splitting experiments showing plasticity in developmental 
potential as late as the 32-cell stage embryo challenged this hypothesis (Rossant, 1976; 
Tarkowski et al., 2010).  
 
An alternative explanation was provided by the ‘inside-out’ model which based on 
experimental observation concluded that blastomere position in the morula determined cell 
fate. The inner cells tended to contribute to the developing inner cell mass whereas the outer 
cells preferentially populated the trophectoderm (Figure 1.2A) (Tarkowski and Wróblewska, 
1967; Yamanaka et al., 2006). 
 
The ‘polarization-model’ supported the inside-out hypothesis and attempted to provide a 
mechanism to explain this occurrence. Coinciding with the spatial organization of blastomeres 
into an inside-outside arrangement is the acquisition of cell polarity. It was observed that at 
the eight-cell stage, cell divisions produced a polar-apolar pair. The polarized cell defined 
based on the presence of microvilli and surface ligand expression became localised to the 
outside and committed to the developing trophectoderm. The non-polarized inner cell 
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(Johnson and Ziomek, 1981; Yamanaka et al., 2006). The conclusions of the study from 
Johnson et al. was that lineage restriction was instituted at the eight-cell stage at the time of 
acquisition of polarity and the differential inheritance of this polarity was a potential 
mechanism to explain the first cell fate decision. However, challenging part of this assertion is 
the finding that outer cells in the morula can still can contribute to the inner cell mass when 
aggregated with eight-cell stage embryos (Rossant and Vijh, 1980). 
 
The combined inside-outside and polarization models provide a good conceptual framework 
to explain some aspects of pre-implantation development but it still remains unclear what 
initiates this spatial organization of cells and subsequent differential inheritance of polarity. Is 
this a stochastic process, dictated entirely by chance or are there intrinsic and extrinsic 
determinants present at an earlier stage in development that we are as of now unaware?  
 
Recent work has presented data suggesting that even as early as the four-cell stage embryo, 
the fate of a single blastomere is deterministic and not stochastic as previously thought 
(Piotrowska-Nitsche et al., 2005; Tabansky et al., 2013). This difference in developmental 
potential between individual blastomeres may be explained in part by differential expression 
of transcription factors and / or epigenetic regulators  (Burton et al., 2013; Plachta et al., 2011; 
Torres-Padilla et al., 2007). PRDM14 is heterogeneously expressed in four-cell stage 
blastomeres and it was found that forced expression of this transcription factor at the two-cell 
stage preferentially induced a pluripotent inner cell mass fate (Burton et al., 2013).  
Epigenetic factors such as the H3-specific arginine methyltransferase CARM1 when 
overexpressed in blastomeres can direct their fate preferentially to the inner cell mass also 
(Torres-Padilla et al., 2007). Interestingly, the kinetics of Oct4 expression in the pre-
implantation embryo is thought to be a determinant of blastomere fate (Plachta et al., 2011). 
Those blastomeres with ‘fast’ and ‘slow’ Oct4 kinetics are biased to a trophectoderm and 
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pluripotent inner cell mass fate respectively. Oct4 and Sox2 and their target Sox21 are 
heterogeneously expressed in the four-cell stage embryo (Goolam et al., 2016). Loss of Sox21 
expression results in an upregulation of Cdx2 and initiation of trophectoderm specification 
(Goolam et al., 2016). Conversely, inhibition of Sox21, as can be achieved by expression of 
CARM1 supports an inner cell mass fate. Similar to the binding kinetics of OCT4 in 
determining blastomere fate, temporal DNA binding of SOX2 in the four-cell embryo also 
orchestrates the first cell fate decision (White et al., 2016). SOX2 binding was found to be 
heterogeneous in the four-cell stage embryo and again was regulated by histone 3 arginine 26 
methylation (H3R26me). Increasing H3R26 methylation increased long lived DNA binding 
by SOX2 which was associated with an inner cell mass fate (White et al., 2016). 
 
The preceding paragraphs have provided an overview of the proposed models and 
mechanisms to explain why a cell may become inherently biased to a trophectoderm or inner 
cell mass fate but the next logical step is to explore the signalling pathways and networks that 
are differentially active at the time of the first lineage specification. 
 
1.4.2 Signalling networks involved in the first cell fate decision 
Caudal type homeobox 2 (Cdx2) is a transcription factor known to be involved in 
trophectoderm specification. Up until the eight-cell stage embryo, Cdx2 is ubiquitously 
expressed in blastomeres (Ralston and Rossant, 2008). Coinciding with the acquisition of 
polarity, Cdx2 mRNA becomes localised in the apical segment of the polarized outer cell and 
subsequent asymmetric cell divisions produce differential inheritance of Cdx2 which remains 
localised to the outer cells (Skamagki et al., 2013). Cdx2 cooperates with additional 
transcription factors including Gata3, Eomes and Elf5 to initiate trophectoderm specification 
and reciprocally inhibit the pluripotency transcriptional network, specifically Oct4 and Nanog 
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in the trophectoderm (Ng et al., 2008; Niwa et al., 2005; Ralston et al., 2010; Russ et al., 
2000; Strumpf et al., 2005). The importance of Cdx2 is illustrated from combined knockout of 
maternal and zygotic Cdx2 which results in failure of appropriate polarization of cells at the 
eight to 16 cell-stage embryo and subsequent failure of trophectoderm specification which is 
embryonically lethal (Jedrusik et al., 2010; Jedrusik et al., 2015). Cdx2 is a downstream 
effector of trophectoderm specification. So what are the signalling pathways that converge on 
Cdx2? 
 
Firstly, the highly conserved Hippo signalling pathway is differentially active between the 
inner and outer cells of the pre-implantation embryo. The transcription factor Tead4 has been 
shown to be the earliest expressed gene which is essential for specifying the trophectoderm 
lineage (Yagi et al., 2007). The Tead4 null phenotype is embryonically lethal due to failed 
placentation as the morulae do not produce trophectoderm or blastocoel cavities. Tead4 
initiates trophectoderm specification by inducing Cdx2 (Yagi et al., 2007). This process; 
however, is modulated by the coactivator protein YAP. In outer cells, YAP localises to the 
nucleus and leads to changes in Tead4 and Cdx2 expression. In the inner cells, YAP is 
phosphorylated and cytoplasmic which suppresses Tead4 activity and inhibits trophectoderm 
differentiation (Figure 1.3) (Nishioka et al., 2009; Piccolo et al., 2014). 
 
Phosphorylated YAP is marked for ubiquitination and proteasomal degradation. This 
degradation occurs in the cytoplasm where phosphorylated YAP/TAZ forms part of a complex 
with AXIN, APC (adenomatous polyposis coli), glycogen synthase kinase 3 (GSK3) and 
Beta-Catenin. This complex creates an important interaction between the Wnt and Hippo 







catenin (Azzolin et al., 2014). In the presence of a Wnt ligand or GSK3 inhibition, β-catenin 
remains unphosphorylated and translocates to the nucleus where it binds to TCF (T-cell 
factor) / LEF (lymphoid-enhancer binding factor) target genes. Similarly, the GSK3 inhibtion 
induced dissociation of the degradation complex allows nuclear translocation of YAP and 
interaction with Tead4 initiating trophectoderm specification. Despite the classic teaching that 
Hippo signalling is regulated by the phosphorylation status of YAP as described above, recent 
studies have discovered an additional level of complexity in the Hippo signalling network 
whereby stabilisation of AXIN can regulate the Hippo pathway independent of YAP 
phosphorylation (Wang et al., 2015). Additionally, it has been shown that AMOT family 
proteins can suppress YAP activity by translocating YAP from the nucleus into the cytoplasm 
through direct protein-protein interactions independent of YAP phosphorylation status (Chan 
et al., 2011; Wang et al., 2011a; Zhao et al., 2011). YAP null embryos do not survive beyond 
E8.5 secondary to defective placentation specifically, failure of chorioallantoic fusion which 
is the critical event necessary for the establishment of the site of exchange between the 
maternal and fetal vasculature (Morin-Kensicki et al., 2006).  
 
Notch signalling is active in pre-implantation embryos and acts in parallel with Hippo, both of 
which converge on the first cell fate specification. In the outer cells, which are committed to 
trophectoderm, the Notch signalling pathway is active and the Hippo pathway is inactive with 
the opposite pattern observed in the inner cells (Rayon et al., 2014). This observation was 
further supported from observations in Drosphilia where inhibition of Hippo resulted in apical 
accumulation of Notch receptors (Genevet et al., 2009). Beyond the reciprocal relationship 
that exists between Hippo and Notch in promoting trophectoderm versus ICM specification, it 
is possible that Notch signalling may influence the initial spatial organization of blastomeres 
prior to the first cell fate decision. This hypothesis comes from the observation that forced 
activation of Notch caused inner cells to relocate to an outside position and adopt a 
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trophectoderm fate. This happened independent of Cdx2 suggesting that Notch may be acting 
on additional pathways to influence lineage segregation (Rayon et al., 2014).  
 
The mitogen activated protein kinase (MAPK) signalling network is active in pre-
implantation embryos. An overview of the MAPK signalling components active in pre-
implantation development is illustrated in Figure 1.4. In keeping with the polarization model, 
Extracellular signal-Regulated Kinases 2 (ERK2), the downstream effector of Ras– MAPK 
signalling, is asymmetrically expressed in the apical membranes of the eight-cell stage mouse 
embryo. Inhibition of MAPK signalling reduced the trophectoderm outgrowth and Cdx2 
expression from embryo explants (Lu et al., 2008). Additional components of the MAPK 
pathway including p38 and JNK have also been implicated in pre-implantation development. 
Inhibition of these two pathways compromises blastocele formation at the time of the first cell 
fate decision (Maekawa et al., 2005). The importance of the MAPK kinase pathway in the 
first cell fate decision was further highlighted in a recent publication that described the 
interaction of calcineurin-NFAT signalling with Ras-Erk-AP-1 to activate Src which is the 
terminal downstream effector of the MAPK pathway. In eight-cell stage mouse embryos that 
were treated with a Src inhibitor, development was arrested at the morula-stage before the 
first cell fate decision (Li et al., 2011). 
 
The PI3-kinase / Akt pathway is active in pre-implantation mouse embryos and plays an 
important general role in the promotion of survival and prevention of apoptosis (Gross et al., 
2005; Riley et al., 2005). Subunits of the PI3-kinase/Akt pathway are detectable from the one-









Akt demonstrate an apical distribution pattern in trophectoderm and inhibitors of this  
signalling pathway not only promote apoptosis but also result in delayed blastocyst hatching 
(Riley et al., 2005). A functional interaction between Hippo and PI3K/Akt was identified in 
Drosophila where Akt is negatively regulated by Hippo signalling resulting in growth 
inhibition (Ye et al., 2012). Although studies are needed to confirm, this would fit with the 
observed asymmetric activity of PI3K/Akt in the outer cells where the Hippo pathway is 
known to be inactive. 
 
Bone morphogenetic protein (BMP) signalling is active in pre-implantation mouse embryos 
from as early as the four-cell stage embryo and is involved in regulating blastomere cleavage 
divisions (Reyes de Mochel et al., 2015). Moreover, BMPs are required for the appropriate 
specification of the extra-embryonic lineage including both the trophectoderm and primitive 
endoderm but interestingly not the embryonic lineage (Graham et al., 2014). 
 
We can conclude that the first cell fate decision is complex with various hypothetical models 
proposed in an attempt to reconcile the experimental observations to date. The inside-outside 
and polarization models appear to provide the best explanation to date accounting for 
asymmetric cell divisions and localisation of transcription factors and proteins known to be 
essential to trophectoderm specification. However, the shortcoming of this model and all 
remaining hypothetical frameworks is that the process that dictates blastomere location and 
acquisition of polarity whether it is deterministic or stochastic remains uncertain. 
 
1.5 The second lineage specification 
The second cell fate decision occurs approximately 24 hours after formation of the blastocyst 
when the inner cell mass segregates into the epiblast and primitive endoderm. The epiblast is 
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embryonic and will give rise to all somatic cell types in the developing organism. The 
primitive endoderm is extra-embryonic and gives rise to the developing yolk sac. The 
primitive endoderm is further divided into the parietal and visceral endoderm with the anterior 
visceral endoderm playing a major role in anterior patterning of the developing fetus 
(Beddington and Robertson, 1999). 
 
In the first cell fate decision, Cdx2 was demonstrated to be a key transcription factor in 
determining successful trophectoderm specification. The homeobox transcription Nanog and 
the zinc finger transcription factor Gata6 are the key determinants in the second cell fate 
decision.  Nanog null embryos fail to develop an epiblast and only differentiate to parietal 
endoderm (Chambers et al., 2003; Mitsui et al., 2003). Conversely, Gata6 null embryos fail to 
produce visceral or parietal extra-embryonic endoderm (Morrisey et al., 1998). 
 
Similar to the first cell fate decision and reflecting the complexity of the process, there are 
competing theories to explain the second lineage specification. The first theory pre-supposes 
that every cell in the inner cell mass has bipotential and can give rise to either the epiblast or 
primitive endoderm. As an abstraction of the previously described inside-outside model, it 
was concluded that cells in immediate proximity to the blastocele cavity would become the 
primitive endoderm and the cells in proximity to the polar trophectoderm would become the 
nascent epiblast (Figure 1.5 Positional Epi-PrE segregation) (Yamanaka et al., 2006).This 
hypothesis was based on in vitro observation of the differentiation behaviour of embryonic 








In recent years, single cell transcriptional profiling and lineage tracing experiments generated 
evidence which appeared to cast doubt on the preceding hypothesis. It was found that as early 
as E3.5 the inner cell mass is heterogeneous with a ‘salt and pepper’ distribution of Nanog 
and Gata6 in individual cells (Chazaud et al., 2006). Beyond the expression of these two 
genes, single cell microarray analysis demonstrated that stochastically arranged individual 
cells in the inner cell mass at this embryonic time point already had a global transcriptional 
profile of the epiblast or primitive endoderm, but not both (Figure 1.5 Non-positional Epi-
PrE segregation) (Kurimoto et al., 2006; Yamanaka et al., 2006). 
 
Mechanistically, this may provide an explanation for the actual process of cell specification; 
but, how does an individual cell in the inner cell mass become selected for an epiblast or 
primitive endoderm phenotype? This remains unknown, but there are two theories which I 
will briefly outline.  The basis of both hypotheses is that differential activation of Grb2-Ras-
MAP kinase signalling will induce primitive endoderm differentiation. In FGFR2/FGF4 null 
embryos, primitive endoderm does not develop (Arman et al., 1998; Feldman et al., 1995). 
Grb2 is an adaptor protein essential in this pathway of receptor tyrosine kinase mediated 
activation of MAPK signalling. Grb2 null embryos phenocopy the FGFR2/FGF4 null 
embryos with no primitive endoderm formation (Chazaud et al., 2006). The cleavage 
hypothesis argues that the two waves of inner cell production in the morula at the 8 – 16 cell 
and 16 – 32 cell stage introduces heterogeneity into the inner cell mass (Figure 1.5A(i) and 
(ii)) (Yamanaka et al., 2006). Inner cells from the first division are more likely to contribute to 
the epiblast and; therefore, have lower Grb2-Ras-MAPK activity. Whereas, inner cells from 
the second division have higher activity of this pathway and preferentially develop into 
primitive endoderm. The basis for this model comes from experimental observation on the 
spatial distribution of the extra-embryonic trophectodermal cytokeratin, ENDO A, which was 
found to derive almost entirely from the inner cells from the second division (Chisholm and 
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Houliston, 1987). The second model, is much more simplistic and assumes that the process of 
epiblast / primitive endoderm specification is stochastic with it being entirely random which 
specification a cell will ultimately adopt (Figure 1.5B) (Yamanaka et al., 2006). 
 
1.6 Derivation of stem cells from the mouse embryo 
By the time of implantation, three distinct cell lineages will have formed in the developing 
embryo. On the outside, enclosing the embryo lie the trophectoderm which is divided into 
mural and polar components. The mural trophectoderm surrounds the blastocele cavity and 
will have a key role in implantation and formation of primary giant cells. The polar 
trophectoderm located adjacent to the inner cell mass which give rise to the extra-embryonic 
ectoderm and ectoplacental cone. The inner cell mass consists of the epiblast and hypoblast 
with the epiblast located adjacent to the polar trophectoderm giving rise to all somatic cell 
types in the developing organism including the germ cell lineage. The hypoblast located 
adjacent to the blastocele cavity will form the primitive endoderm from which the yolk sac 
will develop (Yamanaka et al., 2006). From each of these three anatomical sites we can derive 
stem cells which retain the expression profile and growth factor requirements characteristic of 
the lineage from which it was derived (Evans and Kaufman, 1981; Kunath et al., 2005; 
Martin, 1981; Tanaka et al., 1998). These stem cells have provided a biological resource to 
study the factors that induce and maintain their respective cellular identities.  
 
1.6.1 Embryonic stem cells 
A defining moment in stem cell biology occurred when two independent groups discovered 
that in vitro culture of the epiblast from the pre-implantation mouse blastocyst on a 
mitotically inactivated feeder layer in the presence of serum allowed derivation in vitro of 
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embryonic stem cells lines (Evans and Kaufman, 1981; Martin, 1981). These embryonic stem 
cells were pluripotent defined by their ability to differentiate into all somatic lineages.  
 
Since their discovery, experiments on mouse embryonic stem cells have revolutionized our 
understanding of stem cell biology, the process of self-renewal and the mechanisms 
controlling differentiation. Genetic manipulation of these cells including the development of 
knockout technology facilitated the modelling of disease in vitro.  
 
The culture condition in which embryonic stem cells were first derived was heterogeneous 
and the factors responsible for self-renewal were initially unknown. Dissection of the 
individual components within the culture identified Leukaemia inhibitory factor (LIF) as the 
key component mediating self-renewal in the feeder layer (Smith et al., 1988; Williams et al., 
1988). LIF mediated its effect through downstream activation of signal transducer and 
activator of transcription 3 (STAT3) (Niwa et al., 1998). Bone morphogenetic protein 4 
(BMP4) was identified as the key component in serum which suppressed differentiation 
through activation of Id (inhibitor of DNA binding) genes. The combination of LIF and 
BMP4 allowed in vitro maintenance of undifferentiated ES cells in defined conditions (Ying 
et al., 2003). 
 
Oct4 and Sox2 are at the centre of the pluripotency transcriptional network as embryonic stem 
cells cannot be derived from Oct4 and Sox2 null embryos (Avilion et al., 2003; Nichols et al., 
1998). Additional transcriptional factors that enhance self-renewal but which are individually 
dispensable include Nanog, Klf4, and Esrrb (Chambers et al., 2007; Martello et al., 2013; 
Martello et al., 2012). In conventional ESC culture conditions many groups observed 
heterogeneity in transcription factor expression suggesting sub-populations existed within the 
culture. For example, sub-populations expressing high and low levels of Nanog and Rex1 
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were identified (Chambers et al., 2007; Toyooka et al., 2008). Nanog-low cells were 
predisposed to differentiation and Rex1-low cells were unable to contribute to the developing 
embryo following microinjection to blastocyst-stage embryos (Chambers et al., 2007; 
Toyooka et al., 2008). This observation suggested that our knoweldge of the factors necessary 
for the self-renewal of a homogenous population of ES cells was sub-optimal with the 
existing culture conditions permitting the existence of multiple metastable states. The next 
major advance came with the discovery of a culture condition that maintained a homogenous 
ES cell culture at the so-called ‘ground-state’ of self renewal (Ying et al., 2008). 
 
The maintenance of self-renewal is dependent on the inhibition of differentiation inducing 
signals (Burdon et al., 1999). In ES cells, FGF4 acts in an autocrine fashion to mediate exit 
from the self-renewal program and initiate lineage committement  (Kunath et al., 2007). The 
donwstream effector of FGF signalling is extracellular-signal-regulated-kinase (ERK) 
(Kunath et al., 2007). Studies in vivo demonstrated that inhibition of FGF signalling in 
morula-stage embryos blocked formation of the hypoblast and expanded the epiblast 
compartment (Nichols et al., 2009b). In mouse ES cells treated with MEK (MAPK-ERK) 1/2 
inhibitors, differentiation was blocked but clonal expansion was severely compromised.  The 
addition of a glycogen synthase kinase (GSK) inhibtor rescued the clonogenicity and 
permitted stable derivation and expansion in vitro of germline competent mouse ES cells 
(Ying et al., 2008). 
 
Beyond the anabolic effects, GSK3 plays a critical role in the canonical Wnt pathway. GSK3 
regulates the ubiquitination and degradation of Beta-catenin. In the cytoplasm, GSK3 
phorphylates β-catenin, marking it for degradation where it forms part of a complex with 
AXIN and APC (adenomatous polyposis coli). In the nucleus, β-catenin interacts with TCF 
(T-cell factor) / LEF (lymphoid-enhancer binding factor) target genes. TCF3 is a 
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transcriptional repressor. In the presence of GSK3 inhibition, β-catenin remains 
unphosphorylated and translocates to the nucleus where it binds to TCF3 and prevents it 
binding at key pluripotency loci. By repressing a transcriptional repressor, GSK3 inhibtion 
serves to promote ES cell self-renewal (Wray et al., 2011). 
 
This combination of a MEK1/2 inhibitor (PD0325901) and a GSK3B inhibitor (CHIR99021) 
was named 2i media (Nichols et al., 2009a; Nichols and Smith, 2009; Wray et al., 2010; Ying 
et al., 2008). 2i media permitted the derivation of ES cell lines from STAT3 null embryos so 
the authors argued that extrinsic stimuli are dispensable for the maintenance of pluripotency 
and that ES cells in this culture condition have ‘an innate programme for self-replication that 
does not require extrinsic instruction’ (Ying et al., 2008). In stark contrast to serum, 2i 
cultured ES cells had minimal expression of lineage specifiers and reduced amounts of 
repressive histone modifications at key promoters (Marks et al., 2012). Furthermore, the 
culture was homogenous with no apparent subpopulations identified. ES cells cultured in 2i 
based media are referred to as being in the ‘ground-state’ of self-renewal.  Using 2i media, 
germline competent ES cells were also derived from rat embryos (Buehr et al., 2008; Li et al., 
2008). This exciting finding raised the possibility that the ground-state may be a conserved 
inter-species mechanism  of self-renewal. If this were true, it may be possible to derive naïve 
ES cells from human embryos as human embryonic stem cells are felt to be more 
representative of a ‘primed’ pluripotency state. 
 
Primed pluripotency traditionally referred to embryonic stem cells derived from the post-
implantation mouse blastocyst referred to as epiblast stem cells (EpiSC) (Brons et al., 2007; 
Tesar et al., 2007). These cells although pluripotent and with expression of core pluripotency 
transcription factors (Oct4, Sox2, Nanog) were categorically distinct from ES cells derived 
from pre-implantation embryos. EpiSCs were derived and cultured in the presence of FGF 
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and Activin, had low clongenicity and although pluripotent in vitro and in teratoma assays, 
these cells contributed poorly in blastocyst chimeras. Epigenetically, female EpiSCs had 
inactivated one of the X-chromsomes, reflecting dosage compensation during differentiaiton. 
Naïve mouse ES cells possessed two active X-chromosomes (Nichols and Smith, 2009). 
 
Human ES cells are also derived and cultured in the presence of FGF and possess many 
similarities with the mouse EpiSC state (Tesar et al., 2007; Thomson et al., 1998). Human ES 
cells in this ‘primed’ state are often difficult to culture in vitro with a low clonogenicity which 
hampered genetic manipulation and single cell passaging. X-linked disease modeling was also 
limited due to the presence of X-chromsome inactivation in human cells (Mekhoubad et al., 
2012). The ability to derive human embryonic stem cell with properties more akin to the 
mouse ground-state would facilitate the use of these cells for disease modelling, gene 
modification / correction and cell based regenerative medicine. 
. 
1.6.2 Trophoblast stem cells 
 
The mouse trophoblast stem cell niche is thought to exist in the extra-embryonic ectoderm / 
ectoplacental cone portion of the polar trophectoderm. The reciprocal expression of FGF2 
receptor and its ligand FGF4 led to the hypothesis that embryonic fibroblast growth factor 
signalling may be promoting trophoblast development (Feldman et al., 1995; Orr-Urtreger et 
al., 1993). Indeed, self-renewing trophoblast stem cell lines can be derived by in vitro culture 
of E3.5 or E6.5 embryo explants in media containing FGF4, heparin, serum and activators of 
Activin / Nodal signalling (Tanaka et al., 1998). These trophoblast stem cells are indefinitely 
self-renewing and demonstrate multipotency in vitro following the removal of FGF4 which 
permits terminal trophoblast differentiation (Tanaka et al., 1998) . Gene expression profiling 
during in vitro differentiation demonstrated an appropriate temporal-spatial pattern with 
upregulation of Mash2 known to be expressed in the ectoplacental cone, followed by Hand1 
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in developing giant cells and finally placental lactogen 1 (Pl-1) in mature giant cells (Cross et 
al., 1995; Faria et al., 1991; Guillemot et al., 1994). Moreover, in chimeric embryos, the 
trophoblast stem cells contributed exclusively to the placenta and secondary to a high 
percentage of contribution, these cells were able to support normal development to term 
indicating their functionality in the mature placenta (Tanaka et al., 1998). 
 
Fibroblast growth factor signalling is essential for the maintenance of trophoblast stem cell 
identity. Targeted deletions of FGF4, FGFR2 or Erk2/MAPK1 result in embryonic lethality 
due to inability to maintain the trophoblast stem cell niche (Arman et al., 1998; Feldman et 
al., 1995; Saba-El-Leil et al., 2003). Importantly, however, MAPK is not required for the 
initial specification of the trophoblast lineage as implantation can still occur in these 
respective knockouts (Arman et al., 1998; Feldman et al., 1995). As previously discussed, 
trophoblast specification is thought to reflect differential blastomere polarization, asymmetric 
activation of signalling pathways including Hippo and Notch with resulting activation of 
downstream trophoblast lineage specific transcription factors including Tead4 and Cdx2. 
 
Investigating the transcriptional network in mouse trophoblast stem cells allowed an 
understanding to be attained of the reciprocal inhibition that exists between the inner cell 
mass and the trophectoderm. Mouse trophoblast stem cells cannot be derived from Cdx2 null 
embryos reinforcing the importance of this transcription factor in the maintenance of the niche 
(Strumpf et al., 2005). Embryonic stem cells cannot be derived from Oct4 null embryos which 
again indicated the central role of Oct4 in maintaining pluripotency (Nichols et al., 1998). In 
Oct4 null embryos there is initial specification of the trophectoderm but the trophoblast stem 
cell compartment does not expand. This phenotype can be rescued by the addition of FGF4 
demonstrating the paracrine interaction that exists between the developing inner cell mass and 




Many experiments have demonstrated the interaction of Oct4 and Cdx2 in ICM versus TE 
specification. Deletion or repression of Oct4 expression in ES cells induces differentiation to 
trophectoderm (Niwa et al., 2000). Similarly, overexpression of Cdx2 induces trophectoderm 
differentiation in ES cells (Niwa et al., 2005). This reciprocal inhibitory interaction has been 
shown to occur at the protein level where inhibition of OCT4 by CDX2 will positively 
reinforce its own expression and permit trophectoderm specification (Niwa et al., 2005). As 
OCT4 and CDX2 are initially co-expressed in blastomeres at the morula-stage, this finding 
may explain how initial lineage segregation occurs (Strumpf et al., 2005). 
 
1.6.3 Extra-embryonic endoderm (XEN) stem cells 
Mouse extra-embryonic endoderm cell lines have been derived from blastocyst-stage embryos 
(Kunath et al., 2005). In vitro, these cells lines have a gene expression profile similar to their 
in vivo counterparts and in vivo chimeric experiments show exclusive contribution to the 
extra-embryonic visceral and parietal endoderm. Surprisingly, FGF was not always necessary 
in the derivation or maintenance of these cells (Kunath et al., 2005). After derivation, XEN 
cells can be grown feeder free in medium supplemented with EMFI-CM. At present, the exact 
signalling requirements that are necessary for optimal expansion of these cells remains 
unknown (Kunath et al., 2005).  
 
1.6.4 Hierarchy of potency – is there an in vitro totipotent-like stem cell? 
The preceding sections have described the derivation in vitro of self-renewing multipotent 
populations from the three lineages produced during the first and second cell fate decisions. 
The logical next question to consider is, if a self-renewing state can be isolated from these 
three lineages is it therefore possible to derive a ‘master’ or ‘totipotent-like’ stem cell? Such a 
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cell line should be relieved from the lineage restriction of the preceding stem cells states and 
acquire expanded potential to contribute to all cellular lineages in embryonic development. 
 
It remains unclear whether it is possible to experimentally derive and maintain stable cell 
lines from early embryos that contain features of cleavage-stage blastomeres. Recently 
however, a transient subpopulation in ESC culture that is thought to correspond to totipotent 
two-cell (2C)-stage blastomeres was reported (Macfarlan et al., 2012). These 2C-like ESCs do 
not express pluripotency factors such as POU5F1 (OCT4), SOX2 or NANOG protein and 
demonstrate the ability to contribute to both embryonic and extra-embryonic tissues. The 
authors argue that entry into this ‘privileged state’ may partially be controlled by histone-
modifying enzymes implicating epigenetics as a potential determinant of totipotency.  
 
Similarly, another group reported a rare Hex positive subpopulation in ESCs cultured in 
2i/LIF, a defined medium that maintains ESCs at an intrinsically stable ground-state (Wray et 
al., 2010; Ying et al., 2008) which could also apparently contribute to both trophoblast and 
embryonic lineage development (Morgani et al., 2013). The authors proposed leukaemia 
inhibitory factor (LIF) as the cytokine responsible for the observed phenotype as the 
percentage of proliferating HEX positive cells increased in response to increasing 
concentrations of LIF. Traditionally, LIF is known for its critical role in the self-renewal of 
serum-cultured mouse ESCs due to its ability to activate the transcription factor STAT3 
(Niwa et al., 1998). In serum conditions, STAT3 null ESCs rapidly succumb to differentiation 
(Ying et al., 2008). Although dispensable for the maintenance of pluripotency in 2i cultured 
mouse ESCs, LIF is routinely added to improve cell growth and clonal expansion (Ying et al., 
2008). As LIF was found to enrich for the HEX positive subpopulation, the authors presented 
data to implicate LIF as a potential explanation for supporting ‘extra-embryonic priming’ 
(Morgani et al., 2013). Additional support for the authors claim came from the observation 
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that increasing LIF concentrations upregulated the expression of the Hex transgene and 
STAT3 -/- ESCs had decreased extra-embryonic gene expression. Moreover, whole genome 
expression analysis confirmed that the upregulated gene set in LIF containing media showed 
the strongest correlation with placental gene expression (Morgani et al., 2013).  
 
A system-wide analysis comparing mouse ESCs cultured in 2i media in the presence or 
absence of LIF offered further support to the potential role of LIF in mediating extra-
embryonic priming by demonstrating relative enrichment of Zscan4 (zinc finger and SCAN 
domain containing 4) expression in the presence of LIF (Cerulo et al., 2014). The Zscan4 
gene cluster has been described as a marker for the 2-cell embryo and mouse ESCs (Falco et 
al., 2007). One in twenty cells in an in vitro ESC culture will express Zscan4 at any given 
time. This Zscan4 positive state is associated with the maintenance of genomic integrity and 
long term developmental potency (Amano et al., 2013; Zalzman et al., 2010). Repression of 
Zscan4 expression in ESCs results in a shortening of telomere length, an increased number of 
karyotypic abnormalities and a quantitative reduction in cellular proliferation rates (Zalzman 
et al., 2010). Overexpressing this gene cluster on the other hand, produced ESCs that could 
contribute to a whole mouse at a much greater frequency than wild type ESCs in tetraploid 
complementation assays (Amano et al., 2013).  
 
The aforementioned papers led one to the following conclusions. Firstly, cells with expanded 
potential exist in ESC culture conditions albeit transiently and at extremely low percentages 
of the total cell population. Secondly, this infrequency may be explained by the fact that the 
culture condition is not optimized for the capture and expansion of these rare cell types. As 
stem cell populations can be established from the epiblast, hypoblast and polar trophectoderm 
through the addition of chemicals that suppress extrinsic developmental cues and promote the 
inherent self-renewal programme, it may be reasonable to speculate; that if signalling 
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pathways that are known to be active and critical for pre-implantation development could be 
selectively targeted using small molecule inhibitors, one may be able to enrich for or capture 
these cells with expanded potential from standard ESC cultures in the first instance.  
 
1.7 Is the pre-implantation developmental process conserved between mouse 
and human? 
 
Human pre-implantation development at first glance appears to behave similar to the mouse. 
Following fertilization, there is the onset of zygotic gene activation (ZGA) followed by 
blastomere cleavage divisions which ultimately result in the production of the trophectoderm 
(TE) and inner cell mass (ICM), similar to the mouse.  In fact, much of our understanding of 
human pre-implantation development is from extrapolation from studies on mouse due to the 
scarcity of available human embryonic material to study and often, the ethical difficulties 
associated with its use. A potential milestone in human embryo research occurred recently 
when two independent groups demonstrated that the early stages of post-implantation human 
development could be successfully modelled in vitro. This amazing feat occurred due to the 
proposed self-organizational capacity of the human embryo. In the absence of maternal 
proteins, early post-implantation development was observed with expansion of the epiblast, 
formation of the bilaminar disc, amniotic and yolk sac cavities and trophoblast differentiation. 
This model, if reproducible, conceivably in the future will permit identification of the key 
pathways essential for the correct spatio-temporal progression of human development 
(Deglincerti et al., 2016; Shahbazi et al., 2016). 
 
So how similar is the process of pre-implantation development in mouse and human? Firstly, 
even though the spatial pattern of pre-implantation development is similar, there are very 
distinct temporal differences as regards the timing of blastocyst formation and subsequently 
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its implantation. In mouse, the  blastocyst is formed by E3-3.5 dpc; however, in humans, this 
doesn’t occur until Day 5. Secondly, the mouse blastocyst implants at E4-4.5 but in humans, 
this process is protracted and doesn’t occur until Day 7 to 9 (De Paepe et al., 2014). 
Furthermore, the process of implantation is different. Human embryos invade into the lining 
of the uterine wall called the endometrium which is termed interstitial implantation. In 
contrast, the mouse embryo does not invade the endometrium but merely attaches to it in a 
process called secondary interstitial implantation (De Paepe et al., 2014; James et al., 2012).  
 
But, do these differences reflect a fundamental biological dissimilarity or rather, can they 
potentially be explained by the larger size of the human and therefore, the need for more cell 
divisions to produce an adequate number of cells for successful implantation.  
 
Although there are known species differences in the timing of embryonic gene activation 
(EGA) and the epigenetic regulation of X-chromosome inactivation (XCI) in the pre-
implantation embryo, available studies appear to suggest that the fundamental processes 
involved in the first cell fate specification may in fact may conserved. Global mRNA 
expression data from surgically isolated human ICM and TE found expression patterns to 
suggest that the first cell fate decision is controlled by the same signalling pathways that are 
active in the mouse including WNT, mitogen-activated protein kinase (MAPK) and NOTCH 
(Adjaye et al., 2005). Additional evidence to support the claim that developmental processes 
may be conserved is the shared localisation pattern of transcription factors in the ICM 
(Nanog, Oct4, Rex1) and TE (Cdx2) and epigenetically, both species possess global 
hypomethylation in the TE as compared to the ICM (Adjaye et al., 2005; Santos et al., 2002; 




Beyond the specification event, it has been argued that the factors involved in establishment 
of the trophoblast lineage also appear to be conserved between mouse and man (Senner and 
Hemberger, 2010). Firstly, there is shared mutual activation of the transcription factors Cdx2, 
Elf5 and Eomes which are thought to represent the trophoblast equivalent of the core 
pluripotency transcription factor network active in embryonic stem cells (ESCs) (Ng et al., 
2008). Secondly, the transcription factors involved in controlling terminal trophoblast 
differentiation, GATA2/3 and TCFAP2A/C are shared (Senner and Hemberger, 2010). Finally, 
the epigenetic barriers involved in the control of trophoblast lineage specification are also the 
same. In mouse and human this epigenetic barrier is ELF5 hypomethylation which is specific 
to the trophoblast lineage (Hemberger et al., 2010). 
 
Traditionally, an argument against the conservation of early embryonic states between 
humans and rodents was the inability to derive ground-state ESCs from human embryos. 
Established human ESCs differed from mouse ESCs in many biological aspects and were 
considered to be more akin to mouse EpiSCs (Tesar et al., 2007; Thomson et al., 1998; Yu 
and Thomson, 2008). However, challenging this hypothesis, several groups have recently 
reported multiple in vitro conditions to maintain human ESCs with transcriptional and 
metabolic similarities to mouse ESCs in 2i/LIF conditions (Chan et al., 2013; Gafni et al., 
2013; Takashima et al., 2014; Theunissen et al., 2014; Ware et al., 2014). 
 
1.8 Thesis Hypothesis and Objectives 
 
The experimental hypothesis was that through chemical modulation of pathways implicated to 
be involved in mouse pre-implantation development it may be possible to establish in vitro a 
homogenous stem cell state that possesses expanded fate potential to both the embryonic and 
32 
 
extra-embryonic lineage. Secondly, assuming inter-species conservation of early embryonic 
signalling networks, a similar state may be identifiable in human. 
 
1.8.1 Mouse 
I would therefore apply a hypothesis driven chemically defined media to established cultures 
of mouse ESCs, individual blastomeres and reprogrammed somatic cells in an attempt to 
establish a stable stem cell line with expanded potential.  Expanded potential would be 
defined based on the cell’s ability to differentiate into the embryo proper and both extra-
embryonic lineages, the primitive endoderm and trophectoderm. Molecular analyses including 
single cell RNA sequencing would also be performed to discern whether these cells were 
enriched in a pre-implantation transcriptional signature. 
 
1.8.2 Human 
If successful in mouse, I would then apply the same chemical formulation to established 
cultures of human ESCs and reprogrammed somatic cells in an attempt to establish a stem cell 
line with expanded potential. In human, expanded potential would be defined based on the 
cell’s ability to differentiate into all somatic lineages of the embryo proper and trophectoderm 
in vitro. Epigenetic profiling and molecular analyses including RNA sequencing would also 








2 MATERIALS AND METHODS 
 
2.1 Expanded Potential Stem Cell Medium (EPSCM)  
EPSCM media contained DMEM/F12 (Invitrogen), 20% KnockOut serum replacement 
(Invitrogen), 1X MEM Non-essential amino acid (Invitrogen, 11140), 1X Glutamine-
Penicillin-Streptomycin (Invitrogen, 10378), 0.1mM β-ME (Sigma), PD0325901 1μM, 
CHIR99021 5μM, 1 x 106 U/mL human LIF, Recombinant human IGFII 30 ng/mL (R&D, 
292-G2), JNK Inhibitor VIII 4μM (Santa-Cruz, sc-202673), SB203580 Hydrochloride 10μM 
(Tocris, 1402/10),  A419259 Trihydrochloride 0.3μM (Santa-Cruz, sc-361094) and XAV939 
5μM (Sigma, X3004). 
 
2.2 Mouse Cell Culture 
2.2.1 Mouse ESC / iPSC Culture Media 
Standard mouse ESCs were cultured in M15 medium which contained Knockout DMEM 
(Invitrogen), 15% FBS (HyClone), 1X MEM Non-essential amino acid (Invitrogen, 11140), 
1X Glutamine-Penicillin-Streptomycin (Invitrogen, 10378),  0.1 mM β -ME (Sigma, M6250), 
and 1 x 106 U/mL recombinant LIF. Alternatively, 2i/LIF media was used which contained 
NDiff 227 (Stem Cells, SCS-SF-NB-02), CHIR99021 3μM, PD0325901 1μM and 1 x 106 
U/mL LIF. PD0325901, CHIR99021 and LIF were purchased from Cambridge Stem Cell 
Institute. Standard ESCs used in this study were AB2.2 (Hooper et al., 1987), E14Tg2a 
(Ramirez-Solis et al., 1995), Rex1-GFP ESCs (Guo et al., 2011) and Oct4-GFP reporter ESCs 
(Silva et al., 2008). 
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2.2.2 Mouse ESC Expansion and Passaging 
EPSCs were cultured feeder-free on 0.1% gelatin coated tissue culture plates. Where 
indicated, mitomycin C-inactivated SNL feeder cells (STO / SNL) were used. Cells were 
enzymatically passaged using Accutase (Millipore, SCR005) as per the manufacturer 
guidelines. For routine expansion, EPSCs were split 1:40.  
 
2.2.3 Mouse ESC Conversion 
Conversion of conventional ESCs to EPSCs was performed by culturing ESCs on SNL 
feeders at low plating density for three passages in EPSCM. The conversion experiments were 
performed on the publicly available and widely used ES cell lines, AB2.2 and E14Tg2a 
(Hooper et al., 1987; Ramirez-Solis et al., 1995). To test if EPSCM selected for a rare 
subpopulation of cells in ESC culture, a single Rex1-GFP ESC which was pre-cultured in 
2i/LIF or M15 was plated in either EPSCM or in their original media on SNL feeders. The 
numbers of GFP positive colonies that formed in EPSCM or in 2i/LIF was assessed. 
 
2.2.4 Mouse ESC Cryopreservation 
For cryopreservation, EPSCs were resuspended in 500 μl Freezing Buffer (80% EPSCM, 10% 
FBS (HyClone) and 10% DMSO). Cryovials were placed at -80 degrees Celsius overnight 
then transferred to liquid nitrogen the following day for long term storage. 
 
2.2.5 Reprogramming and mouse iPSC generation 
Reprogramming was performed using the published 6 factor reprogramming platform 
developed by (Wang et al., 2011b). Primary colonies were established into lines using 
EPSCM. To reprogram mouse embryonic fibroblasts (MEFs), episomal vectors with Oct4, c-
Myc, Klf4 and Sox2 (OCKS 4F, 5µg), and Rarg, Lrh1 (RL 2F, 5.0µg) were first mixed with 
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1.0 x 106 cells in OptiMEM (Invitrogen) and the cells were electroporated with Amaxa 
Nucleofector (Lonza, Germany). After electroporation, the cells were plated onto 10 cm 
dishes with STO feeders in M15 for recovery for 24 hours. Medium was changed every two 
days. At day 7, colonies emerged and at day 14, medium was switched to EPSCM for an 
additional 6 days. Colonies were picked into 24 wells on STO feeders in EPSCM for 
expansion and characterization.  
 
2.2.6 In vitro Differentiation of mouse ESCs 
For three germ layer in vitro differentiation, an embryoid body (EB) assay was used. Cells 
were harvested and transferred to ultra-low attachment 6-well plates (Costar, 3471) at a 
density of 1 x 104 – 1 x 105 cells/cm2.  EB differentiation media contained Knockout DMEM 
(Invitrogen, 10829-018), 15% Fetal Bovine Serum (HyClone), 1X MEM Non-essential amino 
acid (Invitrogen, 11140), 1X Glutamine-Penicillin-Streptomycin (Invitrogen, 10378) and 0.1 
mM β -ME (Sigma, M6250). Media was changed every 48 hours. After 5 days, intact EBs 
were transferred to gelatinized 6-well plates. Once EBs attached to gelatinized substrate, they 
were cultured for another 7-10 days before fixation and immunostaining. 
 
In vitro trophoblast differentiation was performed as per the protocol of (Abad et al., 2013). 
Briefly, cells were plated on mitomycin-C-inactivated fibroblasts (MEFs) at a density of 
7 × 104 cells per well of a 6-well plate in EPSCM. After 24 hours, medium was changed to 
trophoblast stem cell (TSC) medium that contained: 70% MEF conditioned medium 
(Millipore, AR005), 30% RPMI 1640 (A1049101) with 20% FBS (HyClone), 1mM pyruvate, 
2mM L-glutamine, 100µM β-mercaptoethanol,  25 ng/ml FGF4 (R&D Systems, 235-F4-025) 
and 1 µg/ml of heparin (R&D, 2812). Medium was changed every other day. At day 2, cells 
were split and differentiation was continued until day 5. Trophoblast stem cell-like cells 
(TSCLCs) were maintained on MEF feeders in TSC media.  For terminal trophoblast 
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differentiation, TSCLCs and in vivo derived trophoblast stem cells were plated on gelatin and 
cultured in TSC media without heparin and FGF4. 
 
2.2.7 Flow Cytometry 
Oct4-GFP and Rex1-GFP ESCS were harvested by enzymatic passaging and subsequently 
centrifuged at 200 × g for 3 min. The medium was aspirated and the ESCs were resuspended 
in PBS solution and analysed by BD LSRFortessa (BD Bioscience). Wild type unstained E14 
ESCs were used as the negative control. 
 
2.2.8 RT-PCR  
RNA was isolated using the RNeasy Mini Kit (Qiagen). The samples were subsequently 
quantified and treated with gDNA WipeOut. First-strand cDNA was prepared by using the 
QuantiTect Reverse Transcription Kit (Qiagen). For real-time PCR, I used TaqMan Gene 
Expression Assays. TaqMan probes were purchased from Applied Biosciences. Quantitative 
PCR was performed in a 7900HT Fast Real-Time PCR System (Applied Biosciences). Mouse 
gene expression was determined relative to the Gapdh gene using the ΔCt method.  
 
2.3 Chemical screen for PD0325901 substitutes in mouse ESCs. 
The screen was designed so as to identify potential substitutes for PD0325901 (Mek1 
inhibitor). On Day 0, 1 x 103 cells were plated in each well of a gelatinized 96-well flat 
bottomed plate in triplicate. On Day 1, the media was changed to N2B27 plus the GSK3 
inhibitor CHIR99021 3µM or N2B27 alone in the presence or absence of the inhibitor of 
interest. After 4-6 days, 96-well FACS analysis was performed to identify any target 
compound(s) that could maintain Rex1-GFP expression. In each experiment, N2B272i, 
N2B272i/LIF and N2B27CHIR/LIF were included as positive controls. Cells cultured in 
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N2B27 alone served as an internal negative control with complete loss of Rex1-GFP 
expression identified. If a potential ‘hit’ was identified, the compound was first tested in its 
ability to support undifferentiated ESC self-renewal in the presence of CHIR99021 +/- LIF. 
Next, the identified pathway was confirmed by testing an additional commercially available 
selective inhibitor from the same signalling family. The list of chemicals tested is provided in 
Table S1.  
 
2.4 Pre-implantation Mouse Embryo Culture 
2.4.1 Derivation of new lines from pre-implantation mouse embryos 
C57B6 females were superovulated and two to four-cell stage embryos were collected and 
cultured in KSOM (Millipore, MR-121-D) until the 8-cell stage (8C). 8C embryos were 
transferred to 24-well plates, 1-embryo per well on SNL feeders in M15, 2i/LIF or EPSCM. 
Partial media change was performed every 48 hours. At day 10, the embryo had attached to 
the feeder layer and a primary outgrowth was observed. Using enzymatic passaging with 
Accutase (Millipore, SCR005), each primary outgrowth was split to one well of a six-well 
SNL feeder plate. Generated lines were expanded for characterization and early 
cryopreservation was performed. Lines derived from 8C embryos were DR10 (EPSCM), 
DR25 (EPSCM), DR9 (2i/LIF) and DR47 (2i/LIF). 
 
2.4.2 Derivation of new lines from single blastomeres 
For derivation of lines from single blastomeres, 8-cell stage embryos were collected from 
oviducts of plugged super ovulated females mated by stud males at 1.5 or 2.5 dpc. Before 
separating the blastomeres, the embryos were cultured in 1.0 ml KSOM containing 3.0 mg/ml 
BSA and 5.0 μg/ml CB (Sigma, C6762) for at least 30 min. Embryos were suspended in a 
100μl Tyrode’s Solution (Sigma, T1788) drop for about 15-20 seconds, and then the embryos 
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were transferred into a new 100μl Tyrode’s Solution drop until the zona pellucida had 
disappeared. The embryos were transferred into a fresh 100 μl M2 drop immediately after 
zona pellucida removal. The embryos were washed a few times in M2 drops. The embryos 
were sucked and blown a few times by a blunt needle (inner diameter: 40 μm). Individual 
blastomeres were collected for seeding to 96-well SNL feeder plates in M15, 2i/LIF or 
EPSCM.  
 
Genetic backgrounds of ESCs and EPSCs: DR10 and DR25 are from a mixed 129S5 and 




2.5.1 Embryo immunostaining 
Immunostaining of early embryos was performed according to the published protocol by Dr. 
Jenny Nichols (Cambridge University) with slight modification. Briefly, embryos were 
washed in PBS / PVP, fixed in 2.5% PFA for 15 minutes at room temperature; permeabilised 
in PBS / PVP / 0.025% Triton-X-100 for 30 minutes; blocked in PBS / PVP / 0.1% BSA / 
0.01% Tween-20 / 2% Donkey serum for 1 hour at room temperature; then incubated with 
primary antibodies in blocking solution at 4 ℃ overnight; washed with blocking solution 3 
times for 15 minutes each; incubated with Alexflor secondary antibodies 1 hour at room 
temperature; washed with blocking solution 3 times for 15 minutes each; mounted the 
embryos in a small drop of VectaShield with DAPI; covered with a coverslip and sealed with 
nail varnish. For the embryo outgrowth, cells in a 96-well were fixed in 4% PFA. Blocking 
solution is PBS / 0.1%Triton-X-100 / 1% BSA / 3% Donkey serum, the staining procedure is 
similar to that listed above. After secondary antibody incubation, cell nuclei were stained with 
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DAPI and observed under fluorescence microscope. The primary antibodies used are Cdx2 
(BioGenex); Oct4 (Abcam), Oct4 (Santa Cruz), Cleaved Caspase 3 (Cell Signalling) and Ki-
67 (Cell signalling). 
 
2.5.2 Cellular Immunostaining 
Cells were grown to the required density on tissue culture plastic for use with fluorescence 
microscope or chamber slides for use with confocal microscope. Cells were fixed using 4% 
PFA for 30 mins at room temperature (RT) and subsequently blocked and permeabilised with 
3% serum* in PBS (Invitrogen, 14190) + 0.3% Triton-X-100 for 30 minutes. Cells were 
incubated with the primary antibody that had been diluted to working concentration in 0.3% 
Triton + 10% serum* in PBS for 2 hours at 37 degrees or overnight at 4 degrees. Secondary 
antibody was diluted to working concentration in 2% serum* in PBS and cells were incubated 
for 30 mins at 37 degrees or 1-2 hours at room temperature in the dark. Between each step, 
cells were washed 3 times with PBS, 5 minutes per wash. Cells were counter stained with 
DAPI.  
Note: * Normal serum from same species that secondary antibody was raised in. See 
Supplementary Table 4 for list of antibodies that were used in this study. 
 
2.5.3 General Immunohistochemistry 
Tissue samples were fixed in 10% buffered formalin phosphate for 24 hours then paraffin-
embedded and cut in 3-µm sections. Alternatively, samples were fixed for 24 hours as 
described previously then placed in 30% sucrose followed by snap freezing in isopentane and 
embedding in OCT for cryosectioning. Prior to staining, samples were deparaffinised, 
rehydrated, permeabilized in 0.5% PBS-Triton-X-100 for 5mins and underwent antigen 
retrieval. This was achieved by incubating slides in boiling 10mM Sodium Citrate Buffer (pH 
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6.0) for 10mins in a pressure cooker. Samples were blocked for 1 hour in 10% normal goat 
serum made up in 0.05% PBS-Triton-X-100. Primary antibody in blocking buffer was 
incubated with sample overnight at 4 degrees Celsius. Conjugated secondary antibody was 
incubated for 1 hour at room temperature. Counterstaining with VectaShield plus DAPI was 
performed and the samples were mounted with 30µl 50% PBS-50% glycerol.  
 
2.5.4 Placental and Yolk Sac Immunostaining 
Paraffin-embedded E14.5 placenta and yolk sac sections were deparaffinized in Xylene, 
100%, 95%, 80%, 70% and 50% ethanol for 3 minutes each and rinsed with running cold 
water. Antigens were retrieved in sodium citrate buffer (10mM Sodium Citrate, 0.05% 
Tween-20 pH 6.0) by microwaving for 15 minutes, followed by rinsing with cold water. The 
slides were then washed in PBS / 0.025% Triton-X-100 (PBST) 2 times, 5 minutes each, 
blocked in PBST / 1% BSA / 5% Donkey serum for 1 hour at room temperature, briefly 
rinsed with PBST and incubated with anti-mCherry antibody (Abcam) at 4 degrees Celsius 
overnight. The slides were washed with PBST 3 times, 5 minutes each, blocked for at least 15 
minutes, incubated with secondary antibody for 1 hour at RT and finally washed with PBST 3 
times, 5 minutes each. The sections were mounted in a small drop of DAPI (VectaShield), and 
covered with a coverslip and sealed with nail varnish. 
 
2.6 In Vivo Differentiation 
All mouse experiments were performed in accordance with the UK’s 1986 Animals and 
Scientific Procedures Act and local institute ethics committee regulations.  
 
2.6.1 Teratoma Formation 
Mouse ESCs were harvested and resuspended in PBS containing 30% matrigel.  5 x 106 cells 
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in 100μl were injected subcutaneously into the dorsal flank of NSG mice (NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ, The Jackson Laboratory) under general anaesthesia. Teratomas developed 
within 4 - 8 weeks. The mice were culled using Schedule 1 methods once the teratoma 
reached the legal limit (1.2mm2) as per Home Office Guidelines. Teratomas were dissected 
and fixed in 10% buffered formalin phosphate for at least 24 hours before paraffin 
embedding, sectioning and H & E staining. All slides were evaluated by a histopathologist. 
 
2.6.2 Chimera generation  
2.6.2.1 Preparing the embryos and foster recipients 
For the production of 8-cell stage embryos, over 8-week-old CD1 females were super 
ovulated by intraperitoneal injection of Pregnant Mare Serum Gonadotropin (PMSG , 7.5 IU 
each) (Intervet, PMSG-Intervet) followed 46-48 hours later by injection of human Chorionic 
Gonadotropin (hCG 7.5 IU each) (Intervet, Chorulon) and set up with proven studs. Vaginal 
plugs were checked the following morning (0.5 days post coitum, dpc), and 8-cell stage 
embryos were collected at 2.5 dpc and cultured in 1.0 ml KSOM (Millipore) medium 
containing 3.0 mg/ml BSA (Sigma) in incubator in humidified atmospheres of 5% CO2  at 37 
°C. CD1 females were mated with vasectomized C57BL6/JCBA F1 males and used as 
recipients for embryos transfer at 2.5 dpc.  
 
2.6.2.2 Injection of ESCs and EPSCs 
EPSCs and conventional ESCs were transfected with a PB-CAG-mCherry-PGK-Puro 
expression vector using Amaxa nucleofection (Lonza) according to the manufacturer’s 
protocol. Following two rounds of cell sorting, a homogenous mCherry positive cell line was 
generated. Serial FACS analysis revealed that the cells continued to stably express mCherry. 
No significant silencing was observed. Injections were carried out with a Nikon Eclipse 
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TE2000-U inverted microscope unit. ESC/EPSC microinjection was performed at room 
temperature on the inverted lid of a 100-mm falcon culture dish in an injection drop of 1.0 ml 
M2 medium (Sigma). For in vitro observation, mCherry tagged EPSCs or conventional ESCs 
were microinjected to morula stage CD1 (ICR) embryos. The injected embryos were allowed 
to develop to blastocysts in vitro for 24-48 hours prior to assessment of contribution to the 
ICM and trophectoderm.  
 
For in vivo chimera generation, the embryo was injected with 6-8 cells per 8-cell stage 
embryo for bulk injection or 1 cell per embryo for single cell injection. After 45-50 embryos 
had been injected, the injected embryos were washed three times in KSOM (Millipore) 
containing 3.0 mg/ml BSA. Embryos were then transferred into a well of a four-well plate 
containing 1.0 ml KSOM. After overnight culture, 20-25 injected embryos were transferred 
into both uterine horns of a foster recipient.  
 
2.7 Assessment of Embryonic and Extra-Embryonic Contribution  
2.7.1 Microscopy, embryo dissection, placenta dissociation and FACS analysis. 
E14.5 embryos were dissected and imaged using Leica M205FA Automated Fluorescence 
Stereo Microscope (100 ms for phase and 5 seconds for mCherry). Placenta, yolk sac and 
embryo samples from mCherry positive embryos were taken for genotyping. Dissected 
placentas were cut into fragments of around 1 mm diameter on ice and digested with 2.35 ml 
placenta digestion solution (5% FBS, 10mM HEPES, 100 μl Enzyme D, 50 μl Enzyme R and 
12.5 μl Enzyme A in HBSS according to the instruction of Lamina Propria Dissociation Kit) 
for 30 min at 37 °C with shaking. After digestion, the placentas were dissociated into single 
cells by pipetting vigorously and filtered through a 70 µm cell strainer (BD Bioscience). 
Single cells from placenta were treated with ACK Lysing Buffer (BioWhittaker) to remove 
the red blood cells and resuspended in FACS buffer (BD Pharmingen) for FACS analysis or 
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sorting. E14.5 fetal livers and fetal brains were dissociated in HBSS by pipetting vigorously 
and filtering through a 70 µm cell strainer. All FACS analysis was performed on BD 
LSRFortessa Cell Analyzer (BD Biosciences). Placenta cells were sorted on MoFlo™ XDP 
(Beckman Coulter). 
 
2.7.2 DNA genotyping and placental gene expression analysis 
Genomic DNA was extracted from placenta, yolk sac and embryo samples from mCherry 
positive embryos, quantified and diluted to 10 ng/ml. DR10-EPSCs have a Cre cassette at the 
Rosa26 locus. A pre-designed TaqMan® Copy Number Assay (Supplementary Table 2) was 
used to determine the contribution of DR10-EPSCs. AB2.2-EPSCs or ESCs have a non-
functional Neo cassette at the Hprt locus. A custom-designed TaqMan® Copy Number Assay 
(Supplementary Table 2) was used to determine the contribution of these cells. Genomic 
DNA from parental DR10-EPSCs or AB2.2 ESCs were used as the positive controls, and 
DNA from a wild type embryo was used as the negative control. Cre/Neo copy number was 
first normalized to Tert using ΔCt method (TaqMan® Copy Number Reference Assay, Life 
Technologies). The contribution of DR10/AB2.2 in individual placenta, embryo proper, and 
yolk sac samples was then determined by normalizing them to parental DR10/AB2.2 cells. 
In order to check the expression of trophoblast specific genes in sorted placenta cells, SYBR 
Green ROX qPCR Mastermix (QIagen) was used. Primer pairs are listed in Supplementary 
Table 6. All qPCR reactions were performed on ABI 7900 HT Sequence Detection System 
(Life Technologies). Gene expression was determined relative to Gapdh using ΔCt method. 
 
2.8 Evaluation of Signalling Pathways 
2.8.1 Mouse ESC / EPSC signalling dependence in vitro 
On Day 0, 100 cells were plated per well of a 24-well gelatinized tissue culture plate in ES 
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media (M15, 2i/LIF or EPSCM) with four technical repeats per condition. After 24 hours, 
media was changed to test condition. Media was changed daily until day 10 when colonies 
were fixed and stained for Leucocyte Alkaline Phosphatase (Sigma). Inhibitors used were 
JAKi 0.6μM (Santa-Cruz, SC-204021), SB505124 1μM (Tocris, 3263), A83-01 0.5μM 
(Tocris 2939), and Su5402 2μM (Tocris, 3300).  
 
2.8.2 Western Blot demonstration of Kinase Inhibition  
1 x 106 ESCs were seeded into gelatinized wells of a 6-well plate in one of the media: M15, 
2i/LIF, KSR2iLIF or EPSCM, respectively. After 48 hours, whole cell protein was extracted 
from harvested cells and quantified using BCA assay (Thermo Scientific). Total protein (40 
µg) was fractioned on a 4-12% Bis-Tris Novex gel (Invitrogen) and electroblotted onto PVDF 
membranes and probed with the following antibodies:  pERK, ERK, pSRC, SRC, pp38, p38, 
pJNK, JNK and AXIN1 (all from Cell Signalling). α-Tubulin (Abcam) was used as loading 
control. Blots were incubated with horseradish peroxidase-coupled anti-rabbit or anti-mouse 
IgG and developed with ECL Prime (Amersham).  
 
2.8.3 JAK STAT signalling activity 
For LIF stimulation, 1 x 106 cells were seeded in EPSCM for 24 hours. Cells were washed 
with PBS and cultured in DMEM/F12 and 20%KSR for 4 hours, then LIF was added at 
concentrations of 0.0, 0.5, 1.0, 5.0 and 10.0 ng/ml for 30 minutes. Whole cell protein was 
extracted for Western blot using pSTAT3 (Cell signalling) and STAT3 (BD Biosciences) 
antibodies. α-Tubulin (Abcam) was used as loading control. 
To analyse the expression of down-stream target genes of Jak-Stat3 and MAPK signalling at 
transcription level, both E14Tg2a ESCs and EPSCs were deprived of LIF for 4 hours as 
above, then LIF 1.0 ng/ml was added for 1 hour. Total RNA was extracted and reverse 
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transcribed to make cDNA. qPCR was performed using Taqman Gene Expression Assays 
(ABI) (Supplementary Table 5). 
 
2.8.4 Wnt signalling detection 
To investigate Wnt signalling in EPSCs, 1 x 106 cells were seeded in M15, 2i/LIF, KSR2iLIF 
and EPSCM for 48 hours. Cytoplasmic and nuclear protein were extracted with a NE-PER 
nuclear and cytoplasmic extraction kit (Thermo Scientific) for Western blot to detect pβ-
catenin (Cell Signalling), β-catenin (Sigma) and active- β-catenin (Millipore). α-Tubulin 
(Abcam) and H3 were used as loading control for cytoplasmic and nuclear protein 
respectively. 
 
For TOPflash assay, 4 x 106 cells were co-transfected with TCF-LEF1 TOPflash and pRL-TK 
by Nucleofection (Amaxa). Cells were split 1:9 into a 24 well plate for 24 hours in M15, 
2i/LIF and EPSCM for 48 hours, cell lysate was prepared for luciferase assay. 
 
2.9 Bioinformatics  
The methodology described herein was prepared in collaboration with Dr Cheuk-Ho J. Tsang 
(PhD thesis of Dr Cheuk-Ho J. Tsang, Sanger Institute). 
 
2.9.1 Single-cell RNA-seq library preparation  
The preparation is previously described by (Brennecke et al., 2013). In brief, five thousands 
trypsin-dissociated mouse EPSC (DR10) were loaded onto the 10-17-μm C1 Single-Cell Auto 
Prep IFCs (Fluidigm) and cell capture was performed according to the manufacturer’s 
protocol. Individual capture site was inspected under light microscope to confirm the presence 
of single cell. The locations of empty capture sites and sites containing multiple cells or burst 
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cells were noted for downstream quality control during data analysis. The lysis and reverse 
transcription mixes were then prepared with the SMARTer PCR cDNA Synthesis kit 
(Clontech) and the Advantage 2 PCR kit (Clontech) according to Fluidigm recommendations. 
1.0 μl of the ERCC Spike-In Control Mix (Ambion) in a 1:400 dilution was added to the lysis 
mix to allow control of technical variation of the library preparation protocol. Lysis and 
cDNA reverse transcription and PCR were performed and cDNA harvested by the C1 Single-
Cell Auto Prep system according to manufacturer’s settings. The success of cDNA 
preparation was confirmed by optimal DNA signal detected by a 2100 Bioanalyzer with high-
sensitivity DNA chip (Agilent). Multiplex sequencing libraries were prepared using the 
Nextera XT DNA Sample Preparation Kit and the Nextera Index Kit (Illumina) according to 
the recommendation in the C1 Single-Cell Auto Prep manual. The libraries of individual cells 
were then pooled and sequenced on 4 lanes of HiSeq 2500 (Illumina) to generate 100bp 
paired-end reads through the Sanger Institute in-house sequencing pipeline.   
 
2.9.2 Reads alignment and quality control of dataset  
Pair-end reads from both bulk and single-cell RNA-seq datasets were aligned to the Mus 
musculus genome (GRCm38.74) by STAR (version STAR_2.3.0e_r291) with specific 
additional parameter settings: ‘--outFilterMultimapScoreRange 1 --outSAMstrandField 
intronMotif’ (Dobin., 2013). The quantification of gene expression was performed by the 
htseq-count module from the HTSeq package (http://www-
huber.embl.de/users/anders/HTSeq/) with gene annotation from GTF files (GRCm38.74) with 
parameter “–s no” in union mode (Anders et al., 2015). The count matrix of individual cells 
were normalized by size factors with DESeq2. As quality control in the single-cell dataset, 
cells with less than 500,000 counts in annotated features, expression of less than 4000 genes 
or high percentage (>10%) of counts mapping to mitochondria-encoded genes were removed 
from subsequent analysis.  
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2.9.3 Chromatin immunoprecipitation and analysis 
The H3K4me3, H3K27me3 and input ChIP library of EPSCs (DR10) were prepared based on 
a modified ChIP protocol from (Lee et al., 2006). In short, about 20 million cells were cross-
linked 1.1% formaldehyde for 10 mins at room temperature. Cross-linking was then quenched 
with 0.125 M glycine. Cell pellets were washed with PBS, snap frozen by liquid nitrogen and 
stored in -80 °C until further processing. The chromatins were sheared by Bioruptor Pico 
(Diagenode) for 5 mins in 30 sec: 30 sec on and off cycles. Immunoprecipitation were 
performed with 2.5 μg antibodies pre-washed and pre-attached to protein A Dynaebeads (Life 
Technologies) overnight at 4 °C. Antibodies: H3K4me3 (Cell Signaling: CST 9751S), 
H3K27me3 (Millipore: 07-449). The beads were then washed and cross-linking was reversed 
with the elution buffer at 65 °C for 4 hours. Immunoprecipitated DNAs were purified with 
proteinase K digestion and the Qiagen miniElut kit (Qiagen). The multiplex sequencing 
libraries were prepared with the microplex library construction kit (Diagenode) following 
manufacturer’s instruction. The DNAs were amplified for 11 cycles and quality of the library 
was checked on a bioanalyzer (Ailgent) using a high sensitivity DNA kit. The library was 
sequenced on 2 lanes of HiSeq2500 in multiplex.  
The single-end 50 bp reads were then mapped to the mouse reference genome GRCm38 by 
the Burrows-Wheeler Aligner (Li and Durbin, 2009) (bwa-0.5.10) according to the in-house 
Sanger DNA pipeline. The H3K4me3 and H3K27me3 ChIP-seq data of TNGA mouse ES 
cells cultured in 2i/LIF and a TNGA gnomic DNA control were downloaded from the NCBI 
GEO SuperSeries GSE23943. The data were remapped to the GRCm38 mouse genome by 
bowtie2 (Langmead and Salzberg, 2012) with default parameters. Read depth between 
datasets were then normalized by read shuffling and random sampling to 20,664,503 reads 
(H3K27me3) and 10,311,175 reads (H3K4me3). H3K4me3 and H3K27me3 enriched peaks 
were detected by MACS (version 2.1.0) with the flag “--broad” turned on for detection of 
broad histone modification peaks. The signal tracks were generated by MACS (version 1.4.2) 
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(Zhang et al., 2008) and visualized by the UCSC genome browser. Peaks coordinates were 
then intersected with the gene promoter windows (+/-1kb from TSS) by Bedtools (Quinlan 
and Hall, 2010) to identify H3K4me3 and H3K27me3 associated genes. Bivalent genes were 
defined as genes that were both H3K4me3 and H3K27me3-associated. Comparison of 
H3K4me3 and H3K27me3 signals at the extended promoter window (TSS+/-3kb) and gene 
body were performed by ngs.plot (version 2.41.3) (Shen et al., 2014). To compare the 
H3K4me3 and H3K27me3 signals distribution at genes with different expression levels, 
expressed genes of EPSCs were first ranked based on their average length corrected mean 
normalized count level and genes in the 1st, 2nd, 3rd and 4th quartiles were classified into 
four groups as “Very High”, “High”, “Low” and “Very low”. Signal plot across gene body 
were then generated by ngs.plot. Length correction was performed by dividing the normalized 
count by union exon length (in kilobase). 
 
2.9.4 Differential gene expression analysis  
For the comparison of the transcriptomes of mouse EPSCs and 2i/LIF ESCs, differential 
expression analysis was performed with DESeq2. Cooks distance testing was turned off to 
accommodate the noisy expression nature in single-cell data and counts from the ERCC 
spikes in the EPSCM datasets were removed from the input matrix. Differential expression 
with adjusted p-value <0.05 and |log2 fold change| >1 were considered as significantly 
differentially expressed. Cell lines and passage numbers: DR25 and DR10, in serum, passage 
5; in 2i/LIF, passage 5; in EPSCM, passage 15. DR9 and DR4, in 2i/LIF, passage 4 and in 
EPSCM, passage 5. AB2.2 ESCs, M15 passage 18, 2i/LIF passage 6, EPSCM passage 7. E14 
ESCs, M15 passage 20, 2i/LIF passage 5, EPSCM passage 6.  
 
2.9.5 Gene ontology enrichment analysis  
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Gene ontology term enrichment analysis was performed by DAVID (Huang da et al., 2009) 
(http://david.abcc.ncifcrf.gov/). Gene symbols were used as input gene list and the mouse 
genome was chosen as background. 
 
2.9.6 Embryonic stage-enriched gene set enrichment analysis  
Gene set enrichment analysis was performed with the javaGSEA application (version 2.1.0) 
available online (http://www.broadinstitute.org/gsea/downloads.jsp) with “weighted” 
enrichment statistics setting (Subramanian et al., 2005). The mouse pre-implantation 
embryonic stage-enriched gene sets were compiled by analysing the published expression 
count matrix from (Deng et al., 2014). The top 500 genes that showed higher average 
expression than other stages after size factor normalization by DESeq2 were considered stage-
enriched and used as testing gene set. The normalized count matrices of the EPSC and 
standard 2i/LIF ESC single-cell dataset were used as input expression dataset. Enrichment is 
considered significant if FDR is below 0.1 and nominal P value is below 0.05. 
 
2.9.7 Estimating the pre-implantation embryonic developmental time frame of EPSCs  
The whole transcriptome or the normalized count values of the 36 epigenetic modifiers 
defined by Burton et al were used to estimate the pre-implantation embryonic developmental 
time point of EPSCs (Burton et al., 2013). The expression of the selected epigenetic modifiers 
has been previously shown to provide superior segregation of blastomeres of different pre-
implantation embryonic stages to pluripotency-associated transcription factors by single-cell 
qPCR (Burton et al., 2013). The normalized count matrix of the whole transcriptome or the 
epigenetic modifiers from the dataset of Deng et al were transformed by log2(nCount+1) to 
stabilize the variance of the data and principal component analysis were performed by the 
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prcomp() function in R on the transformed matrix (Deng et al., 2014). The scores were then 
used to predict the scores of EPSCs or 2i/LIF ES cells by the predict () function in R. 
 
2.9.8 Comparison of EPSCs, Hhex-Venus+ ES cells, MERV-TdTomato+ ES cells and in 
vivo iPS cells 
The raw RNA-seq data of in vivo reprogrammed iPS cells (iviPS1-6) from Abad et al, Hhex-
Venus+ ES cells from Morgani et al (both 2i/LIF and serum/LIF) and MERV-Tdtomato+ 
reporter ES cells from MacFarlane et al were downloaded from GSE48364, GSE45182 and 
GSE33923, respectively, and aligned to GRCm38 mouse genome by STAR (Abad et al., 
2013; Macfarlan et al., 2012; Morgani et al., 2013). Gene expression was then quantified as 
described above by HTSeq-count. To normalize the difference between studies and 
sequencing platforms, the gene expression profile of EPSCs (DR9, DR25, DR4, DR10-
EPSCM), MERV-TdTomato+ ES cells and in vivo iPS cells were quantified as the relative 
log2 fold change of expression of the genes compared to 2i/LIF ES cells (DR9, DR25, DR4, 
DR10-2i/LIF) by DESeq2. For Hhex-Venus+ ES cells, the unsorted 2i/LIF datasets 
(GSM1098629 and GSM1098630) were used for normalization. Genes with unavailable log2 
fold change value in DESeq2 were removed from comparison. Sequences of repeat elements 
(mouse and shared) were downloaded from (http://www.girinst.org/repbase/index.html). A 
custom GTF file and genome index was constructed by STAR with individual repeat class 
treated as individual chromosome. Reads were then realigned to the new index. Expression 
was quantified by HTSeq-count as described above and normalized by size factors computed 
by DESeq2. The relative expression of EPSCs and MERV-TdT+ ES cells were then calculated 
relative to that of MERV-TdT- ES. 
 
2.9.9 Mass Spectrometry 
Genomic DNA was quantified using picogreen assay (Invitrogen), digested using DNA 
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Degradase plus (Zymo Research) for 90 minutes at 37 degrees and analysed by liquid 
chromatography-tandem mass spectrometry on a LTQ Orbitrap Velos mass spectrometer 
(Thermo Scientific) fitted with a nanoelectrospray ion-source (Proxeon, Odense, Denmark). 
Mass spectral data for C, 5mC and 5hmC were acquired as previously described (Ficz., 
2013)).  5mC and 5hmC levels are normalized to total cytosine levels. Error bars represent 
standard deviation of at least 3 technical replicates per sample. 
 
2.10 Human ES cell and Human EPSC Culture 
The import and use of human ES cells were approved by The Steering Committee for the 
UK Stem Cell Bank and for the use of Stem Cell Lines 
 
2.10.1 Human ES  and human iPSC conversion to EPSCs 
Two widely used human ESC lines H1 and H9 were used for the conversion experiments 
(Thomson et al., 1998). Individual human ESCs cells were seeded in EPSCM on MEF feeder 
cells at a low cell density. Approximately 0.3% of H1 cells formed undifferentiated colonies 
which could be subcloned and expanded in EPSCM to establish stable cell lines. In contrast, 
none of the colonies of H9 cells that initially survived in EPSCM could be further expanded. 
The converted H1 cells (H1-EPSCs) were dissociated to single cells for passaging with a 15-
20% single cell subcloning efficiency in the presence of a selective ROCK inhibitor (10 μM 
Y27632) and could be expanded in EPSCM for over 30 passages on SNL feeders. Two 
standard human iPSC lines from the CGAP facility (BOB-iPSCs and FSPS186-iPSCs) were 
obtained and the conversion strategy was repeated. BOB survived the conversion process with 
EPSC colonies emerging from single iPSCs which were plated at low density on SNL feeders. 




2.10.2 Picking, expansion and cryopreservation of human EPSCs 
Using a P20 pipette (set to 5 μl), a single primary colony was detached from the feeder layer 
by careful scraping and subsequently aspirated. Each colony was placed in a 96-well round 
bottomed plate (1 colony / well) that contained 20μl PBS. 30 μl Accutase was added per well 
and the 50 μl total volume was mixed by pipetting up and down 10 times. The 96-well plate 
was transferred to the incubator (37 degrees Celsius, 5% CO2) for 5-10 minutes. Using a 
multichannel pipette set to 50μl, the colony was dissociated to single cells. Each well was 
checked under microscope to confirm a single cell suspension. 50μl EPSCM media containing 
10 μM Y27632. was added to each well and the total 100μl volume (20μl PBS + 30μl 
Accutase + 50μl EPSCM) was transferred to a pre-prepared 24 well SNL feeder plate with 
pre-equilibrated EPSCM media plus 10 μM Y27632. One well of a 96-well plate was 
transferred to one well of a 24-well plate.  The plate was placed in the incubator at 37 degrees 
Celsius. The ROCK inhibitor was removed after 24 hours by changing the media with fresh 
EPSCM. The media was subsequently changed daily. Colonies re-emerged after 3-5 days 
however as they were growing from single cells recovery did occasionally take 7-10 days. 
 
For routine bulk culture passaging of human EPSCs, enzymatic dissociation with Accutase 
was used. Following aspiration of media and washing once with PBS, Accutase was added to 
cover the base of the well. After five minutes of enzymatic dissociation in an incubator at 37 
degrees Celsius, 5% CO2, a pipette was used to assist in cell detachment and create a single 
cell suspension which was passed through a 100 μm filter into a 15ml falcon tube. The filtered 
sample was centrifuged at 1200rpm for 3 minutes with subsequent aspiration of the 
supernatant and resuspension and plating in EPSCM  plus 10 μM Y27632.  Cell counting was 
routinely performed using trypan blue exclusion. EPSCs were plated at a density of 1.5 – 5 x 




For cryopreservation, human EPSCs were resuspended in 500 μl Freezing Buffer (80% 
EPSCM, 10% FBS (HyClone), 10% DMSO and 10 μM Y27632). Cryovials were placed at -
80 degrees Celsius overnight then transferred to liquid nitrogen the following day for long 
term storage. 
 
For cryorecovery, the cryovial was first thawed in a water bath at 37 degrees Celsius. After 
thawing, the cryovial was centrifuged briefly at 1200 rpm. The contents of the cryovial were 
then transferred to a 50ml falcon tube which contained 15 ml of pre-equilibrated EPSCM 
containing 10 μM Y27632. The falcon tube was centrifuged for 3 minutes at 1200rpm. The 
supernatant was aspirated and the cell pellet was re-suspended in pre-equilibrated ROCK 
inhibitor containing EPSCM and plated on SNL feeder plates. The media was changed after 
12 hours to ensure removal of any residual DMSO. 
 
2.10.3 Differential Adhesion Feeder Removal Strategy 
For downstream experiments including differentiation, gene targeting, RNA sequencing etc. 
feeder removal was often required. Differential adhesion based feeder removal was routinely 
used as described herein. Firstly, the media was aspirated from the tissue culture plate and 
washed once with PBS. Following aspiration of the PBS, Accustase was added in a volume 
sufficient to cover the base of the well. After incubation for 5 minutes at 37 degrees Celsius a 
pipette was used to assist cell detachment. EPSCM plus 10 μM Y27632 was added to the 
plate and the total cell suspension was collected and passed through a 100 μm filter into a 15 
ml falcon tube which was centrifuged at 1200rpm for 3 minutes. The supernatant was 
aspirated and the cell pellet was resuspended in EPSCM plus 10 μM Y27632. The cells were 
transferred to a non - gelatinized 10cm plate containing EPSCM plus 10 μM Y27632 and 
placed in an incubator for 30 minutes. The supernatant was then collected from the plate and 
54 
 
the cells were counted using trypan blue exclusion. The volume containing the required 
number of cells was centrifuged at 1200rpm for 3 minutes. 
 
2.11 Culture of human fetal neural stem cells (hfNSCs) 
BRC1019, a human fetal neural stem cell line (a gift from Dr. Colin Watts) was routinely 
expanded in T75 tissue culture flasks in NDiff 227 media (StemCells Inc) supplemented with 
10 ng/ml Fibroblast Growth Factor-Basic (Invitrogen) and 10 ng/ml Epidermal Growth 
Factors (Invitrogen). Prior to cell plating, the tissue culture flasks were coated with ECM gel 
from Engelbreth-Holm-Swarm murine sarcoma (Sigma). To prepare ECM gel working 
solution, 1 ml ECM was mixed with 9 ml KnockOut-DMEM (Invitrogen) and the10-ml 
aliquots were stored at -20°C. Before use, a 10-ml aliquot was thawed at 4°C overnight and 
used to coat tissue culture flasks. During expansion of BRC1019 cell line, the media was 
changed every other day. Cells were passaged enzymatically using Accutase. 
 
2.12 Reprogramming and generation of human iPSCs 
2.12.1 Reprogramming human fetal neural stem cells to iPSCs 
Before electroporation, BRC1019 cells were plated at a density of 0.5–5 x 104 cells/cm2 in a 
T75 tissue culture flask. Once the cells reached 70% - 80% confluence, they were dissociated 
using Accutase and harvested for electroporation. Human fetal neural stem cell transfection 
was performed using an Amaxa machine (Lonza) according to the manufacturer’s protocol 
(murine neural stem cell, program A-033) with a transfection efficiency of 75%. For episomal 
(integration-free) 6F reprogramming, 1 x 106 hfNSCs were usually transfected. After 
electroporation, hfNSCs were seeded in M15 media supplemented with hLIF (1 x 106 U/ml, 
Merck Millipore) and Vitamin C (50 μg/ml, Sigma) on mitomycin C-inactivated SNL feeder 
plates. The media was changed every other day. When colonies emerged 10-14 days after 
55 
 
electroporation, the media was switched to EPSCM for a further 5-7 days before picking. 
Electroporation of 1 x 106 hfNSCs cells typically generated 10-20 primary iPSC colonies with 
a line establishment rate of 50%. 
 
2.12.2 Reprogramming human dermal fibroblasts to iPSCs 
Before electroporation, 5 x 105 HDFs were plated in a T75 tissue culture flask. When HDFs 
were 70-80% confluent, they were typsinized and collected for electroporation. Transfection 
of HDFs was performed using an Amaxa machine according to the manufacturer’s protocol 
(human dermal fibroblast cell, program U-020). After electroporation, HDFs cells were 
seeded in M15 plus hLIF for 24 hours. From the second day, transfected cells were cultured in 
M15 media supplemented with hLIF (1 x 106 U/ml, Merck Millipore), Vitamin C (50 μg/ml, 
Sigma) and doxycycline (1.0 μg/ml, Clontech). The media was changed every other day. 
Human iPSC colonies emerged 16-20 days after electroporation, the media was changed to 
EPSCM for a further 5-7 days before picking. Electroporation of 1 x 106  HDFs typically 
produced 1,000-2,000 primary iPSC colonies with a 50% stable line establishment rate. 
 
2.13 Gene targeting in human EPSCs 
The methodology described herein was prepared in collaboration with Dr Wei Wang PhD, 
Sanger Institute. Targeting vectors used to generate the ROSA26-SA-H2B-Venus-PGK-Puro, 
OCT4-2A-H2B-Venus-EF1α-Puro and OCT4-2A-Puro-2A-H2B-Venus and NANOG-2A-
Bsd-2A-H2B mCherry reporter EPSC lines were all made using E.coli recombineering. SA-
H2B Venus-PGK-Puro, 2A-H2B-Venus-EF1α-Puro and 2A-H2B-mCherry-EF1α-Puro 
constructs were gifts from Dr. Manousos Koutsourakis and Dr. Bill Skarnes Sanger Institute. 
To generate 2A-Puro-2A-H2B-Venus and 2A-Bsd-2A-H2B-mCherry constructs, EF1α-Puro 
selection marker was deleted from 2A-H2B-Venus-EF1α-Puro and 2A-H2B-mCherry-EF1α-
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Puro constructs and the 2A-Puro or the 2A-Bsd cassette was inserted in front of 2A-H2B-
Venus or 2A-H2B-mCherry, respectively. 
 
For targeting, EPSCs were washed with PBS and dissociated using Accutase. After 
dissociation, cells were collected, counted, and resuspended in EmbryoMax ES Cell 
Electroporation Buffer (Merck Millipore). For one electroporation, 5 μg Cas9 expression 
vector (George Church lab, Addgene), 5 μg gRNA expression vector (George Church lab, 
Addgene) and 10 μg of targeting vector were mixed with 1 x 107 cells, and electroporated 
with Biorad Gene Pulser using a condition of 320 v, 250 μF. After electroporation, the cells 
were plated onto SNL feeder plates in EPSCM supplemented 10 μM Y27632 for 24 hours. 
Drug selection (Puromycin 1.0 μg/ml, Blasticidin 5.0 μg/ml) was performed 48 hours after 
electroporation. When drug resistant colonies emerged, the medium was switched to EPSCM 
for an additional 2 days before picking. 
 
2.14 Human EPSC Differentiation  
2.14.1 Human embryoid body (EB) differentiation  
EPSCs were routinely expanded on 10cm SNL feeder plates. Following enzymatic passaging 
and feeder removal as previously described, EPSCs were re-suspended in DMEM/F12 / 20% 
KSR and filtered with a 0.4μM cell strainer to make a single cell suspension. 9 x 105 cells 
were plated into 1 well of an AggreWellTM400 (Stem Cell Technologies) to form embryoid 
bodies (EB). After 24 hours, the EBs were harvested and re-suspended in DMEM/F12 / 
20%KSR. Approximately 1000 EBs were plated into one 6 well of a low attachment plate and 
grown for 5 days. At day 6, the EBs were collected and plated into a gelatinized 12-well plate 
in N2B27 for neural differentiation and M10 for mesoderm and endoderm lineage 
differentiation for 5 more days. At day 11, cells were fixed in 4% PFA and  immunostained 
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with antibodies against neuron-specific class III beta-tubulin (Tuj1), alpha smooth muscle 
actin (SMA) and alpha fetoprotein (AFP). 
 
2.14.2 Targeted Neural Differentiation of EPSCs 
Neural Induction Media contained NDIFF 227 (Stem Cell Sciences, SCS-SF-NB-02), 
10ng/ml FGF-BASIC Life Technologies Ltd. (Invitrogen), PHG0021 and 1 μM 
Dorsomorphin (Sigma, P5499-5MG).  Neural Stem Cell Culture media (NSC-CM) contained, 
NDIFF 227 (Stem Cell Sciences, SCS-SF-NB-02), 10ng/ml FGF-BASIC Life Technologies 
Ltd. (Invitrogen), PHG0021 and 10ng/ml Epidermal Growth Factors (EGF) Life Technologies 
Ltd. (Invitrogen),  PHG0311. 
 
EPSCs were differentiated on 6 well plate(s) at a cell density of 2.5 – 5 x 104 cells / cm2. Prior 
to cell plating the well was coated with ECM Gel from Engelbreth-Holm-Swarm murine 
sarcoma (Sigma, E1270). Briefly this was prepared by thawing the ECM and adding 1ml 
ECM to 9ml KO-DMEM. This was mixed and stored in 10ml aliquot(s) at -20 degrees. For 
use, a 10ml tube was thawed at 4 degrees overnight. Once thawed, ECM will form a gel at 
room temperature. ECM was added to coat the base of the well and then aspirated and 
discarded. Cells were plated immediately in Neural Induction media plus 10 μM Y27632. The 
ROCK inhibitor was removed the following day. (Note: ROCK inhibitor is only required 
during the first 24 hours to enhance the single cell survival and plating of EPSCs). During 
differentiation, the media was changed after the first 24 hours, then, every 48 hours thereafter.  
 
Neural rosettes appeared after 2.5 - 3 weeks of differentiation. At the rosette stage, to 
establish a neural stem cell line, the culture was passaged enzymatically using Accutase and 
split 1:1 or 1:2 into NSC-CM onto ECM coated plates. During NSC expansion, the media was 




For terminal neuronal differentiation, 35mm tissue culture plates were first coated with 
laminin at a working concentration of 1‑2 μg/cm2 (Sigma, L6274), 2 hours before cell plating.  
NSCs were subsequently plated at a density of 5 x 104 cells / cm2 in NSC-CM. The following 
day, the media was removed, cells were washed once with PBS and NDIFF 227 medium 
(Stem Cell Sciences, SCS-SF-NB-02) was added. Media change was performed every other 
day. With prolonged differentiation (~3 months for electrophysiological maturity), the culture 
was often observed to partially detach from plate. When this was observed a few microliters 
of laminin was added to the media which resulted in cellular re-attachment to the base matrix. 
Neuronal electrophysiology was performed in collaboration with Peter Kirwan, Livesey Lab 
at the Gurdon Institute. 
 
2.14.3 Pancreatic Differentiation 
Pancreatic differentiation was performed in collaboration with Mariya Chhatriwala, Vallier 
Lab at the Sanger Institute using their published monolayer differentiation protocol (Cho et 
al., 2012). 
 
2.14.4 Differentiation of human EPSCs to trophoblasts 
For trophoblast differentiation, H1-ESCs, H1-EPSCs (passage 15) or EC5-EPSCs (passage 
20) were plated in 20% KSR media at a density of 5 x 105 cells/well in a gelatinized 6-well 
tissue culture plate. After 24 hours, the media was changed to 20% KSR with 10.0 ng/mL 
human recombinant BMP4 (R&D Systems) and 10.0 μM SB431542 (Tocris) (Amita et al., 
2013; Bernardo et al., 2011). Media was changed daily. Differentiated cells were harvested 
and used for FACS analysis or qRT-PCR analysis at different time points. All experiments 
were repeated at least twice on different passages of cells to ensure that the patterns of gene 
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expression described were reproducible. 
 
2.15 Human EPSCs cell cycle analysis 
Click-iT® Plus EdU Alexa Fluor® 647 Flow Cytometry Assay Kit (Life Technologies, 
C10634) was used for cell-cycle analysis according to manufacturer’s instructions. EdU 
incorporation (Alexa Fluor 647 labelled anti-EdU antibodies) was measured with DNA 
content (DAPI) in fixed and permeabilized cells. 
 
2.16 Spectral karyotyping 
Human and mouse karyotyping including DAPI banding and Multicolour FISH was 
performed at the molecular cytogenetics core facility at the Sanger Institute (Thanks to 
Beiyuan Fu and Fengtang Yang for technical assistance). For mouse karyotyping, a 10 cm 
plate of feeder free EPSCs at 60 – 80% confluence was submitted. For human karyotyping, 
once the cells reached 60-80% confluence the media was changed with the addition of fresh 
equilibrated EPSCM containing 10 μM Y27632, 1 hour before sample submission. 
 
2.17 Array CGH 
Array comparative genome hybridization of human ESC, human EPSCs and human iPSCs 
was performed at the Sanger Institute core facility. 
 
2.18 Single Cell RNA FISH 
Human EPSCs were passaged as per previously stated method using enzymatic dissociation. 
After centrifuging at 1200rpm for 3 mins, 1 x 105 cells were resuspended in 1ml of PBS plus 
10 μM Y27632.  For each cytospin, 200μl (2 x 104 cells) was used with an optimal 
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centrifugation speed range of 500-800 rpm for 5 mins. The cell containing slides were fixed 
and submitted to the Molecular Cytogenetics core facility at the Sanger Institute for further 
analysis (Thanks to Beiyuan Fu and Fengtang Yang for technical assistance). 
 
2.19 Digital microscopy imaging 
Immunofluorescence stained samples were examined with a Leica DM5000B microscope 
equipped with narrow bandpass filters for Cy3.5, fluorescein and DAPI fluorescence. Images 
were captured via a monochrome digital camera (ORCA-03G, Hamamatsu) and processed 
with the SmartCapture software (Digital Scientific UK). 
 
2.20 Human DMR analysis  
The methodology described herein was prepared in collaboration with Dr Wei Wang PhD, 
Sanger Institute. Bisulfite treatment was performed using the EpiTect Bisulfite Kit (Qiagen) 
according to the manufacturer’s recommendations. Genomic DNA PCR for promoter regions 
was performed using primer pairs described in Supplementary Table S3. PCR products were 
cloned using pGEM-T Easy Vector Systems and sequenced from both ends. 
 
2.21 Human Bioinformatics 
The methodology described herein was prepared in collaboration with Dr Cheuk-Ho J. Tsang, 
Sanger Institute. 
2.21.1 Processing of human data 
Standard TruSeq mRNA-seq library were generated by in-house Sanger DNA pipeline. At 
least four million cells were submitted for RNA extraction and multiplex library preparation. 
The library was sequenced on HiSeq2500 to generate 100bp paired-end reads and were 
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aligned to the GRCh37 genome using STAR aligner. Gene expression was quantified by 
Cufflinks2. 
 
2.21.2 Culture condition signature enrichment in different stages of human embryos 
The signature genes were defined as the top 1000 mostly expressed differential genes between 
PSCs (EC2, EC5, H1) cultured in EPSCM and H1 ESC cultured in FGF conditions. 
Differential gene analysis was performed using Cufflinks 2. The enrichment of the signature 
genes of the two culture conditions were tested in individual pre-implantation stage against 
passage 10 human ESC cultured in FGF conditions. The human embryo single-cell RNA-seq 
data were retrieved from (Yan et al., 2013). Positive end of the x-axis indicates the level of 
enrichment in passage 10 FGF human ESCs in each pairwise comparison, the negative end 
indicate enrichment towards the respective embryonic stage. For instance, human 8C embryos 
showed significant enrichment of EPSCM signature (score: -1.51), compared to passage 10 
FGF human ESCs, while the FGF signature is enriched towards p10 FGF ESCs as expected 
(score 2.44). *p<0.05, **p<0.01. 
 
 
2.21.3 Human single-cell RNA sequencing and X-chromosome reactivation analysis 
Single-cell RNA-seq data of 96 human EPSCs (EC5-Rosa26-Venus) were generated using 
Fluidigm C1 AutoPrep system according to manufacturer instruction using medium sized 
integrated fluidic circuits (10-14um). 100bp paired-ends reads were generated on HiSeq2500 
according to in-house Sanger DNA pipeline. Reads were aligned to GRCh37 human genome 
using STAR aligner with default parameters. In total, 44 cells passed quality control 
(including removal of lysed cells, doublets, unique aligned reads <500,000, mitochondrial 
reads >10%, gene detection <8000). Samtools mpileup and Vcftools were used to identify 
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variant sites at the X-chromosome. Heterozygous SNP sites were then annotated by 
intersecting their coordinates with that of annotated X-chromosome genes. A SNP is only 
considered valid if it can be detected in more than 4 cells. The number of probable SNPs in 
each X-chromosome-linked gene was then summarized and selected for mRNA-FISH 
validation. 
 
2.22 Statistics analysis 
Experimental data are shown as mean and standard deviation. All statistical analyses were 
either conducted with Prism (GraphPad) or specified in relevant sections. 
 
Supplementary Methods Tables 
Table 1. Chemical Screen Compounds 
Table 2. QPCR Probes for DNA Copy Number 
Table 3. DMR Analysis Primers 
Table 4. Antibodies 
Table 5. Mouse QPCR Probes for RNA expression 
Table 6. Mouse Primers for Trophoblast Gene Expression 















GSK1904529A IGF-1R/IR 0.2 
Sunitinib PDGFRA, KIT 1 
VX-680 (MK-0457) AURK A/B/C, ABL, FLT3 0.2 
Imatinib Abl, KIT, PDGFR 0.2 
TAE684 ALK 0.2 
PF2341066 MET, ALK 0.2 
Dasatanib Src, Bcr-Abl 0.05 
XAV 939 TNKS1/2 (Wnt/b-catenin) 1 
Gefitinib EGFR 0.1 
ABT-263 Bcl-2, Bcl-xl 0.5 
SAHA (Vorinostat) HDAC I/II 0.5 
AZD2281 (Olaparib) PARP1/2 1 
Lenalidomide TNF alpha 1 
Axitinib PDGFR, KIT, VEGFR 0.5 
AZD 7762 Chk 1/2 0.2 
GW 441756 Trk A 0.5 
CEP-701 (Lestaurtinib) JAK2, FLT3 0.1 
CHIR-99021 GSK-3 1 
17-AAG Hsp90 0.05 
VX-702 p38 1 
KU-55933 ATM 0.2 
Elesclomol  Hsp70 inducer 0.005 
BIBW 2992 EGFR, ERBB2 0.1 
GDC-0449 SMO (Hedgehog) 2 
BX 795 PDK1, TBK1, IKKe 1 
SL 0101-1 Rsk, AURKB, PIM3 2 
BIRB 0796 p38, JNK2 2 
JNK inhibitor VIII JNK 1/2/3 2 
PD173074 FGFR 0.2 
ZM447439 AURK B 0.5 
MK-2206 AKT 1 
PD-0332991 CDK 4/6 0.5 
GW843682X (AN-13) Plk1 0.05 
NVP-BEZ235 PI3K/mTOR 0.01 
GDC0941 PI3K (a,b,d) 1 
AZD8055  mTORC1/2 0.5 
SB590885 BRAF 0.5 
AZD6244 MEK 1/2 0.5 
WO2009093972 PI3K beta 0.2 
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AZD6244 + MK-2206 Comb [MEK1/2 + AKT] 0.5/1 
GSK 269962A ROCK1/2 0.2 
BMS-708163 Gamma-secretase 0.2 
Obatoclax mesylate Mcl-1 0.05 
Nutlin-3 MDM2 2 
Embelin XIAP 2 
Rapamycin mTOR 0.002 
BMS-536924 IGF-1R 0.5 
SB-505124 TGFβR-I (ALK5) 1 
CGP77675 Src  1 
GM6001 MMP inhibitor 150 
Go6983 PKC inhibitor 5 
Cyclosporin A Calcineurin inhibitor 15 
PP2 Src  10 
Compound C AMPK,KDR/VEGFR2, ALK2/BMPR-I 1 
PD0325901 ERK 1 
PP1 Src 10 
 









Tert Copy Number  
Reference Assay 
4458368 N/A N/A 
Cre Copy  
Number Assay 
MR00635245_CN N/A N/A 
 
 
Neo Copy  
Number Assay 
 
custom-designed Neo-QPCR-F CGACCACCAAGCGAAACAT 
custom-designed Neo-QPCR-R CGACAAGACCGGCTTCCAT 
custom-designed Neo-QPCR-Probe CATCGAGCGAGCACG 
 
Table 3 DMR Analysis Primers 
DMR Region Primer 
Name 

































Table 4 Antibodies 
















p44/p42 MAPK (ERK) Cell Signaling 9102 1:1000 
p-p44/p42 MAPK (Thr202/Tyr204) Cell Signaling 9101 1:1000 
p38 Cell Signaling 9212 1:1000 
p-p38 (Thr180/Tyr182) Cell Signaling 9215 1:1000 
SAPK/JNK Cell Signaling SC-571 1:1000 
p-SAPK/JNK (Thr183/Tyr185) Cell Signaling 9251 1:1000 
Src Cell Signaling 2110 1:1000 
p-Src (Tyr416) Cell Signaling 2101 1:1000 





p-Stat3 (Tyr705) Cell Signaling 9131 1:1000 
B-catenin Sigma C7082 1:1000 
p-B-catenin (Ser33/37/Thr41) Cell Signaling 9561 1:1000 
active B-catenin Millipore 05-665 1:1000 
Histone H3 Cell Signaling 4499 1:1000 
Alpha-Tubulin Abcam Ab7291 1:3000 
Cdx2 Biogenex MU392A-UC 1:150 
Oct4 Abcam Ab1985 1:250 
Oct (C10) Santa-Cruz SC-5279 1:100 
Cleaved Caspase 3 Cell Signaling 9579 1:100 
Ki-67 Cell Signaling 9129 1:100 
B III Tubulin (Tuj1) 
R & D 
Systems 
MAB1159 1:150 
Alpha-Smooth Muscle Actin 




R & D 
Systems 
MAB1368 1:150 
Gata4 (C-20) Santa-Cruz SC-1237 1:100 
Gata6 
R & D 
Systems 
AF1700 1:6000 
Placenta Lactogen I (P-17) Santa-Cruz SC-34713 1:100 
Integrin alpha 5 (H-104) Santa-Cruz SC-10729 1:50 
Cytokeratin 7 (5F282) Santa-Cruz SC-70936 1:50 
HLA-G Abcam Ab52454 1:150 
HCGBeta Abcam Ab80786 1:150 
mCherry Abcam Ab125096 1:100 
GFP Abcam Ab13970 1:200 
NeuN C-A60 Millipore MAB377 1:100 

































Table 5 Mouse QPCR Probes for RNA expression 




















Table 6 Mouse Primers for Trophoblast Gene Expression 











































Table 7 Human QPCR Probes for RNA Expression 
Gene Name 
 


























3 NOVEL CHEMICALLY DEFINED MEDIA 
PERMITS ESTABLISHMENT IN VITRO OF A 





In this chapter, I describe the formulation of a novel chemically defined medium which 
permitted the maintenance in vitro of a unique mouse stem cell state. In contrast to 
conventional embryonic stem cells, following micro-injection to morula and early blastocyst 
stage embryos, these cells demonstrated expanded fate potential with donor cell contribution 
identified in both the embryonic and extra-embryonic compartments including the 
trophectoderm and primitive endoderm. This chapter begins with a description of the 
serendipitous sequence of events that resulted in the creation of this medium and the 
preliminary observations that resulted in the generation of the hypothesis and experimental 
aims for this thesis. In the Results section, I characterize this in vitro state and evaluate the 
individual components of the medium.  Based on published genetic and biochemical data, I 







3.2  Introduction 
 
3.2.1 Science and serendipity 
In keeping with the empirical importance of serendipity in science, initially, this project did 
not set out to investigate signalling pathways in the early mouse embryo or the presence of 
self-renewing stem cell states in early mammalian development. Rather, the focus was on 
further exploring the human naïve state. 
 
In 2006 and 2007, two revolutionary papers were published which challenged our 
understanding of differentiation induced fate restriction. The authors demonstrated that mouse 
and human induced pluripotent stem cells (iPSCs) could be generated by ‘reprogramming’ 
fully differentiated somatic cells through overexpressing  the transcription factors Oct4, c-
Myc, Sox2 and Klf4 (OCKS) (Takahashi et al., 2007; Takahashi and Yamanaka, 2006). These 
findings resulted in an entirely new field of scientific research where considerable effort was 
invested in elucidating the reprogramming process. 
 
With this end in mind, our group performed a genetic screen with the aim of identifying 
additional or replacement transcription factors which could be used in the reprogramming of 
mouse embryonic fibroblasts (Wang et al., 2011b). The authors reported that enhancing 
retinoic acid (RA) signalling by expressing Retinoic acid receptors (RARs) or by adding RA 
agonists promoted reprogramming and inhibiting RA signalling using a RAR-α dominant- 
negative form completely blocked the reprogramming process. In addition, co-expressing 
retinoic acid receptor gamma (RAR-γ) and liver receptor homologue 1 (Lrh-1 / Nr5a2) with 
the original four Yamanaka factors (OCKS) markedly accelerated reprogramming. Using this 
six-factor platform, reprogramming of mouse embryonic fibroblast cells to iPSCs required 
only four days of induction, the overall reprogramming efficiency was increased and  >90% 
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of the primary colonies  were ground-state iPSCs (Wang et al., 2011b; Ying et al., 2008). 
 
This six-factor combination also readily reprogrammed primary human neonatal and adult 
fibroblast cells to iPSCs which resembled ground-state mouse ES cells in growth properties, 
gene expression and signalling dependency. However, it was consistently observed that when 
the human cell culture deteriorated and became differentiated, it was always towards a 
GATA4 positive population despite the presence of 20% Knockout Serum Replacement, a 
Mek1 inhibitor (PD0325901), a GSK3 inhibitor (CHIR99021), comprising the original 2i 
inhibitors and  Leukemia inhibitory factor (LIF) referred to as KSR2iLIF (Wang et al., 2011b; 
Ying et al., 2008) (Figure 3.1A). Furthermore, subsequent unpublished experiments 
demonstrated that new human embryonic stem cells (hESCs) could not be established from 
pre-implantation human embryos using this medium. Therefore, I sought to stabilize the six-
factor reprogrammed human iPSCs by refining the KSR2iLIF medium. 
 
In the mouse embryo, inhibition of MEK (MAPK-ERK) signalling prevents formation of the 
putative hypoblast and expands the pluripotent epiblast compartment (Nichols et al., 2009). In 
humans, in contrast, it has been show that segregation of the hypoblast is not dependent on 
FGF signalling (Roode et al., 2012) suggesting that the Mek1 inhibitor, PD0325901 by itself 
would be insufficient to prevent differentiation. We speculated that if our 6 factor human 
iPSCs were similar to the human inner cell mass, perhaps, this differentiation bias was 
towards a lineage bearing resemblance to the human hypoblast. As the molecular mechanism 
of hypoblast segregation in the human embryo is unknown, a chemical screen approach was 
chosen. Rex1-GFP mouse embryonic stem cells (Guo et al., 2011) were chosen for the pilot 
screen as the experimental hypothesis was that a naïve media should allow maintenance of 




The screen was designed so as to identify potential substitutes for PD0325901 (Mek1 
inhibitor). A chemical library from the CGP at the Sanger Institute (kindly provided by Dr 
Ultan McDermott) was used for the screen. In total, 56 individual inhibitors were tested in 
their ability to maintain Rex1-GFP expression. Experimental strategy is shown in Figure 
3.1B.  It was found that multiple single and combined inhibitor sets could maintain Rex1-GFP 
expression in mouse ESCs with many known signalling pathways identified including 
inhibitors of MEK1/2, FGFR and TGFBR-1 (ALK5). The full list of chemicals tested in 
provided in the material methods section (Supplementary Table 1).  
 
A consistently identified pathway which could maintain Rex1-GFP expression in the presence 
or absence of GSK3 beta inhibition was inhibition of the Src-family kinases (SFKs). A recent 
publication has presented data supporting a model where calcineurin-NFAT signalling 
collaborates with Ras-Erk-AP-1 to activate Src which promotes the epithelial-mesenchymal 
transition (EMT) and subsequently initiates lineage specification in mouse ESCs (Li et al., 
2011). Moreover, it was demonstrated that SFK inhibition blocked segregation of the GATA4 
positive primitive endoderm. Based on these promising findings, we decided to further 
characterize mouse ESCs maintained in inhibitors of the SFKs to ensure that the key features 
of pluripotency were maintained prior to testing SFK inhibitors in six-factor human iPSCs.  
 
mCherry-expressing AB2.2 mouse ES cells maintained in CHIR99021 plus A-419259, a 
potent pyrrolopyrimidine inhibitor of the SFKs and Leukemia inhibitory factor (LIF) named 
CHAL media were injected to morula / early blastocysts to assess their ability to contribute to 
the developing inner cell mass (ICM), a fundamental characteristic of pluripotent cells. 
mCherry-expressing AB2.2 mouse ESCs were generated by transfecting them with a PB-
CAG-mCherry-PGK-Puro expression vector using Amaxa nucleofection according to the 
manufacturer’s protocol (see material methods section Chapter 2).  Following two rounds of 
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cell sorting, a homogenous mCherry positive cell line was generated. Serial FACS analysis 
revealed that the cells continued to stably express mCherry and no significant silencing was 
observed. Remarkably, we observed that in contrast to mouse ES cells cultured in serum/LIF 
or 2i/LIF media, the ES cells cultured in these inhibitors showed significant contribution in 
the region of the trophectoderm in addition to the expected ICM contribution (Figure 3.2).  
 
In an attempt to explain the apparent in vitro contribution to both embryonic and extra-
embryonic lineages, the published literature was reviewed specifically focussing on the role of 
Src inhibition in the first fate specification. Interestingly, it has been shown that the 
Calcineurin-NFAT pathway is essential for early lineage segregation as its inhibition at the 
eight-cell stage in mouse embryos arrests development at the morula blocking the first lineage 
segregation into the trophectoderm and the inner cell mass (Li et al., 2011).  
 
3.3 Hypothesis 
If this observation was correct that modulation of Src, a pre-implantation signalling pathway 
could confer some degree of expanded potential to conventional mouse embryonic stem cells, 
it was plausible to consider that in order to capture and maintain stem cells that have features 
of blastomeres, one possible approach is to modulate additional signalling pathways known to 














Genetic and developmental studies have implicated the conserved mitogen-activated protein 
kinases (MAPKs), Src, and the Hippo pathways in the segregation of the TE and ICM 
lineages and in the development of pre-implantation embryos (Abad et al., 2013; Li et al., 
2011; Lu et al., 2008; Maekawa et al., 2007; Maekawa et al., 2005; Natale et al., 2004; 
Nishioka et al., 2009; Saba-El-Leil et al., 2003; Strumpf et al., 2005).  
 
As previously described, inhibiting Src completely eliminates CDX2-expressing TE cells in 
the pre-implantation embryo (Li et al., 2011). In addition, FGF and Wnt signalling pathways 
are implicated in producing enough pluripotent cells in the embryo for successful 
implantation (Morris et al., 2012). Furthermore, important functional interactions of the Wnt 
and MAPK pathways with Yap, the key Hippo pathway downstream effector, have recently 
been uncovered (Kapoor et al., 2014; Shao et al., 2014). We therefore reasoned that 
modulating the kinases and pathways mentioned above would interfere with segregation of 




3.4.1 Media Development 
We chose to modulate the pathways that are causally involved in the earliest pre-implantation 
developmental stages in particular the first lineage segregation, e.g. MAPKs, Src, and Wnt. 
To target MAPKs, we used Mek1 inhibitor PD0325901, JNK Inhibitor VIII (for Jun N-
Terminal Kinase) and SB203580 (for p38). For Src family kinases (SFKs), A-419259, a 
potent pyrrolopyrimidine inhibitor of the SFKs, was chosen (Wilson et al., 2002). We also 
selected XAV939, which stabilizes AXIN1, the concentration-limiting component of the β-
catenin and Yap destruction complex (Azzolin et al., 2014; Huang et al., 2009). GSK3 
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inhibitor CHIR99021 was included to promote metabolic and biosynthetic processes (Doble 
and Woodgett, 2003). The Leukemia inhibitory factor (LIF) was also added, as it enhances 
ESC self-renewal and may promote the rare totipotent cells in mouse ES cell culture (Morgani 
et al., 2013). The base media contained DMEM/F12 (Invitrogen) and 20% KnockOut serum 
replacement (Invitrogen), see methods. Hereafter, this medium that contains all six inhibitors 
is called the EPSC Medium or EPSCM, which was used in all mouse and human EPSC 
experiments in this thesis.  
 
In collaboration with Dr Jian Yang PhD, Sanger Institute, mCherry-expressing AB2.2 mouse 
ESCs were then cultured in various combinations of inhibitors for at least 5 passages and then 
injected into eight-cell stage embryos for blastocyst development. Blastocysts were stained 
with antibodies against mCherry and CDX2 for co-staining. Adding A419259 or XAV939 to 
the KSR/2i/LIF (2i) medium substantially increased the expanded potential with ICM and TE 
contribution observed in 48% and 46% embryos respectively as compared to <7% in the 
KSR/2i/LIF control and 37% in Chir/ A419259/LIF (CHAL) media. Combined embryonic 
and extra-embryonic contribution was identified in 49% of embryos injected with cells 
cultured in the Chir/ A419259 / XAV939 and LIF without PD0325901. The addition of a 
JNKi and p38i to 2i media had moderate effects, with ICM and TE contribution in 15% and 
24% respectively.  Combined, these six inhibitors (EPSCM) produced the largest contribution 
with TE and ICM contribution observed at a frequency of 53%. (Figure 3.3). 
 
The conversion experiments were performed on two widely used ES cell lines, AB2.2 and 
E14Tg2a (Hooper et al., 1987; Ramirez-Solis et al., 1995). ESCs previously cultured in either 















and proliferated similarly to ESCs in M15 or 2i/LIF. We tested the plating efficiency of 
seeding a single Rex1-GFP ESCs (pre-cultured in 2i/LIF or M15) in either EPSCM or in their 
original media on SNL feeders. The numbers of GFP positive colonies formed in EPSCM or 
in 2i/LIF were comparable (Figure 3.4), indicating that EPSCM was permissive for mouse 
ESCs and did not select for a rare subpopulation of cells. We used ESCs cultured in EPSCM 
for at least three passages in the subsequent studies. We also investigated whether EPSCM 
was able to convert EpiSCs to EPSCs. EpiSCs are derived from early post-implantation 
embryos and are distinct from ESCs in culture properties, gene expression, pluripotency and 
epigenetic profiles. They are believed to exist at a primed pluripotent state (Brons et al., 2007; 
Nichols and Smith, 2009; Tesar et al., 2007). Unlike ESCs, EpiSCs rapidly succumbed or 
differentiated in EPSCM, indicating that conversion or reprogramming by EPSCM is only 
permissible in ESCs (data not included). 
 
3.4.2 Conventional mouse ESCs cultured in EPSCM contribute to the trophectoderm, and 
epiblast in blastocyst contribution assays. 
In order to state expanded potential, one must demonstrate contribution to the epiblast 
(OCT4+) and the trophectoderm (CDX2+) therefore, we repeated the contribution experiment 
in order to co-stain for mCherry and the above lineage markers. mCherry-expressing AB2.2 
mouse ESCs were injected into morulas which later developed into blastocysts in vitro. In 8 
of 17 (47.1%) embryos injected with EPSCM cultured cells, mCherry+ cells were found in 
both the ICM (OCT4+) and the TE (CDX2+),  respectively (Figure 3.5A - D) , whereas 2i/LIF 

















Interestingly, once EPSCs were returned to 2i/LIF for three passages, a much lower 
contribution to the TE was observed (Figure. 3.5B), indicating that EPSCM is necessary to 
maintain the expanded potential.   
The functions of these inhibitors on conferring the capacity for extra-embryonic contribution 
were further confirmed by the removal of individual inhibitors from EPSCM. Removal of 
XAV939 or A419259 individually from EPSCM reduced the observed rate of ICM and TE 
contribution to 36% and 31% respectively (Figure 3.3). The reduction in observed extra-
embryonic contribution following the removal of CHIR99021 was less dramatic at 44% 
compared to 53% in the EPSCM control (Figure 3.3). However, CHIR99021 was essential in 
maintaining the integrity of the culture. AB2.2 ESCs were cultured in EPSCM or EPSCM 
minus CHIR99021 for five passages and one thousand cells from each culture condition were 
re-plated to form single colonies. Removing CHIR99021 substantially decreased AP+ colony 
numbers (Figure 3.6). 
 
3.4.3 In vitro trophoblast differentiation of EPSCM cultured mouse ESCs 
Cdx2, Eomes, Gata3 and Elf5 have been shown to promote or regulate the transcriptional 
network in TE development (Chen et al., 2010). Rapid up-regulation of these genes indicates 
the commitment of embryonic cells to trophoblast differentiation. After 2 days in Trophoblast 
stem cell (TSC) medium, expression of Cdx2 and Eomes was increased 10-20-fold, indicating 
an increased propensity of these cells toward trophoblast differentiation (Figure 3.7A). By 
contrast, no obvious Cdx2 or Eomes expression changes were detected in the control ESCs 
(serum or 2i/LIF) under the same differentiation conditions (Figure 3.7A), even though 
2i/LIF ESCs in general have a hypomethylated genome (Leitch et al., 2013), indicating that 
DNA demethylation alone is not sufficient for the expanded potential. Following a published 
protocol (Abad et al., 2013), those cells from EPSCs were differentiated into PLACENTAL 
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LACTOGEN 1 (PL-1) positive trophoblast-like cells following the removal of FGF4 (Figure 
3.7B). Trophoblast stem cells were differentiated in parallel as a control. 
 
3.4.4 In vitro characterization of converted mouse EPSCs 
3.4.4.1 Pluripotency gene expression 
Zfp42 (Rex1) and Pou5f1 (Oct4) are pluripotency genes (Toyooka et al., 2008). Rex1-GFP or 
Oct4-GFP reporter ESCs (Guo et al., 2011; Silva et al., 2008) cultured in EPSCM retained 
robust GFP expression as seen using microscopy and additionally confirmed by FACS 
analysis (Figure 3.8). Quantitative PCR was performed which demonstrated that mouse ESCs 
cultured in EPSCM expressed similar levels of pluripotency genes, and lineage-specific 
genes, including T (Brachyury), Gata6, Sox1, Cdx2, Eomes and Elf5, as in standard ESCs 
(Figure 3.9A and 3.9B).  
 
3.4.4.2 Oct4 Enhancer Activity in EPSCs 
The distal enhancer of the Oct4 locus is specifically active in naïve ESCs, whereas the 
proximal enhancer dominates in epiblast stem cells (EpiSCs) (Bao et al., 2009; Yeom et al., 
1996). Functionally, activity of the distal enhancer of the Oct4 locus is critical in maintaining 
ES cell identity. Transcription-activator-like effectors (TALEs) activators targeting the distal 
enhancer of the Oct4 locus induces epigenetic change, reactivates endogenous expression and 
can substitute for exogenous Oct4 in the reprogramming of mouse embryonic fibroblast cells 
(MEFs) to induced pluripotent stem cells (iPSCs). Furthermore, repression of the Oct4 distal 
enhancer induces rapid differentiation of ES cells (Gao et al., 2013). Oct4 enhancer activity in 






















constructs schematically represented in Figure 3.10A. Similar to standard ESCs, ESCs in 
EPSCM preferentially used the distal enhancer (Figure 3.10B).  
 
3.4.4.3 Somatic differentiation of EPSCs in vitro and in vivo 
Mouse ESCs were cultured in EPSCM for over 30 passages and were able to differentiate in 
vitro into cell types of all three somatic germ layers (Figure 3.11A). Beta 3-Tubulin 
expressing neurons, α-smooth muscle actin (SMA) muscle cells and Gata4 endodermal 
derivatives were the three in vitro representative cells types of ectoderm, mesoderm and 
endoderm differentiation respectively. Following gene targeting of a GFP cassette to the 
Rosa26 locus with approximately 60% efficiency (thanks to Dr Wei Wang, Sanger Institute) 
(Dupuy et al., 2009) these cells were injected into blastocysts. The targeted cells contributed 
efficiently to live chimeras with no obvious abnormalities at 10 months (Figure 3.11B). 
Furthermore, donor cells contributed to the germline as confirmed by PCR based detection of 
the Rex1-GFP allele from the injected EPSCM-cultured ESCs (Figure 3.11C). ESCs cultured 
in EPSCM therefore retained canonical pluripotency features.  
 
3.4.5 Western blot confirms inhibition of targeted kinase activity in EPSCM. 
We next confirmed inhibition of the respective kinase activities in EPSCM (Figure 3.12A). 
When compared to the KSR2iLIF control, the ERK, JNK, p38 and Src pathways were 
appropriately inhibited with reduction in their overall level of protein phosphorylation. 
EPSCM contains XAV939, which stabilizes AXIN1 by inhibiting its ubiquitination (Huang et 
al., 2009). EPSCs had considerably elevated levels of AXIN1 compared with controls (Figure 















catenin in both the cytoplasm and nuclei (Figure 3.12B) and decreased active β-catenin in the 
nucleus (Figure 3.12B). The TopFlash luciferase assay confirmed reduced β-catenin-
LEF/TCF activity (Figure 3.12C).  
 
The signalling dependence of EPSCM-cultured ESCs was assessed by plating one hundred 
ESCs cultured in EPSCM, 2i/LIF or M15 in the presence of inhibitors targeting the JAK2, 
FGFR, TGFBR or ALK5 pathways. Alkaline phosphatase (AP) positive colony number was 
scored after 10 days. Mouse ESCs in EPSCM were dependent on the Jak/Stat pathway, as a 
Jak inhibitor substantially reduced the number of AP positive colonies from these cells 
(Figure 3.13A). Adding LIF increased phosphorylation of STAT3 in a concentration 
dependent fashion (Figure 3.13B) and up-regulated the expression of Jak/Stat downstream 
genes, Socs3 and Egr1 (Figure 3.13C). By contrast, ESCs cultured in EPSCM did not appear 
to be sensitive to FGFR or TGFBR inhibitors, similar to 2i/LIF ESCs (Figure 3.13A) (Ying et 
al., 2008).  
 
3.4.6 Establishing de novo EPSC lines from pre-implantation embryos. 
3.4.6.1 Eight-cell stage embryo culture and line derivation 
I next explored deriving stable cell lines from pre-implantation embryos using EPSCM. I 
cultured eight-cell stage embryos in M15, 2i/LIF or EPSCM either on feeder cells or feeder-
free (Figure 3.14A). On day two, 19 of 42 (45.2%) embryos in M15 and 17 of 45 (37.7%) in 
feeder-free EPSCM progressed to blastocysts. In 2i/LIF, only 5 of 54 (9.3%) embryos reached 
the blastocyst stage, but these embryos died soon after. All blastocysts in M15 hatched by day 
5. In striking contrast, the blastocoel in many blastocysts in EPSCM was obliterated and filled 














This structure was described as a “filled” blastocyst (Figure 3.14A and Figure 3.14B). All 
the blastocysts in EPSCM developed into “filled” blastocysts by day 6, and eventually almost 
all attached and hatched. Primary outgrowths appeared after day 10. Stable cell lines were 
established from eight-cell stage embryos in EPSCM with an efficiency of approximately 
20% under feeder-free condition, and up to 100% on SNL feeder cells (Figure 3.14A). 
 
3.4.6.2 EPSCM induces a complex embryo reprogramming process involving cell death 
and proliferation accompanied by the disappearance of the TE and ICM cells 
To monitor the dynamic changes in pre-implantation embryos in EPSCM, immunostaining 
with antibodies against OCT4 and CDX2 was performed. From the four-cell stage to the 
blastocyst, the expression of OCT4 and CDX2 in embryos in EPSCM was similar to that in 
embryos cultured in M15, where OCT4 protein expression was first detected in 4C and CDX2 
protein in 8C embryos (Figure 3.15A and 3.15B) (Dietrich and Hiiragi, 2007; Ralston and 
Rossant, 2008). OCT4 was later restricted to the ICM, and CDX2 to the TE. Interestingly, we 
observed a gradual loss of both OCT4 positive and CDX2 positive cells in the “filled” 
blastocysts (Figure 3.15A). Eventually, the remaining cells in the embryos had large nuclei, 
but most expressed neither OCT4 nor CDX2 in the nucleus. Several days later, a population 
of OCT4 positive cells with small nuclei re-emerged at the periphery of the “filled” 
blastocysts. Once the embryos hatched, the cells in the early outgrowths expressed OCT4 
and/or CDX2 but eventually became uniformly OCT4 positive and CDX2 negative (Figure 
3.15A).  
 
In an attempt to understand the cause of the loss of OCT4 positive and CDX2 positive cells in 















against Ki67 and cleaved Caspase 3 respectively. Many cells in embryos cultured in EPSCM 
were Ki67 positive (Figure 3.16A), indicating that they were still proliferating. However, 
apoptotic cells as detected by Caspase 3 antibody were clearly observed (Figure 3.16B), 
particularly between the time when the OCT4 positive / CDX2 positive cells disappeared and 
when the OCT4 positive cells re-emerged. Therefore, the small OCT4 positive cells did not 
appear to directly arise from the blockade of the initial TE and ICM segregation. 
Nevertheless, EPSCM induced a complex reprogramming process involving cell death and 
proliferation accompanied by the disappearance of the TE and ICM cells, which warrants 
future investigation.  
 
3.4.6.3 Derivation of new lines from single blastomeres using EPSCM 
Single blastomeres from 8C embryos were plated into a well of a 96-well plate with SNL 
feeders (Figure 3.17A). In the following days, in 9 of 32 (28.1%) wells with EPSCM, 
blastomeres proliferated and by day 12 formed large outgrowths consisting predominantly of 
OCT4 positive and CDX2 negative cells (Figure 3.17A and Figure 3.17B), whereas the 
other blastomeres did not form obvious outgrowths. By contrast, no outgrowths were obtained 
in either M15 (n=32) or 2i/LIF (n=32) on feeders (Figure 3.17C), or when blastomeres were 
cultured in feeder-free conditions in any medium (n=96).  
 
3.4.6.4 Characterization of newly derived EPSC lines. 
Two lines derived de novo from pre-implantation embryos in EPSCM: DR10 and DR25-
EPSCs were chosen for further characterization. Two pre-implantation embryo-derived 2i/LIF 
ESC lines (DR4 and DR9) were included in the analysis. DR10-EPSCs and DR25-EPSCs 










and 3.18B), had a normal karyotype (Figure 3.19), were able to form mature teratomas 
(Figure 3.20A) and contributed to both somatic (Figure 3.20B) and germline lineages 
(Figure 3.20C) in chimeras. In keeping with best practice and satisfying the principles of the 
3Rs strategy (reduce, refine, replace), germline contribution was determined by assessing 
contribution of mCherry positive EPSCs to the 14.5dpc gonad relative to the control 2i/LIF 
ESCs (Figure 3.20C). 
 
Importantly, once injected into morulas, DR10-EPSCs contributed to both the inner cell mass 
and the mural trophectoderm in the formed blastocysts (Figure 3.21A and 3.21B). We also 
asked whether we could obtain EPSCs directly from somatic cells (MEFs) by reprogramming 
them to iPS cells. We took advantage of the efficient six-factor reprogramming technology 
(Wang et al., 2011b; Yang et al., 2015) and cultured primary iPS cell colonies directly in 
EPSCM. Established iPS cells cultured in EPSCM for over 5 passages expressed levels of 
core pluripotency factors comparable to those of ESCs (Figure 3.18A and 3.18B), and also 
contributed to both the ICM and TE in the blastocysts developed from injected morulas 
(Figure 3.21A and 3.21B). 
 
3.5    Discussion 
 
In this chapter I have described the fortuitous sequence of events where a chemical screen 
designed to identify PD0325901 substitutes for the maintenance of naïve like human iPSCs 
identified the SFK pathway, inhibition of which conferred expanded potential to conventional 
mouse embryonic stem cells.  With a knowledge of the role of Src in pre-implantation 
development based on published data, we speculated that inhibition of additional pathways 





























cell line that possessed expanded potential in its ability to contribute to both the embryonic 
and extra-embryonic lineages in the developing mouse embryo. This resulted in the 
formulation of a novel cell culture medium, EPSCM, which enabled the conversion of 
conventional mouse ESCs to expanded potential stem cells (EPSCs), the derivation of new 
lines with expanded potential from pre-implantation embryos and from single blastomeres of 
eight-cell stage embryos. Mouse iPSC lines could also be maintained in EPSCM and were 
similarly conferred with expanded differentiation potential.  
 
EPSCM contained six inhibitors targeting the MAP kinase pathway, Src, and Wnt. The 
MAPK and SFK pathways have clearly established roles in pre-implantation development 
with genetic studies implicating these pathways in the segregation of the trophectoderm and 
inner cells mass (Abell et al., 2009; Li et al., 2011; Lu et al., 2008; Maekawa et al., 2007; 
Maekawa et al., 2005; Natale et al., 2004; Nishioka et al., 2009; Saba-El-Leil et al., 2003; 
Strumpf et al., 2005). The microinjection of mCherry-expressing AB2.2 mouse ESCs cultured 
in the presence or absence of MAPK (ERK, p38 and JNK) and Src inhibition into eight-cell 
stage embryos for blastocyst development confirmed the individual and additive role of 
inhibiting these pathways and conferring expanded potential. Correct inhibition of the 
downstream effectors of the MAPK and Src pathway was confirmed by Western blot where 
the phosphorylated proteins of p38, JNK, ERK and Src were all reduced relative to the 
KSR2iL control.  
 
Modulation of Wnt signalling appears to be more complicated. EPSCM contains XAV939, 
which stabilizes AXIN1 by inhibiting its ubiquitination (Huang et al., 2009). EPSCs had 
considerably elevated levels of AXIN1 compared with the control which caused accumulation 
of phosphorylated β-catenin in both the cytoplasm and nuclei and decreased active β-catenin 
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in the nucleus. The TopFlash luciferase assay confirmed the reduced β-catenin-LEF/TCF 
activity.  Functionally, Wnt signalling appears to be a balancing act in EPSCs. The addition of 
a WNT inhibitor, XAV939 confers expanded potential, its removal causes a significant loss of 
expanded potential. One may then consider that CHIR99021, a GSK3B inhibitor and 
stimulant of canonical WNT signalling therefore would not be required. However, the 
removal of CHIR99021 causes a modest reduction in expanded potential but more 
significantly its removal causes a deterioration in the robustness of the culture with 
substantially decreased AP positive colony numbers. 
 
In pre-implantation development, Wnt and FGF signalling pathways are implicated in 
producing enough pluripotent cells in the embryo for successful implantation (Morris et al., 
2012). This may explain in part the reduction in colony number following the removal of 
CHIR99021. In ground-state embryonic stem cells, part of the self-renewal network relies on 
the presence of canonical WNT signalling. In EPSCs, despite the presence of GSK3B 
inhibition, the stabilisation of AXIN1 results in the accumulation of phosphorylated β-catenin 
in both the cytoplasm and nuclei and decreased active β-catenin in the nucleus. Therefore, the 
cells cannot be using the canonical WNT signalling network. Although speculative to 
consider, perhaps the pre-implantation embryo is reliant on non-canonical WNT signalling. 
One study in bovine embryos has suggested that this may be the case however, further studies 
are required (Denicol et al., 2013). 
 
Furthermore, important functional interactions of the Wnt and MAPK pathways with YAP, 
the key Hippo pathway downstream effector, have recently been uncovered (Kapoor et al., 
2014; Shao et al., 2014). Nuclear translocation of YAP and interaction with TEAD4 is 
instrumental in initiating trophectoderm commitment and the first fate decision. Although 
provisional data on EPSCs did not find a difference in total or phosphorylated YAP levels in 
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EPSCs, a recent publication has shown that XAV939 targets YAP independent of YAP 
phosphorylation (Wang et al., 2015). As the authors highlighted, these findings are consistent 
with previous studies showing that AMOT family proteins suppressed YAP activity by 
translocating YAP from nucleus into cytoplasm through direct protein-protein interaction but 
independent of YAP phosphorylation status (Chan et al., 2011; Hirate et al., 2013; Hirate and 
Sasaki, 2014; Wang et al., 2011a; Zhao et al., 2011). Further experiments are required to 
precisely elucidate the role of WNT in EPSCs. 
 
A recent challenge to our understanding of ground-state pluripotency was the controversial 
description of the presence of 2C-like cells and HEX positive subpopulations in standard ESC 
culture conditions (Macfarlan et al., 2012; Morgani et al., 2013). These subpopulations were 
shown to possess expanded potential being able to contribute to both embryonic and extra-
embryonic lineages. However, these subpopulations are rare and only existed transiently. In 
light of these published findings, we considered, what is the origin of EPSCs? Are EPSCs a 
subpopulation of conventional ESC cultures?  Single cell plating of mouse ESCs in EPSCM 
suggested that EPSCM was permissive for ESCs and did not select for any rare subpopulation 
of cells. However, EPSCs could not be derived from mouse epistem cells. Unlike ESCs, 
EpiSCs rapidly succumbed or differentiated in EPSCM, indicating that conversion or 
reprogramming by EPSCM is only permissible in ESCs. Intriguingly, derivation of EPSCs 
from embryos reveals the transient loss of OCT4 and CDX2 expression in the “filled” 
blastocysts. This transient “blank” state bears certain similarities with the 2C-like ESCs 
(Macfarlan et al., 2012), where OCT4 protein expression is absent. This phenomenon could 
be due to global translational repression by Eif1a as in 2C embryos (Hung et al., 2013). The 
fact that this “blank” state is only transient and OCT4 expression is reactivated in the cellular 
outgrowths indicates that eventual activation of the canonical pluripotency network is 
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necessary for stable in vitro adaptation and propagation of EPSCs. Future single-cell 
experiments are warranted to provide deeper characterization of these molecular events. 
 
Despite the presence of expanded potential, EPSCs also show activation of the ground-state 
embryonic stem cell pluripotency network expressing similar levels of pluripotency genes and 
lineage-specific genes as standard ESCs. EPSCs preferentially use the Oct4 distal enhancer, 
which is specifically active in naïve ESCs. Moreover, EPSCs were genetically stable and 
retained the ability to robustly differentiate into the three somatic germ layers in vitro and in 
vivo and could contribute to the germline. The signalling dependence of conventional ESCs 
and EPSCs was similar in terms of FGFR and TGFBR inhibition, to which both were 
insensitive (Ying et al., 2008). A difference between the two cell states was identified with 
regards to dependence on the Jak/Stat pathway. Mouse ESCs in EPSCM were dependent on 
the Jak/Stat pathway, as a Jak inhibitor substantially reduced the number of alkaline 
phosphatase positive colonies from these cells and adding LIF increased phosphorylation of 
STAT3 and up-regulated the expression of Jak/Stat downstream genes. By contrast, 
conventional ESCs cultured in 2i/LIF were insensitive to Jak inhibition. This finding may add 
further evidence for the maintenance of a distinct stem cell state as  a recent publication has 
suggested that the Leukemia inhibitory factor (LIF) and STAT3 activation was necessary to 
promote the self-renewal and expansion of the rare totipotent HEX positive subpopulation in 
mouse ES cell culture (Morgani et al., 2013).  
 
EPSCs demonstrated the capacity for trophoblast specification in vitro and consistent 
contribution to the embryonic and extra-embryonic lineages in blastocyst contribution assays. 
However, multiple in vitro differentiation attempts failed to produce a self-renewing EPSC 
derived trophoblast stem cell. Speculatively, this may be explained by a lack of knowledge of 
the cues that are necessary for trophoblast induction. Published data has demonstrated the role 
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of FGF4/FGFR2 interaction in mediating trophoblast stem cell renewal but FGF is not 
required for initial trophectoderm specification (Arman et al., 1998; Feldman et al., 1995).  
Further experiments are necessary to precisely define the signalling requirements necessary 
for efficient trophoblast induction. 
 
In conclusion, I have described herein the development of a novel chemically defined medium 
which permitted the establishment of stable embryonic stem cell lines that possess expanded 
fate potential in vitro. In Chapter 4, I proceed to evaluate the capacity of these cells to 





CHAPTER 4   
4 EPSCS DEMONSTRATE EXPANDED FATE 
POTENTIAL IN VIVO 
 
4.1  Summary 
 
In this chapter, I demonstrate that EPSCs can contribute to the embryo proper, placental 
trophoblasts and yolk sac endoderm in chimeras. To formally exclude the presence of 
unipotent subpopulations within EPSCM, I proceeded to generate chimeras from injection of 
a single EPSC. Generated single cell chimeras demonstrated extensive contribution to all 
lineages in the developing organism providing additional evidence that EPSCM permits 
maintenance of a homogenous stem cell population that possesses expanded fate potential in 











4.2 Introduction  
Recent reports have described the existence of a rare subpopulation of cells within ground 
state culture conditions that possess totipotent-like properties (Macfarlan et al., 2012; 
Morgani et al., 2013). This claim was supported by the demonstration of inner cell mass 
(ICM) and trophectoderm (TE) contribution in blastocyst stage embryos. Additionally, these 
cells had expanded fate potential in late gestation chimeric embryos with contribution 
identified in the embryo proper, yolk sac and placenta.  
 
Currently, there is inconsistency in the choice of assays that are used to claim extra-
embryonic contribution. Published studies may define expanded potential based on apparent 
contribution on whole mount fluorescence microscopy, DNA genotyping of extra-embryonic 
membranes or immunostaining. Exceptional claims require exceptional data in support and 
multiple independent assays are often needed to confirm or refute such findings.  
 
The presence of donor cells in the vicinity of the placenta or yolk sac does not equal expanded 
potential as both of these organs have cellular descendants from the embryonic and extra-
embryonic lineages. An understanding of this cellular composition is a necessary prelude to 
designing any experiments assessing in vivo expanded fate potential. 
 
4.2.1 Placenta 
The placenta is located at the maternal-fetal interface and has many critical functions during 
pregnancy including gas, nutrient and waste exchange between the fetus and mother, 
production of hormones to support pregnancy and is involved in immunoprotection of the 
developing fetus. Descendants of the trophoblast lineage occupy the majority of the placenta 
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but there is a fundamental contribution from the embryonic mesoderm which gives rise to the 
placental vasculature and umbilical cord. 
 
Placental development begins at the first cell fate specification which gives rise to the inner 
cell mass and trophectoderm (TE). Schematic representation of murine placental development 
is shown in Figure 4.1A. First, the trophectoderm surrounding the blastocyst cavity which is 
the mural TE differentiates almost immediately to form the primary giant cells. Giant cells are 
formed by endoreplication which involves multiple rounds of DNA replication but no 
intervening mitosis which results in cellular polyploidy. At the embryonic pole of the 
blastocyst, the polar trophectoderm is identified which will give rise to the extra-embryonic 
ectoderm (ExEc) and ectoplacental cone. Trophoblast stem cells can be derived from the polar 
trophectoderm and ExEc in FGF4 containing media as described previously (Tanaka et al., 
1998). 
 
As development progresses, the extra-embryonic ectoderm will form the chorionic epithelium 
which is an extra-embryonic membrane lined by mesothelial cells. Simultaneously, at the 
posterior end of the embryo, a focus of embryonic mesoderm will expand to form the allantois 
(Rossant and Cross, 2001). At E8.5 the chorion and allantois come in close proximity which 
is termed chorioallantoic fusion. This event is critical for a pregnancy to progress 
uneventfully to term. Through the allantois, the fetal vasculature migrates into the placenta 
and the blood vessels along with the surrounding trophoblast undergo extensive branching to 
form the labyrinth which will be the future site of exchange between the maternal and fetal 
vasculature. The labyrinth is supported by spongiotrophoblast, derived from the ectoplacental 
cone (Rossant and Cross, 2001). The labyrinthine trophoblast differentiates to produce two 









the surrounding fetal blood vessels and an inner layer of mononuclear trophoblast which will 
surround the maternal vascular sinusoids (Figure 4.1B).  
 
4.2.2 Yolk Sac 
Yolk sac formation begins at the second fate specification where the ICM segregates into the 
epiblast and hypoblast, the latter of which will give rise to the primitive endoderm and extra-
embryonic portions of the developing yolk sac. By E5.0 the primitive endoderm will have 
segregated into the visceral and parietal endodermal portions of the yolk sac (Enders et al., 
1978). Parietal endoderm grows on the inner surface of the primary trophoblast giant cell 
layer and secretes large amounts of basement membrane proteins which in combination with 
the giant cell layer form Reichert’s membrane. The primitive endoderm in contact with the 
epiblast becomes the visceral endoderm which plays an important role in anterior patterning 
of the developing fetus (Beddington and Robertson, 1999). By E8.0 the epiblast derived extra-
embryonic mesoderm in combination with the visceral endoderm will form the definitive yolk 
sac. The visceral endoderm is also thought to secrete proteins including vascular endothelial 
growth factor and Indian Hedgehog which directs haematopoiesis in the overlying extra-
embryonic mesoderm (Damert et al., 2002; Dyer et al., 2001). 
 
4.3 Aims of this Chapter 
The primary experimental aim of this chapter was to evaluate for in vivo embryonic and extra-
embryonic contribution from mouse EPSCs.  If successful, the secondary aim was to 
demonstrate expanded fate potential in vivo from injection of a single EPSC which would 
refute the presence of unipotent populations within EPSCM and provide additional evidence 
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to support a claim that EPSCM permits establishment and maintenance of a homogenous 
population of cells that possess expanded fate potential. 
 
4.4 Results 
4.4.1 EPSCs contribute to the embryo proper and placental trophoblasts in chimeras. 
I proceeded to demonstrate the in vivo differentiation potency of EPSCs by injecting mCherry 
positive EPSCs (DR10, DR25, AB2.2) and the control cells (AB2.2 in 2i/LIF or in M15) into 
pre-implantation embryos.  EPSCs (DR10 and DR25) were microinjected into morula stage 
embryos to generate chimeras which would then be assessed for their contribution to the 
embryonic and extra-embryonic lineage, particularly the placental cells and yolk sac. In the 
14.5dpc chimera embryos, whole-mount fluorescence examination revealed extensive 
mCherry positive donor cell contribution to the embryo proper and the extra-embryonic 
tissues (20/32 (63%) embryos for DR10-EPSCs, and 14/18 (78%) for DR25-EPSCs) (Figure 
4.2). Flow cytometry analysis of dissociated cells from the embryos and the placentas 
confirmed mCherry positive cells in both lineages (Figure 4.3).  
 
To independently confirm this result, I repeated the experiment at another transgenic facility 
(Cancer Research UK-Cambridge Institute), where 6-8 cells were injected into eight-cell host 
embryos for chimera production. mCherry positive chimeras (14.5dpc) were found in 13/39 
(33%) embryos for DR10-EPSCs, 9/23 (39%) for DR25-EPSCs, 21/38 (55%) for AB2.2-
EPSCs and 16/28 (57%) for AB2.2-2i/LIF ESCs (Figure 4.4). DNA genotyping again 
confirmed the contribution of EPSCs in the embryo proper, in the yolk sac and in a number of 
placentas (Figure 4.5A). Flow cytometry analysis of dissociated single placenta, brain and 

























4.5B). By contrast, both DNA genotyping and FACS failed to detect obvious descendants of 
AB2.2-2i/LIF ESCs in the placenta (Fig. 4.5A and 4.5B).  
 
The placenta contains derivatives of both the extra-embryonic and embryonic lineages 
therefore; it is essential to discriminate to which cell types the donor cells are contributing. 
Two approaches were taken to answer this question. First, the mCherry positive placental 
cells were sorted for gene expression analysis (Figure 4.6A and 4.6B). The genes chosen for 
analysis represented multiple cellular subsets within the mouse placenta including the 
trophoblast stem cell niche (Cdx2, Eomes, Elf5, Fgfr), extraembryonic ectoderm (Furin and 
Spc4), ectoplacental cone / spongiotrophoblast (Mash2 / Ascl2), synctiotrophoblast (Gcm1) 
and trophoblast giant cells (Hand1 and Pl1). Excitingly, the EPSC donor cells expressed 
comparable levels of trophoblast genes, such as Ascl2 (Mash2), Gcm1, Pl-1, and Hand1, as 
the mCherry negative placental cells (Hemberger et al., 2010) (Figure 4.6B). By contrast, 
very few mCherry positive placental cells were found in the chimeras of AB2.2-2i/LIF ESCs, 
and we were unable to recover enough mCherry positive placental cells for qRT-PCR (Figure 
4.6A).  
 
Secondly, to further establish the identity of the mCherry positive placenta cells from EPSC 
chimeras,   these cells were stained with DAPI for DNA content analysis. By flow cytometry, 
trophoblasts could be detected as 2N, 4N, 8N and so on due to endoreplication and cell fusion 
during placenta development (El-Hashash et al., 2010). mCherry positive 8N cells were 
unambiguously detected in the EPSC chimera placenta cells, similar to the flow pattern in 
mCherry negative placental cells (Figure 4.7). At the cellular level, immunostaining of 
placental sections identified mCherry positive multinucleated trophoblasts in EPSC chimeras, 



























4.4.2 EPSCs contribute to the yolk sac in chimeras 
I next sought to examine EPSC contribution to the second extra-embryonic lineage, the 
primitive endoderm in the fetal yolk sac. Similar to the placenta, the yolk sac contains cell 
types which are derived from the embryonic (extra-embryonic mesoderm) and extra-
embryonic lineage (extra-embryonic endoderm). Demonstration of contribution to both 
lineages would be required in order to support a claim of expanded fate potential in EPSCs.  
 
In the 14.5dpc yolk sac of chimeras, cells from EPSCs could clearly be found in both the 
extra-embryonic endoderm layer and the extra-embryonic mesoderm cells (endothelial cells 
and mesothelial cells) (Figure 4.9), whereas ESCs, as expected, only contributed to extra-
embryonic mesoderm cells (Nagy., 1990). Therefore, EPSCs have developmental potential to 
the embryo proper and to all extra-embryonic lineages. 
 
4.4.3 A single EPSC demonstrates expanded fate potential in chimeras 
It was still possible that bulk injection of EPSCs produced contribution in the embryonic and 
extra-embryonic lineages due to the presence of unipotent subpopulations within the culture. 
For example, the culture may have possessed TS, XEN and ES-like cells which contribute to 
the placenta, yolk sac and embryo proper respectively in chimeras. This was felt to be 
unlikely, but in order to formally exclude this possibility and to conclusively demonstrate the 
potency of EPSCs, single-cell injection in eight-cell stage embryos was performed. To this 
end, each eight-cell stage host embryo was injected with a single EPSC (DR10, DR25 and 
AB2.2) or with a control ESC (AB2.2-2i/LIF) for chimera production. Embryos were 
harvested at 14.5dpc. Under the fluorescence microscope, mCherry positive cell contribution 
was found in 7 out of 85 (8%) embryos for DR10 cells, 8 of 77 (10.4%) for DR25 cells, 7 of 
51 (13.7%) for AB2.2-EPSCs, and 10 of 82 (12.2%) for AB2.2-2i/LIF ESCs (Figure. 4.10). 
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DNA genotyping and flow cytometry analysis of mCherry positive chimeras showed EPSC 
descendants in the embryo proper, the yolk sac and the placenta (Figure 4.11A and 4.11B). 
FACS purified mCherry positive placental cells from EPSC chimeras (Figure 4.12) were 
analysed for gene expression. Again, trophoblast lineage markers were clearly detected in 
these cells by qRT-PCR, comparable to the host mCherry negative placenta cells (Figure 
4.12). Furthermore, flow cytometry analysis of the mCherry positive placental cells detected 
8N trophoblasts, similar to the host mCherry negative placental cells (Figure 4.13). In a 
couple of embryos, mCherry positive EPSCs contributed up to 40% of the placental cells by 
DNA genotyping. The embryos were morphologically normal, suggesting that placental cells 
from EPSCs were likely functional for normal embryo development, which warrants future 
investigation. In contrast, AB2.2-ESCs cultured in 2i/LIF contributed poorly to the embryo 
proper and little to the placenta in chimeras, as revealed by genotyping. FACS analysis failed 
to detect enough mCherry positive placental cells for sorting or for 8N trophoblast analysis in 
these chimeras. Single AB2.2 cells cultured in M15 medium were also injected into 8C host 
embryos but no chimeras were recovered (0/18). This result reflects the fact that in practice, 
efficient chimera production usually requires injecting 6-8 standard ESCs into an eight-cell 
stage host embryo.  
 
4.5 Discussion 
In this chapter I have demonstrated that consistent with the in vitro observations in Chapter 3, 
EPSCM permits maintenance in vitro of a stem cell state that can contribute to the embryonic 













































Multiple independent assays were performed in an attempt to prove bona fide contribution in 
the placenta and yolk sac. In line with previous publications I began by presenting whole 
mount fluorescent microscopy data showing EPSC contribution in the embryo proper and 
extra-embryonic tissues with additional experimental support from tissue genotyping and 
FACS sorting of the respective tissues. However, as previously discussed, these methods can 
by themselves lead to erroneous conclusions due to normal embryonic and extra-embryonic 
contribution in the placenta and yolk sac.  
 
In the placenta, many terminally differentiated trophoblast cells undergo endoreplication and 
produce giant cells. This cellular descendant has no contribution from the epiblast being 
entirely extra-embryonic in origin. FACS sorting of the wild type placenta and mCherry 
negative placental cells revealed a subset of cells that were polypoid (>8N) consistent with the 
presence of trophoblast giant cells or syncytiotrophoblast. The mCherry positive fraction in 
chimeric placenta generated from EPSCs was found to contain polypoid cells indicating the 
presence of giant cells / syncytiotrophoblast and therefore definitive extra-embryonic 
contribution. 
 
In order to gain a surrogate pan-placenta indication of cell type contribution in the placenta, 
the mCherry positive and negative fractions were sorted and gene expression analysis was 
performed. The genes chosen for analysis represented multiple cellular subsets within the 
mouse placenta. Both cellular fractions expressed comparable levels of these genes indirectly 
suggesting unbiased trophoblast EPSC differentiation.  Further support for the above claim 
was provided by assessing the anatomical localisation of contribution by 
immunohistochemistry. The labyrinthine trophoblast was clearly identified and donor cells 
were seen to contribute to the layers of syncytiotrophoblast lining the maternal vascular 




Similarly, in the yolk sac, EPSC contribution was identified at the cellular level in both the 
extra-embryonic endoderm which is derived from the extra-embryonic primitive endoderm 
and the extra-embryonic mesoderm, an epiblast derivative. In stark contrast, 2i/LIF ESCs, as 
expected demonstrated contribution to the extra-embryonic mesoderm only. 
 
Although the above experiments provide multiple independent sources of evidence to support 
extra-embryonic contribution in the placenta and yolk sac, additional experiments including 
single cell transcriptional profiling and co-staining of donor cells in the placenta and yolk sac 
with antibodies against tissue specific antigens are needed to further support this claim.  
 
An additional unresolved question from the placental contribution experiments is whether 
EPSC can produce functional trophoblast. The experiments described above show integration 
and expression of key placental related genes but could these donor cells support unaided, a 
pregnancy to term? This is a difficult question to answer as in chimeric assays; the donor cell 
contribution is never 100%. In an attempt to solve this problem, future experiments are being 
designed to evaluate the capacity of EPSCs to rescue placentation in parthenogenetic mouse 
embryos. Parthenogenetic embryos die by mid gestation due to placental failure. This is 
thought to be secondary to loss of the normal imprinting pattern of the paternal genome which 
is required for the normal development of the extra-embryonic membranes and trophoblast 
(Surani et al., 1984). A second perhaps more straight forward future experiment to test 
whether EPSCs can produce functional trophoblast in SOCS3 deficient mice. Suppressor of 
cytokine signalling 3 (SOCS3) is a negative regulator of LIF mediated trophoblast 
differentiation in the embryo. The SOCS3 mutation is embryonically lethal at E12.5 due to 
disrupted placentation (Roberts et al., 2001; Takahashi et al., 2006). This phenotype can be 
rescued by tetraploid complementation assays or more intriguingly by the injection of mouse 
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trophoblast stem cells (Takahashi et al., 2003; Takahashi et al., 2006). Therefore, based on the 
experimental data presented thus far, we hypothesise that EPSCs should be able to rescue 
placentation in SOCS3 deficient embryos.  
 
Claims of totipotency require demonstration that a single cell can form an entire organism. 
Plenipotency on the other hand requires that an individual cell can contribute to all cell types 
in the developing organism (Condic, 2014). Following injection of a single EPSC to the eight-
cell stage embryo, extensive donor cell contribution was identified in both the embryonic and 
extra-embryonic lineages using the assays described above. Furthermore, when EPSC 
contribution was observed, it was always in both lineages providing strong evidence that 
EPSCM maintains a homogenous population of plenipotent stem cells. Following injection of 
a single EPSC or group of EPSCs to an empty zona pellucida or two-cell stage embryo, 
embryonic development did not progress (data not included) indicating that EPSCs are not by 
the strictest definition totipotent. EPSCs contribute extensively to all lineages in the 
developing organism when injected at the eight-cell stage. This may reflect the fact that the 
cells require a critical number of carrier blastomeres in order to allow normal development to 
proceed. An alternative explanation is that EPSCs may have biological similarity to the eight-
cell stage embryo. As has been shown in recent studies, synchronization of the donor cell and 
host embryo temporal developmental timelines is critical for embryonic contribution (Huang 
et al., 2012; Mascetti and Pedersen, 2016). 
 
In conclusion, EPSCs possess totipotent-like characteristics in vitro and in vivo but from the 
data presented thus far, there was no definite mechanism to explain their expanded fate 
potential. In Chapter 5, I perform transcriptomic and epigenetic profiling of EPSCs to 
evaluate for the presence of a pre-implantation signature which may provide an explanation 
for the observed pheno 
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CHAPTER 5   
5 TRANSCRIPTOMIC AND EPIGENETIC 
PROFILING OF EPSCS 
 
5.1 Summary 
In this chapter, I demonstrate that the transcriptome of mouse EPSCs is enriched with an early 
pre-implantation blastomere signature, distinct from other rare published totipotent-like cells 
and epigenetically, EPSCs possess bivalent domains at multiple loci encoding key 
developmental regulators. Moreover, I show that the transcriptome of EPSCs shares a 
pluripotency foundation and transcriptomic homogeneity comparable to ground-state ESCs. I 
then discuss how these findings may provide a potential mechanistic insight into the expanded 















Ground-state embryonic stem cells are pluripotent, contributing to all lineages in the embryo 
proper and importantly, have an in vivo counterpart in the nascent epiblast (Nichols and 
Smith, 2009). Contribution experiments in the preceding chapters have provided evidence to 
support the claim that EPSCs represent a distinct self-renewing state with expanded fate 
potential to all lineages in the developing organism. Therefore, I questioned whether EPSCs 
may have biological similarity with a specific stage of pre-implantation development. 
However, initial in vitro characterization in Chapter 3 indicated that EPSCs possessed a core 
pluripotency signature, aspects of which were comparable to ground-state ESCs.  Therefore, 
transcriptomic profiling, DNA methylation content and histone methylation analysis were 
deemed essential to discern what self-renewal network was active in EPSCs, whether this 
network had features in common with naive pluripotency and importantly, if EPSCs 
possessed a transcriptional and / or epigenetic signature suggesting a pre-implantation origin.  
 
5.2.1 The transcriptional and epigenetics characteristics of pluripotency 
Mouse ESCs are pluripotent being ability to contribute to all somatic lineages (ectoderm, 
mesoderm and endoderm) in the developing organism. Mouse ESCs maintained in serum 
albeit pluripotent are considered to represent a ‘metastable’ state with heterogenous 
expression of pluripotency related factors and differentiation related genes, the latter of which 
is referred to as lineage priming (Marks et al., 2012). Epigenetically, serum cultured ESCs 
possess bivalent domains at the promoters of key developmental loci. This co-localisation of 
H3K4me3 and H3K27me3 is thought to mark genes that are poised for activation or 
repression in response to developmental cues (Azuara et al., 2006). The combination of a 
MEK1 inhibitor and GSK3B inhibition permits establishment and maintenance in vitro of a 
substantially homogenous mouse ESC population which is thought to represent the ground 
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state of self-renewal (Ying et al., 2008). In contrast to serum cultured ESCs, 2i cultured ESCs 
possess homogenous expression of key pluripotency regulators and reduced lineage priming 
with minimal expression of lineage specifiers. Epigenetically, there is reduced prevalence of 
the repressive H3K27me3 modification at promoters and fewer bivalent domains are detected 
in naive ES cells (Marks et al., 2012).  Naive ESC possess global DNA hypomethylation 
which is thought to be mediated by high expression of Prdm14 which downregulates the 
expression of Dnmt3a and Dnmt3b (Leitch et al., 2013). 
 
5.2.2 The transcriptional and epigenetics characteristics of totipotency 
Epigenetic remodelling in the pre-implantation embryo involves the erasure of epigenetic 
memories from the maternal and paternal genomes and the establishment of new epigenetic 
signatures including imprinting related gene expression and X-chromosome inactivation. 
Debates on the role of post-zygotic demethylation and subsequent remethylation have also 
considered that this de novo methylation may in fact be linked to the first-lineage decisions 
during mammalian development (Reik et al., 2001). 
 
Mechanistically, this process involves active and passive demethylation of both genomes 
(Guo et al., 2014). Active demethylation is mediated by Tet3  dioxygenase-dependent 
oxidation of  5-methylcytosine (5mC) (Gu et al., 2011). Passive demethylation occurs 
secondary to 5mC dilution from the following cleavage divisions due to DNA replication 
(Rougier et al., 1998).  
 
Pre-implantation development proceeds in a stepwise fashion from the fertilized zygote until 
the first and second cell fate decisions. Analysis of global gene expression during this process 
identified three characteristic events which correspond with the morphological and functional 
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changes that are identified in the pre-implantation embryo. Following degradation of maternal 
RNA, which comprises the first characteristic event, there are two waves of de novo zygotic 
transcription. The first wave corresponds to zygotic gene activation, also referred to as 
embryonic gene activation (EGA). The second wave which is referred to as mid-pre-
implantation gene activation (MGA) immediately precedes the first lineage specification 
event (Hamatani et al., 2004). Moreover, recent studies have succeeded in reconstructing the 
individual steps of pre-implantation development by performing global analysis of allelic 
expression across individual cells of the mouse pre-implantation embryo (Deng et al., 2014). 
 
The existence of subpopulations of totipotent-like cells in ESC culture has recently been 
described. The endogenous retrovirus MuERV-L is restricted in temporo-spatial expression to 
the zygote and two-cell stage embryo. A group recently reported that a small fraction (<2%) 
of mouse ESCs expressed this element. These MuERV-L expressing ES cells expressed 
additional genes known to be associated with the two-cell stage of development and did not 
express pluripotency factors at the protein level. These cells demonstrated expanded potential 
to both the embryonic and extra-embryonic lineage in chimeras (Macfarlan et al., 2012). 
 
A second study described the existence of a totipotent Hex1 expressing population in ground 
state culture conditions. These cells co-expressed pluripotency genes and trophoblast 
determinants which the authors argued was similar to blastomeres during pre-implantation 
development (Morgani et al., 2013). 
 
Another report described the production of a totipotent like cell following in vivo 
reprogramming. Transcriptionally, these in vivo iPSCs (iviPSCs) were very similar to 
conventional ES cells but some of the genes that were differentially highly expressed in the 
iviPSCs were morula specific such as Nlrp4mf (Abad et al., 2013). 
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5.3 Aims of this Chapter 
In this chapter, firstly, I aim to perform bulk and single cell RNA sequencing to characterise 
the transcriptomic properties of EPSCs. Second, using published sequencing data on the pre-
implantation developmental timeline in mouse embryos, I aim to assess for the presence of a 
pre-implantation signature in EPSCs. Finally, I aim to interrogate the epigenetic properties of 
EPSCs by analysing the genome-wide distribution of H3K4me3 and H3K27me3 
modifications. 
 
5.4 Results  
5.4.1 The transcriptome of EPSCs shares a pluripotency foundation with ground-state ESCs 
These experiments were conducted in collaboration with Dr Cheuk-Ho J. Tsang, Sanger 
Institute. Where indicated, reference is made to the thesis of Dr  Cheuk-Ho J. Tsang who 
performed extensive transcriptional and epigenetic characterization of EPSCs lines which I 
generated. In an attempt to understand the molecular characteristics of EPSCs, the 
transcriptomes of EPSCs and ESCs in different culture conditions were profiled by population 
RNA-sequencing. In hierarchical clustering, it is evident that the transcriptomes of the cell 
lines segregated by their maintenance conditions, irrespective of their original derivation 
methods or culture history (Figure 5.1). This suggests that the transcriptomes of EPSCs and 















In addition, 84 individual EPSCs (DR10) were profiled to study the molecular heterogeneities 
of the EPSC culture. The data was compared with the single-cell RNA sequencing dataset of 
2i/LIF and M15 ESCs generated on the same platform with an ES cell line (G4) of similar 
background (Kolodziejczyk et al., 2015). In principal component analysis (PCA), individual 
cells were segregated by their culture conditions (Figure 5.2), demonstrating the global 
differences between EPSCs, 2i/LIF and M15 ESCs at the single-cell level. 2843 and 1465 
genes were detected that were up-regulated in EPSCs and 2i/LIF ESCs, respectively. Gene 
ontology term enrichment analysis revealed that 2i/LIF ESCs were enriched in genes of 
metabolic processes such as oxidative reduction and the electron transport chain (Figure 5.3) 
concordant with a previous report (Marks et al., 2012). By contrast, biological terms related to 
transcriptional regulation and embryonic development, particularly placental development, 
were preferentially featured in EPSCs (Figure 5.3).  
 
Genes instrumental to placental development, such as Eomes (Russ et al., 2000), Peg10 (Ono 
et al., 2006), Ascl2 (Mash2) (Oh-McGinnis et al., 2011), Esx1 (Li and Behringer, 1998) and 
Gata3 (Home et al., 2009), were differentially up-regulated in EPSCs (Figure 5.4, see PhD 
thesis of Dr Cheuk-Ho J. Tsang). In addition, multiple lineage-specific genes such as Gata4, 
Gata6, Pax6, Sox1 and Sox7 were also detected in EPSCs at low levels (Figure 5.4). Despite 
the differences, pluripotency related genes such as Oct4, Sox2, Nanog, Esrrb, Klf2 and Klf4 
were not differentially expressed between EPSCs and 2i/LIF ESCs (Figure 5.4 and Figure 
5.5) consistent with the in vitro Rex1-GFP, Oct4-GFP reporter experiments. These results 
again confirmed that EPSCs and ESCs share the core pluripotency module despite their 
































5.4.2 EPSCs and ground-state ESCs share transcriptomic homogeneity 
It was previously shown that mouse ESCs cultured in serum-containing media exist in 
a “metastable” state and display fluctuation of the pluripotency related genes (Marks et al., 
2012). For instance, Nanog and Rex1 are heterogeneously expressed in ESCs cultured in 
serum-containing medium, whereas their expression in 2i/LIF ESCs is more homogeneous. In 
collaboration with Cheuk-Ho J. Tsang, the single-cell expression variability of key 
pluripotency factors was compared in EPSCs to 2i/LIF and M15 ESCs. It was found that the 
expression variability (quantified by the coefficient of variation) of several pluripotency genes 
remained low (highly homogeneous) and was comparable in EPSCs and 2i/LIF ESCs, unlike 
the high variability observed in M15 ESCs (Figure 5.6A and Figure 5.6B). 
 
Notably, rare sporadic expressions of lineage-specific genes in 2i/LIF ESCs were observed 
but this phenomenon was more frequent and pervasive in M15 and EPSCM (Figure 5.4). The 
expression of the lineage-specific genes in M15 ESCs was associated with variable expression 
of pluripotency genes, suggesting that the pluripotent states in M15 ESCs are unstable and 
that they are poised for differentiation. By contrast, EPSCs maintained uniform expression of 
pluripotency factors. Therefore, the low levels of lineage-specific gene expression observed in 
EPSCs are not due to in vitro differentiation or pluripotent state fluctuation (Figure 5.4). 
Rather, this transcriptomic feature is consistent with the EPSC’s expanded and enhanced 
developmental potential as described hereby and may represent a salient molecular feature of 
EPSCs.  
 
The transcriptional variability of global gene expression, as well as those protein-coding 
genes and putative transcription factors was also assessed and in all cases, EPSCs were 








M15 ESCs (Figure 5.6A). Collectively, this data indicated that EPSCs have similar 
transcriptomic homogeneity to 2i/LIF ESCs.  
 
5.4.3 The transcriptome of EPSCs is enriched with early pre-implantation blastomere 
signatures and is distinct from other rare totipotent-like cells. 
I next assessed the biological similarities of EPSCs to in vivo pre-implantation totipotent 
blastomeres. In collaboration with Cheuk-Ho J. Tsang, mouse embryonic development time 
course single-cell data from Deng et al was retrieved for comparison (Deng et al., 2014). 
EPSCs were separated from the native developmental trajectory of totipotent blastomeres with 
the scores of EPSCs at the range of 4 cell stage blastomeres in PC1 (Figure 5.7, see PhD 
thesis of Cheuk-Ho J. Tsang), the component representing the major embryonic 
development axis. To test whether EPSCs have transcriptomic features of pre-implantation 
embryos compared with standard ESCs,  the top 500 stage-specific genes of each blastomeric 
stage from Deng et al were compiled and compared with the expression of these signature 
gene sets in EPSCs and 2i/LIF ESCs by GSEA. The result showed significantly higher 
enrichment of early pre-implantation (zygote, 2C and 4C) signatures in EPSCs (Figure 5.8A). 
This data suggests that the transcriptome of EPSCs contains molecular features of early 
blastomeres. 
 
In addition, comparison with the published population RNA-seq data showed that EPSCs 
were distinct in PCA from the recently reported rare totipotent-like ESC subpopulations 
(MERV-TdTomato+ and Hex-Venus+) (Macfarlan et al., 2012; Morgani et al., 2013) or in 
vivo reprogrammed iPSCs (iviPSCs) (Abad et al., 2013) (Figure 5.9A). For instance, unlike 
in MERV-TdTomato+ 2C-like cells, only limited up-regulation of endogenous retroviral 

























5.4.4 EPSCs have a dynamic DNA methylome 
It has been suggested that ERK signalling inhibition in ESCs induces global DNA 
hypomethylation, which is associated with Prdm14-mediated down-regulation of Dnmt3a and 
Dnmt3b (Leitch et al., 2013). In collaboration with Cheuk-Ho J. Tsang, intriguingly, we 
observed significant up-regulation of methyltransferases (Dnmt1, Dnmt3a & Dnmt3b) and 
reduction of Prdm14 despite the presence of ERK inhibition in EPSCM (Figure 5.10, see 
PhD thesis of Cheuk-Ho J. Tsang). 
 
Genetic components involved in active DNA demethylation such as Tet1, Tet2 and Tdg were 
also up-regulated in EPSCs. The gene expression pattern is reflected on the global cytosine 
methylation and hydroxymethylation levels quantified by mass spectrometry (Figure 5.11A 
and Figure 5.11B, see PhD thesis of Cheuk-Ho J. Tsang). Consistent with previous reports 
(Ficz et al., 2013; Leitch et al., 2013), substantially lower levels of DNA methylation were 
found in 2i/LIF ESCs, compared to that in M15 (Figure 5.11A), whereas EPSCs showed an 
intermediate level (Figure 5.11A). Strikingly, much higher levels of hydroxymethylcytosine 
were found in EPSCs (Figure 5.11B). Albeit at one point in time, this data suggests that the 
DNA methylome of EPSCs is highly dynamic with active DNA methylation and 
demethylation. 
 
5.4.5 Prevalent bivalent domains in EPSCs at loci encoding key developmental regulators 
In collaboration with Cheuk-Ho J. Tsang, to further understand the epigenetic status of 
EPSCs, the genome-wide distribution of H3K4me3 and H3K27me3 modifications were 
profiled in an EPSC line (DR10) and compared with that in 2i/LIF ESCs (Marks et al., 2012). 














correlated with the level of active gene expression (Figure 5.12A), whereas H3K27me3 peaks 
were distributed throughout the promoters and gene bodies and inversely correlated with gene 
expression (Figure 5.12B). 
Compared with 2i/LIF ESCs, EPSCs contain more genes (6224 vs. 3968) associated with both 
H3K4me3 and H3K27me3 (bivalent) histone modifications (Figure 5.13). Bivalency could be 
detected at the genetic loci encoding key lineage regulators such as Sox1, Pax6, Gata6, T, 
Cdx2 and Eomes (Figure 5.14). By contrast, the H3K4me3 and H3K27me3 signals of EPSCs 
at key pluripotency loci such as Pou5f1, Sox2 and Nanog were highly similar to 2i/LIF ESCs 
(Figure 5.14), consistent with the fact that these pluripotency genes were expressed at similar 
levels in both cell types (Figure 5.4 and Figure 5.5). Gene ontology term enrichment 
analysis showed that EPSC specific bivalent genes  were enriched in biological processes of 
somatic lineage and placenta development (Figure 5.15), including genetic loci such as Cdx2, 
Eomes, Esx1, Hand1, Ascl2, Sox1, Sox17, and Pax6 (Figure 5.14), which provide an 
epigenetic basis for the low expression of lineage-specific genes detected in single cell RNA-
seq (Figure 5.4). See PhD thesis of Cheuk-Ho J. Tsang for extensive characterization of 
the epigenetic state in EPSCs. 
 
5.5 Discussion 
In this chapter I have demonstrated that established EPSC lines are molecularly similar, 
independent of their derivation origins, suggesting that EPSCM is capable of maintaining a 
convergent cell state.  Despite the commonality of self-renewal network in EPSCs with ESCs, 
molecular characterization reveals that EPSCs have a distinct transcriptome, DNA 































By comparing with the single-cell RNA-sequencing data of pre-implantation embryos in 
principal component analysis, it is clear that EPSCs deviate from the native blastocyst cells 
and 2i/LIF ESCs in the embryonic development trajectory towards the direction of earlier 
blastomeres. Moreover, EPSCs contain increased bivalent domains at the genetic loci of 
embryonic and extra-embryonic lineage specifiers. 
 
It has been suggested that “promiscuous” transcription at bivalent loci is a hallmark of 
“metastable” ESCs cultured in serum-containing media, and these genes are ‘poised’ for 
activation upon differentiation induction (Marks et al., 2012; Takashima et al., 2014). In spite 
of the increased bivalent domains in EPSCs, single-cell RNA-sequencing shows that the 
transcriptome of EPSCs has reduced expression variability compared with ESCs maintained 
in serum-containing media. The presence of ‘poised’ promoters at key developmental genes in 
EPSCs may account in part for the expanded potential of these cells by permitting rapid gene 
expression in response to appropriate in vivo or in vitro developmental cues. As a proof of 
concept experiment and in support of this hypothesis it has been shown that EPSCs have 
markedly enhanced hematopoiesis potential which may be explained in part by the 
observation of bivalent domains at key transcription factors involved in blood lineage 
specification (Performed by Adam Wilkinson, Gottgen’s Lab, Cambridge University). 
 
During mouse pre-implantation development there is progressive global DNA demethylation 
which culminates in the formation of the hypomethylated inner cell mass (Leitch et al., 2013).  
The ICM possesses more 5 hydroxymethylcytosine (5hmC) than the trophectoderm with as 
expected a similar finding in ESCs and TS cells, respectively (Ruzov et al., 2011). The global 
expression of Tet1 and Tet2 mRNAs and 5hmC abundance is less in the trophectoderm (Ito et 
al., 2010; Senner et al., 2012).  Moreover, loss of Tet1 expression and resulting loss of 5hmC 
in one of the blastomeres in the two-cell stage embryo biases that blastomere to a TE fate (Ito 
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et al., 2010). In contrast to ESCs, EPSCs express genes related to both methylation and de-
methylation which is functionally supported by the presence of elevated 5mC and 5hmC on 
mass spectrometry. As EPSCs are a homogenous population, this co-expression of 
methylation-demethylation components in each cell may explain in part the observed 
plenipotent or unbiased embryonic and extra-embryonic differentiation potential of an 
individual cell as demonstrated in the single cell chimeric contribution assays in Chapter 4. 
 
The rare 2C-like and Hhex+ ESCs were reported to transiently exist in standard ESC culture 
(Macfarlan et al., 2012; Morgani et al., 2013). Meanwhile, in vivo reprogrammed iPSCs were 
shown to be highly similar to ESCs transcriptionally but express several morula-stage genes 
(Abad et al., 2013). It remains unclear whether the expanded potential observed in the in vivo 
iPSCs is contributed by similar rare ESC subpopulations in culture since no single cell 
genomics or experimental data are available. Nevertheless, EPSCs are categorically different 
from these reported totipotent-like cells. EPSCs do not have up-regulation of endogenous 
retroviral transcripts and express high levels of OCT4 protein.  
 
In chapter 4, I demonstrated that EPSCs possess functional homogeneity of expanded 
potential in single-cell chimera formation experiments. In this chapter, single-cell 
transcriptomic experiments have confirmed this molecular homogeneity further refuting the 
existence of rare privileged subpopulations within EPSCM. Nevertheless, it remains possible 
that stable homogenous long-term 2C-like cell cultures can be established by modulating 












In this chapter, I demonstrate that EPSCM permits the establishment in vitro of a human stem 
cell state that possesses expanded differentiation potential to both the embryonic and extra-
embryonic lineage in vitro. Similar to mouse EPSCs, human EPSCs possess a core 
pluripotency transcriptional self-renewal network and are easily amenable to gene targeting. 
Epigenetic profiling of X-chromosome activation status in EPSCs provides evidence to 
suggest that these cells may correspond to a pre-implantation stage of development and 
provisional gene set enrichment analysis  demonstrates enrichment in genes related to the 











6.2.1 Conservation of signalling pathways in the pre-implantation embryo 
Despite difference in the timing of onset of zygotic gene activation (ZGA) and the temporal 
rate of embryo development, available studies appear to suggest that the fundamental 
processes involved in the first cell fate specification may be conserved between mouse and 
human (Adjaye et al., 2005; De Paepe et al., 2014; Santos et al., 2002; Santos et al., 2010; 
Senner and Hemberger, 2010; Telford et al., 1990). Beyond the specification event, it appears 
that the factors involved in establishment of the trophoblast lineage also appear to be shared 
between mouse and man (Senner and Hemberger, 2010). 
 
This knowledge and recent reports from several groups describing in vitro conditions to 
maintain human ESCs with transcriptional and metabolic similarities to mouse ESCs in 2i/LIF 
conditions led me to consider that if a cell state(s) similar to the mouse ground-state of self-
renewal exists in humans and if many of the signalling processes involved in pre-implantation 
development are conserved, perhaps an EPSC state can also be established in human (Chan et 
al., 2013; Gafni et al., 2013; Takashima et al., 2014; Theunissen et al., 2014; Ware et al., 
2014).  
 
Beyond establishing such a line in vitro, an obvious challenge in humans is evaluating for the 
presence of expanded differentiation potential as in vivo chimeric contribution assays are not 
ethically permissible. Therefore, surrogate functional in vitro assays are necessary for 
evaluating the presence of a pre-implantation signature and secondly, the capacity for 
expanded differentiation potential during differentiation. Epigenetic regulation of X 
chromosome inactivation (XCI) and in vitro trophoblast differentiation are potentially useful 




6.2.2 Epigenetic regulation of X-chromosome inactivation (XCI) 
In terminally differentiated somatic cells of female mammals, one of the X-chromosomes is 
inactive and can be identified as a dense condensation of heterochromatin called the Barr 
body (Lyon, 1961). This process of XCI can be random or imprinted and has evolved to 
mediate dosage compensation of gene expression between the sexes.  
 
In eutherian mammals, the onset of XCI in the pre-implantation embryo coincides with 
embryonic gene activation. In the mouse, this corresponds to the two-cell stage embryo and 
XCI is imprinted with preferential inactivation of the paternal X-chromosome which remains 
silent throughout pre-implantation development and in descendants of the extra-embryonic 
lineage (Huynh and Lee, 2003; Takagi and Sasaki, 1975). The paternal X-chromosome 
becomes re-activated in the inner cell mass and subsequently the cell will undergo random 
XCI during somatic differentiation of the epiblast (Mak et al., 2004). The importance of early 
imprinted XCI in mouse has been demonstrated in parthenogenetic embryos where the lack of 
paternal imprinting due to two maternal genomes is embryonically lethal (Nesterova et al., 
2001; Shao and Takagi, 1990). 
 
Mammals employ different strategies for the initiation and maintenance of XCI. Zygotic gene 
activation occurs at later stages in non-rodent species, specifically the four to eight-cell stage 
in humans and the eight to 16-cell stage in rabbits (Telford et al., 1990). Therefore, and not 
surprisingly, it has been shown that XCI occurs at later stages in these species (Okamoto et 
al., 2011; Van den Berg et al., 2009). An additional difference between human and mouse is 
that initial XCI in humans is not imprinted and XCI is not necessary for correct specification 
of trophectoderm in blastocyst stage embryos (Okamoto et al., 2011). 
 
In mouse, initiation of XCI is controlled by the long non-coding RNA, X inactive specific 
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transcript (XIST) which coats the inactive X-chromosome (Penny et al., 1996). The antisense 
transcription factor Tsix prevents inactivation of the remaining active X-chromosome (Lee, 
2005). Interestingly, Tsix is poorly conserved and in humans, although XIST is present and 
does coat the inactive X-chromosome, it is not thought to be responsible for the initiation of 
XCI (Chang and Brown, 2010; Okamoto et al., 2011). Humans also possess another long non-
coding RNA, XACT which coats the active X-chromosome and which is not present in the 
mouse. XACT is thought to be pluripotency specific and in the absence of XIST will coat both 
active X-chromosomes (Vallot et al., 2015). In the mouse inner cell mass, both X 
chromosomes are active with no repressive XIST transcript identified. In the human inner cell 
mass, XIST is detected but the cells still possess two active X-chromosomes (Okamoto et al., 
2011). 
 
With this understanding of human XCI, it should therefore be possible to temporally place a 
cell of interest at a specific locus in the pre-implantation development timeline based on their 
X activation - inactivation status alone. 
 
6.2.3 Human Trophoblast Specification 
The human placenta just like the mouse is comprised of cell types derived from both the 
embryonic and extra-embryonic lineages. The extra-embryonic portion is contributed by the 
trophoblast cells which are sub-divided into the villous and extra-villous cytotrophoblast and 
syncytiotrophoblast all of which have different biological functions in placental formation. 
The embryonic portion as in the mouse comes from the extra-embryonic mesoderm, a 
derivative of the epiblast, which forms the placental vasculature. At the time of initial 
derivation of human ESCs from embryos, it was noted that spontaneous differentiation to cell 
types that secreted β-HCG occurred suggesting that human ESCs had a capacity to form 
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trophoblast-like cells (Thomson et al., 1998). Further studies elucidated that this phenotype 
could be reproduced by the addition of BMP4 which permitted the establishment in vitro of 
cell lines that had similarity with post-mitotic syncytiotrophoblast and cytotrophoblast (Harun 
et al., 2006; Xu et al., 2002). As human ESCs are thought to represent a ‘primed’ or post-
implantation stage of development, this finding was at odds with our current understanding of 
normal development (Tesar et al., 2007). Numerous debates have centred on whether this 
human ESC differentiation represents bona fide trophoblast induction or whether this 
phenotype may be explained by somatic contribution from the extra-embryonic mesoderm 
(Roberts et al., 2014). Whilst attempting to reconcile this dichotomy, ELF5 was identified as a 
key transcription factor whose epigenetic status would allow identification of genuine 
trophoblast (Hemberger et al., 2010). 
 
ELF5 is a transcription factor expressed in first trimester villous trophoblast but not in extra-
villous or syncytiotrophoblast. In the first trimester, there is a transient highly proliferative 
ELF5, CDX2 double positive sub-population within the placenta which is thought to represent 
the putative human trophoblast stem cell niche (Hemberger et al., 2010). ELF5 along with 
CDX2 and EOMES forms a ‘trophoblast-reinforcing transcriptional network’ (Senner and 
Hemberger, 2010). Critically, the methylation status of ELF5 creates an epigenetic signature 
for the trophoblast compartment. ELF5 is hypomethylated in the trophoblast lineage but is 
significantly hypermethylated in human ESCs. Moreover, differentiated ‘trophoblast’ derived 
from human ESCs remains hypermethylated at ELF5 indicating that this in vitro 
differentiation process may not produce bona fide trophoblast (Hemberger et al., 2010). 
 
Therefore, one can conclude that in order to prove that a cell type has expanded 
differentiation potential to the trophoblast lineage in vitro, demonstration of hypomethylation 
at the ELF5 promoter is paramount. 
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6.3 Aims of this Chapter 
The aim of this chapter was to determine if EPSCM permitted the maintenance in vitro of a 
human stem cell population that possessed expanded differentiation potential in vitro. This 
would be attempted by first converting human ESCs to human EPSCs and by reprogramming 
human somatic cells to iPSCs. After initial characterization of these cells, expanded potential 
would be assessed by evaluating the capacity of these cells to produce bona fide trophoblast in 
vitro, epigenetic profiling of their XCI status and transcriptionally by the presence of a unique 
pre-implantation gene expression signature. 
 
6.4 Results 
6.4.1 Derivation of human EPSCs by conversion of standard human ESCs and iPSCs 
We chose two human ESC lines H1 and H9, which are widely used in the research 
community (Thomson et al., 1998).  Individual H1 cells were seeded in EPSCM on MEF 
feeder cells at a low cell density. Approximately 0.3% of cells formed undifferentiated 
colonies (Figure 6.1B). These colonies could be subcloned again and expanded in EPSCM to 
establish stable cell lines. In contrast, none of the colonies of H9 cells that initially survived in 
EPSCM could be further expanded, consistent with the known heterogeneity among human 
ESC lines. The converted H1 cells (H1-EPSCs) were dissociated to single cells for passaging 
with a 15-20% single cell subcloning efficiency in the presence of a selective ROCK inhibitor 
and could be expanded in EPSCM for over 30 passages on SNL feeders. Two standard human 
iPSC lines from the CGAP facility were obtained (BOB and FSPS186) and the conversion 
strategy was repeated (Figure 6.1A). BOB iPSCs survived the conversion process with EPSC 
colonies emerging from single iPSCs which were plated at low density on SNL feeders 
(Figure 6.1C). FSPS186 iPSCs could not be converted. As with hESCs there is known 
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heterogeneity among human iPSC lines which may in part explain the variation in the 
capacity for conversion. 
H1-EPSCs proliferated faster than H1 ESCs and had a shorter cell cycle time with 69.1% of 
H1-EPSCs in the S phase of the cell cycle as compared to 41.9% in H1 ESCs. Less than 
13.1% of H1-EPSCs were found in the G0-G1 checkpoint in contrast to 44.2% of H1 ESCs 
(Figure 6.2). Converted lines were genetically stable as confirmed by spectral karyotyping 
(Figure 6.3). H1-EPSCs expressed pluripotency genes (OCT4, SOX2, NANOG, STELLA and 
PRDM14) at similar levels with the parental H1 ESCs (Figure 6.4A), but lower levels of 
lineage markers (SOX1, PAX6, T, GSC, GATA6 and SOX17) (Figure 6.4B). H1-EPSCs were 
efficiently differentiated to cells of all three germ layers (Figure 6.5). 
 
6.4.2 Derivation and maintenance of human EPSCs by reprogramming somatic cells 
Using the six factor reprogramming technology (Wang et al., 2011), human neural stem cells 
were reprogrammed to iPSCs by expressing reprogramming factors from episomal vectors, or 
dermal fibroblast cells by Doxycycline (DOX) - inducible factors from piggyBac (PB) 
transposon vectors (Figure 6.6A). Stable iPSC lines could be established directly in EPSCM 
from about half of the primary iPSC colonies (Figure 6.6B). Episome clone 5 iPSC line 
(EC5-EPSC) expressed key pluripotency markers (Figure 6.4A), had minimal expression of 
lineage specific genes (Figure 6.4B) and was further confirmed to have lost the exogenous 
reprogramming vectors after five passages (Figure 6.6C).  Spectral karyotyping (Figure 
6.7A) and aCGH (Figure 6.7B) demonstrated genetic stability in EC5-EPSCs. 
EC5-EPSCs could form mature teratomas in vivo containing derivatives of the three germ 













































teratomal elements (Figure 6.8A and Figure 6.8B). In a collaborative effort with Ludovic 
Vallier’s lab, EC5-EPSCs were differentiated to pancreatic cell types (PDX1) including 
insulin secreting C-peptide beta cells and glucagon secreting alpha cells using their published 
monolayer differentiation protocol (Figure 6.9A and Figure 6.9B) (Cho et al., 2012). 
 
6.4.3 Human EPSCs can be genetically modified efficiently 
In contrast to conventional human ESCs, human EPSCs were easy to culture and proliferated 
robustly (Figure 6.2); therefore, we attempted to genetically modify the genome. These 
experiments were conducted in collaboration with Dr Wei Wang, Sanger Institute.  
The ubiquitously expressed ROSA26 was chosen as the first locus to target. A splice acceptor-
H2B-Venus cassette was targeted to ROSA26 using standard homologous recombination. The 
correct targeting efficiency was 47% which is comparable to that of targeting a similar 
cassette to the Rosa26 locus in mouse ES cells (Figure 6.10A). The CRISPR/Cas9 system has 
made genome editing much simpler (Doudna and Charpentier, 2014). OCT4 and NANOG 
H2B-Venus and H2B-mCherry reporter human EPSC lines were generated using 
CRISPR/Cas9-facilitated targeting. The targeting efficiencies at these loci ranged from about 
50% to 80% (Figure 6.10B and 6.10C).  
The availability of reporter cell lines in mouse ESCs has greatly facilitated studies on 
pluripotency and differentiation. As a proof of concept, a double targeted OCT4 H2B-Venus, 
SOX2 H2B-mCherry reporter line (EC5-EPSCs) was used for neural differentiation. EC5-
EPSCs were rendered feeder-free and subsequently differentiated using a monolayer neural 
induction protocol. The reporter line allowed visualisation of the differentiation kinetics using 
epifluorescent microscopy and FACS (Figure 6.11A and Figure 6.11B). During the 28 day 
induction, there was a progressive loss of OCT4 expression and maintenance of SOX2 
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expression which was highly expressed at the neural rosette stage. The SOX2 positive, OCT4 
negative population in the neural rosette culture was sorted and expanded in neural stem cell 
conditions containing EGF and FGF2. Bulk RNA sequencing confirmed the neural stem cell 
identity of the newly derived line (Figure 6.11C). To functionally confirm the neural stem 
cell identity, C5-derived neural stem cells (C5-dNSCs) were terminally differentiated on 
laminin by removing the mitogens, FGF2 and EGF from the neural stem cell culture. After 3 
months in culture, mature neuronal morphologies were evident. Immunocytochemistry 
confirmed the presence of mature neuronal markers, NeuN and SYNAPTOPHYSIN (Figure 
6.12A). In collaboration with Peter Kirwan at the Livesey Lab, Gurdon Institute, Cambridge, 
these neurons were shown to be mature with synaptic activity and action potential 
transmission identified on electrophysiology (Figure 6.12B). 
 
6.4.4 All components in EPSCM are essential for maintenance of human EPSCs 
As in mouse EPSCs, the presence of a core pluripotency network is necessary for the 
maintenance of human EPSCs. If mouse EPSCs lose pluripotency gene expression and 
become differentiated then, as expected, the expanded potential phenotype is also lost. 
Therefore, I used the human OCT4-H2B-Venus reporter EPSCs as a convenient readout to 
evaluate the inhibitor requirement in maintaining human EPSCs. I found that all inhibitors in 
EPSCM are essential to prevent deterioration of human EPSC colony morphology and the 






















6.4.5 Transcriptomic analysis of newly derived human EPSCs  
These experiments were conducted in collaboration with Dr Cheuk-Ho J. Tsang, Sanger 
Institute. Population RNA-sequencing was performed to compare the transcriptome of human 
EPSCs and human ESCs. Hierarchical clustering showed that the transcriptome of H1-EPSCs 
segregated from H1 and H9 human ESCs (Figure 6.14). Consistent with findings on 
quantitative PCR, human EPSCs showed similar expression of core pluripotency factors such 
as POU5F1 (OCT4), SOX2 and NANOG as in human ESCs (Figure 6.15A). Interestingly, 
multiple genes associated with mouse ESC pluripotency such as KLF4, UTF1 and TFCP2L1 
were significantly up-regulated in H1-EPSCs (Figure. 6.15A). In addition, genes encoding 
key lineage regulators such as EOMES, GATA4, GATA6, T, SOX17, SOX1 and RUNX1 were 
all significantly down-regulated (Figure. 6.15B).  
Recently, there has been significant momentum to derive mouse ESC-like human pluripotent 
stem cells. Several groups have reported multiple in vitro conditions to maintain human ESCs 
with transcriptional and metabolic similarities to mouse ESCs in 2i/LIF conditions (Chan et 
al., 2013; Gafni et al., 2013; Takashima et al., 2014; Theunissen et al., 2014; Ware et al., 
2014). As mouse EPSCs possess a core pluripotency transcriptional network that has many 
similarities with the mouse ground-state of self-renewal, I sought to investigate if human 
EPSCs clustered with the proposed human naïve state. 
Population RNA-sequencing data were retrieved from respective studies and re-analysed. On 
three-dimensional principal component analysis and hierarchical clustering, the transcriptome 
in EPSCM was found to be distinct from standard FGF human ESCs and all proposed human 
naïve states (Figure 6.16 and Figure 6.17). Therefore, similar to mouse EPSCs, human 






























network as a dominant finding. Gene ontology analysis confirmed that the down-regulated 
genes in H1-EPSCs were enriched with terms related to somatic lineage development (Figure 
6.18). 
 
6.4.6 Epigenetic status of X-chromosome suggests that human EPSCs may have similarity 
to the pre-implantation embryo.  
Using single cell RNA FISH, female EPSCs (<10 passages) were found to have lost 
expression of the repressive X-inactive specific transcript (XIST) and had gained biallelic 
expression of the long non-coding RNA, XACT which is known to coat the entire active X 
chromosome (Figure 6.19-1A,B and C) (Vallot et al., 2015). These findings suggested that 
EPSCs had two active X-chromosomes which I further confirmed by assessing the expression 
of individual X-linked genes as, if both X-chromosomes were active then expression should 
be bi-allelic. Indeed, single cell RNA FISH confirmed bi-allelic expression of X-linked genes 
in EC5-EPSCs (Figure 6.20-1A and B). In collaboration with Dr Cheuk-Ho J. Tsang, Sanger 
Institute, bulk RNA-sequencing was performed which further supported this finding by 
revealing global increased X-linked gene expression with associated down-regulation of XIST 
in female EPSCs as compared to the parental NSC (Figure 6.19-2D). As XCI begins at the 
eight-cell stage in humans at which time XIST starts to become detectable, the absence of 
XIST and presence of two active X-chromosomes tentatively may indicate that human EPSCs 
have epigenetic similarity with the eight-cell stage of human embryo development. 
If the loss of XIST expression and the presence of two active X-chromosomes indicated that 
EPSCs were corresponding to a stage of pre-implantation development, then, X-chromosome 
inactivation and dosage compensation should be observed during differentiation. To assess 
whether EPSCs underwent this normal developmental process, differentiation was performed 
using in vitro embryoid body differentiation and targeted neural differentiation as previously 
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described. Embryoid bodies were made from EC5-EPSCs and were allowed to differentiate 
for 14 days before testing for X-chromosome inactivation. Using single-cell RNA FISH, 
differentiated EC5 was found to have inactivated one X-chromosome with re-expression of 
X-inactive specific transcript (XIST) and had lost bi-allelic expression of the X-linked gene, 
HPRT1 (Figure 6.21-1A,B and C). RNA FISH also confirmed that EC5-EPSCs lost 
expression of XACT during differentiation. Interestingly, 3% of differentiated EC5 cells (C5 
dEB Day 14) still had detectable XACT expression which is most likely explained by some 
residual undifferentiated cells in the embryoid body culture as XACT expression is 
pluripotency specific (Figure 6.21-2D) (Vallot et al., 2015).  Further supporting that EPSCs 
underwent bona fide X-chromosome inactivation, I detected evidence for dosage 
compensation with down-regulation of X-linked genes at the pan-X chromosome level during 
the differentiation of EC5-EPSCs to embryoid bodies (EC5 dEB) and neural stem cells (EC5 
dNSC) (Figure 6.21-2E). 
 
6.4.7 Human EPSCs have a pre-implantation transcriptional signature 
In Chapter 4, the transcriptome of mouse EPSCs was shown to be enriched with an early pre-
implantation blastomere signature. Therefore, the analysis was repeated on the converted 
human EPSCs to determine if these cells also possessed a unique signature. In collaboration 
with Cheuk-Ho J. Tsang, the top stage-specific genes of each pre-implantation stage were 
compiled and a gene set enrichment analysis (GSEA) was performed. Although a crude and 
provisional representation, this analysis demonstrated that in addition to possessing a 


































enrichment for genes that are expressed in the morula and eight-cell stage of development 
(Figure 6.22).  
These findings suggested that human EPSCs were distinct from standard human ESCs and 
had some transcriptional and epigenetic characteristics that are known to be associated with a 
pre-implantation stage of human development. If this were true, then these cells in addition to 
being able to differentiate to somatic lineages as seen previously, should also be able to 
produce bona fide trophoblast. Since mouse EPSCs have expanded potential to placental 
trophoblasts, it was logical to next examine the trophoblast differentiation potential of human 
EPSCs. 
 
6.4.8 Trophoblast induction potential of human EPSCs 
These experiments were conducted in collaboration with Dr Wei Wang, Sanger Institute. In 
the first trimester of human placental trophoblast development, ELF5 is expressed in villous 
cytotrophoblast and the ELF5 locus is demethylated. Furthermore, ELF5, in conjunction with 
CDX2, is thought to represent a trophoblast stem cell population within the placental villous 
cytotrophoblast layer (Hemberger et al., 2010). It is known that human ESCs have an 
intriguing property to differentiate to cells that express many trophoblast genes in the 
presence of BMP4 (Amita et al., 2013; Xu et al., 2002). However, in these trophoblast-like 
cells from human ESCs, ELF5 was not found to be highly expressed and the locus was still 
substantially methylated, which is different from the placental trophoblasts of early 
developmental stages (Bernardo et al., 2011; Hemberger et al., 2010). 
To directly compare H1 ESCs and EPSCs (H1 and EC5) for their trophoblast potential, they 








(Amita et al., 2013; Bernardo et al., 2011). The temporal expression of CDX2 and ELF5 was 
monitored. Expression of CDX2 was quickly up-regulated and peaked at day 4 (Figure 6.23), 
which was confirmed by immuno-staining of CDX2 protein (Figure 6.24). The peaking of 
CDX2 expression was followed by a robust up-regulation of ELF5 in differentiated EPSCs 
(Figure 6.23). In both H1-EPSCs and EC5-EPSCs, the levels of ELF5 were at least 10-fold 
higher than those achieved in differentiated H1-ESCs.  
As was described above, the ELF5 locus is demethylated in human early placental 
trophoblast, but is almost fully methylated in human ESCs, human iPSCs, and in human ESC-
derived trophoblast-like cells (Hemberger et al., 2010). Concordantly, the ELF5 locus was 
confirmed to be heavily methylated in H1-ESCs in our study, however; human EPSCs already 
had lower DNA methylation (Figure 6.25A). Moreover, once EPSCs differentiated toward 
trophoblast lineages, DNA methylation at the ELF5 locus was more drastically decreased as 
compared to cells differentiated from H1-ESCs (Figure 6.25A). Similarly, the ELF5 locus 
was also demethylated in cells differentiated from EC5-EPSCs (Figure 6.25B) under the 
same trophoblast differentiation conditions.  
Besides these two key trophoblast transcription factors CDX2 and ELF5, the expression of 
other trophoblast markers was also monitored using immuno-staining (Figure. 6.26) and 
qRT-PCR (Figure 6.23). Following sequential activation of CDX2 and ELF5, differentiating 
EPSCs later expressed high levels of CYTOKERATIN 7 (CK7) and HLA-G (Figure 6.23, 
6.24, 6.26 and 6.27). FACS analysis demonstrated high expression of FGFR4, INTEGRIN a5 
(ITGA5) and permitted quantitative analysis of CYTOKERATIN 7 expression (Figure 6.27). 
The expression of chorionic gonadotropin (CGα and CGβ) and placenta growth factor (PGF) 
was also up-regulated to levels that were substantially higher than that of the differentiated 
H1-ESCs (Figure 6.23). Collectively, these results demonstrate that human EPSCs have 

































6.5 Discussion  
In this chapter, I reported that the same chemical formulation EPSCM permitted the 
conversion of human ESCs and iPSCs to a unique human stem cell state that possessed 
distinct differentiation properties in vitro and combined transcriptional and epigenetic features 
associated with the pre-implantation stage human embryo, similar to what was described in 
the mouse system in Chapter(s) 3, 4 and 5. 
 
6.5.1 EPSCM permits successful conversion of human ESCs and human iPSCs to human 
EPSCs. 
In mouse, successful conversion in EPSCM required embryonic stem cells as the starting 
material as mouse EpiSCs were found not to be ‘convertible’. As human ESCs are thought to 
be more akin to the mouse EpiSC or primed state of self-renewal, how can successful 
conversion of human ESCs be explained assuming the interspecies comparison is valid? (Yu 
and Thomson, 2008). It is known that human ESCs are heterogeneous in terms of marker 
gene expression and differentiation potency with some lines having features close to mouse 
ESCs in particular H1 human ESCs, clones of which we have found to possess preferential 
activation of the distal enhancer of the Oct4 locus (internal communication), a characteristic 
associated with naïve mouse ESCs (Adewumi et al., 2007; Bao et al., 2009; Koyanagi-Aoi et 
al., 2013; Thomson et al., 1998; Yeom et al., 1996). The fact that H1, but not H9 human 
ESCs, which are thought to be more akin to the ‘primed’ or mouse EpiSC state could be 
converted in EPSCM is not unexpected in view of this known line-to-line heterogeneity in 
human ESCs (Cahan and Daley, 2013; Kojima et al., 2014; Koyanagi-Aoi et al., 2013). 
In Chapters 3 and 5, following successful conversion, mouse EPSCs activated a core 
pluripotency transcriptional network that had features in common with the transcriptomic 
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constitution of ground-state mouse ESCs (Marks et al., 2012). Similarly, human EPSCs 
expressed high levels of pluripotency related genes and had low expression of lineage 
specifiers. Interestingly, human EPSCs upregulated multiple genes known to be associated 
with naïve pluripotency in the mouse including KLF4, UTF1 and TFCP2L1. Despite some of 
the shared transcriptional features with ground-state pluripotency, the transcriptome of mouse 
EPSCs was unique and clustered independently of 2i/LIF mouse ESCs. Similarly, the human 
EPSC transcriptome was also found to be unique and clustered independently of conventional 
human ESCs and all published cell types claimed to represent the naïve state of human 
pluripotency (Chan et al., 2013; Gafni et al., 2013; Takashima et al., 2014; Theunissen et al., 
2014; Ware et al., 2014). 
 
Following conversion, human EPSCs adopted cell culture characteristics more akin to the 
mouse ES / EPSC state include shortened cell cycle time, capacity for single cell subcloning, 
ease of gene targeting and robust non-targeted differentiation to all three lineages in embryoid 
body and teratoma assays. Efficient targeted differentiation to functional neuronal and 
pancreatic cell types in vitro was also reported. The ease of cell culture maintenance, 
differentiation and efficiency of gene targeting with generation of lineage specific reporters as 
hereby demonstrated may provide a useful biological resource for future studies on in vitro 
differentiation. 
 
6.5.2 The X-chromosome reactivation status in human EPSCs is unique and may share 
some similarity with a pre-implantation stage of development 
In humans, zygotic gene activation occurs at the four to eight-cell stage which coincides with 
the initiation of XCI, specifically, the first appearance of XIST. Pre the eight-cell stage, XIST 
is not expressed and after this time point, XIST will always be detectable on at least one X 
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chromosome. Single cell RNA FISH revealed that >75% of human EPSCs had no detectable 
XIST expression but had two active X-chromosomes as evidenced by biallelic X-lined gene 
expression on single molecule RNA FISH and pan-X chromosome re-activation on RNA 
sequencing. This epigenetic data may provide indirect evidence to support the notion that 
human EPSCs may possess some features in common with at least the eight-cell stage of 
development. Gene set enrichment analysis again although indirect evidence suggested that a 
pre-implantation signature corresponding to the eight-cell stage of development was enriched 
in human EPSCs. 
 
An important caveat that must be considered when analysing human XCI data in vitro is the 
knowledge that X-chromosome reactivation can be an abnormal finding in cultured cells due 
to erosure of repressive X-chromosomal marks. These abnormal cells can be identified as 
during differentiation there is a failure of dosage compensation and re-inactivation of the 
spuriously reactivated X-chromosome (Mekhoubad et al., 2012; Vallot et al., 2015). 
Therefore, to exclude this possibility in human EPSCs, they were subjected to differentiation 
using non-selective embryoid body induction and targeted neural differentiation protocols, 
respectively. Excitingly, during differentiation, as should be observed in normal development, 
there was reappearance of XIST and silencing of one of the X-chromosomes. 
 
6.5.3 Hypomethyation at the ELF5 locus during trophectoderm induction suggests that 
human EPSCs produce bona fide trophoblast in vitro 
The data reported thus far on human EPSCs suggested a core similarity between mouse and 
human EPSCs. A critical final experiment would be the demonstration of functional expanded 
potential by differentiating human EPSCs to bona fide trophoblast in vitro.   
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Following initiation of trophoblast induction, human EPSCs in contrast to standard human 
ESCs showed rapid and robust upregulation of the TE related genes, CDX2 and ELF5 with a 
greater than 10 fold difference in the expression level of the TE gatekeeper, ELF5 between 
differentiating EPSCs and H1 ESCs (Amita et al., 2013; Bernardo et al., 2011; Hemberger et 
al., 2010). Incredibly, during differentiation of EPSCs, the ELF5 promoter rapidly became 
demethylated and by day 6, two sites within the ELF5 promoter were completely 
demethylated. In stark contrast, ELF5 promoter methylation did not appreciably change in 
differentiating H1 human ESCs. As the human ELF5 locus is demethylated in early human 
placental trophoblasts, this data strongly suggested that EPSCs were differentiating to bona 
fide trophoblast (Hemberger et al., 2010). The lack of demethylation in differentiating human 
ESCs is consistent with published data indicating that BMP mediated human ESC 
differentiation may not produce genuine extra-embryonic trophoblast (Hemberger et al., 2010; 
Roberts et al., 2014). 
Beyond the changes in promoter methylation, differentiating EPSCs later expressed high 
levels of markers known to be expressed in syncytiotrophoblast and extra-villous 
cytotrophoblast suggesting that representative cell types from the full diversity of extra-
embryonic placental subtypes were present in differentiating EPSCs, although further studies 
are necessary to confirm this claim. 
In conclusion, the chemical formulation EPSCM, similar to what was demonstrated in the 
mouse, permits the establishment in vitro of a unique stem cell state that possesses expanded 
differentiation potential to both the embryonic and extra-embryonic lineage. Epigenetic and 
transcriptional profiling indirectly suggests that EPSCs possess some characteristics that are 
thought to be associated with a pre-implantation stage of human development which may 
provide a mechanism for the observed phenotype. However, multiple future experiments are 




7 GENERAL DISCUSSION 
  
7.1 Summary 
This chapter begins by summarizing the thesis on the establishment in culture of mouse and 
human stem cells with expanded fate  potential. I will then evaluate the potential significance 
of my findings in the context of pre-implantation development, stem cell biology and 
totipotency. I will also briefly discuss proposed future experiments and finally, I will make 
the conclusions of my study in this thesis. 
 
7.1.2 Hypothesis driven media formulation, EPSCM, permits the establishment and 
maintenance in vitro of a unique stem cell state 
In Chapter 3, I reported the development of a novel chemically defined medium, EPSCM 
which permitted the establishment and maintenance in vitro of a unique stem cell state that 
demonstrated expanded fate potential to both the embryonic and extra-embryonic lineage in 
chimeric blastocysts.  
 
Preceding studies had described the existence of rare subpopulations of cells within 
conventional ESC culture that possessed totipotent-like features (Abad et al., 2013; Macfarlan 
et al., 2012; Morgani et al., 2013). However, these subpopulations were a transient 
phenomenon and could not be established into stable lines in vitro. Following my chance 
observation that inhibition of Src, a pre-implantation signalling pathway conferred some 
consistent expanded potential to conventional mouse embryonic stem cells, I hypothesised 
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that further modulation of signalling pathways known to be important in pre-implantation 
development may allow ‘capture’ of an expanded potential stem cell state (Li et al., 2011).  
As totipotent-like cells were present in ES cell culture, albeit at low frequency, I chose ESCs 
as the platform to test the novel chemical formulation (Macfarlan et al., 2012; Morgani et al., 
2013). 
 
Excitingly, I reported that stable stem cell lines with expanded potential could be derived 
from mouse ESCs, by reprogramming somatic cells and from individual blastomeres of 
mouse pre-implantation embryos. These cells could be differentiated to mature trophoblast in 
vitro and chimeric blastocyst assays confirmed a high frequency of observed contribution in 
the epiblast and trophectoderm in contrast to ESCs which contributed to the epiblast only. 
Low plating density experiments provided evidence to suggest that the establishment of 
EPSCs in EPSCM cultured mouse ESCs may involve a conversion or reprogramming process 
rather than capture of a pre-existing cell type within the culture. Additional evidence in 
support of this claim came from experiments designed to derive de novo EPSC lines from 
embryos. Here, EPSCM substantially altered the development of pre-implantation embryos. 
The derivation of EPSCs appeared to be a complex reprogramming process involving embryo 
cell proliferation and apoptosis. The transient loss of OCT4 and CDX2 expression in the 
“filled” blastocysts and the re-emergence of OCT4 positive or CDX2 positive cells may 
resemble the normal dynamic expression observed in the four to eight-cell cleavage-stage 
embryo. The mechanisms underlying the embryonic cell reprogramming process in EPSCM 
requires further investigation.  
 
Despite their expanded potential, EPSCs retained the core features associated with 
pluripotency including expression of pluripotency related transcription factors, low expression 
of lineage specifiers and interestingly, preferential activity of the Oct4 distal enhancer 
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suggesting that these cells had features in common with the ground-state of self-renewal 
(Ying et al., 2008). However, the signalling requirements of EPSCs were different from 
2i/LIF ESCs with EPSCs demonstrating sensitivity to JAK inhibition. Consistent with 
reported data on STAT3 null ESCs, JAK-STAT signalling was not required for the 
maintenance of 2i/LIF cultured ESCs (Ying et al., 2008). In contrast, LIF has been shown to 
be involved in extra-embryonic lineage priming and a key component in the promotion of the 
reported totipotent-like HEX1 population in ESC culture (Morgani et al., 2013). Therefore, 
LIF may be responsible for some of the observed expanded potential in EPSCs. 
 
The chemical inhibitors in EPSCM were chosen based on their known role in pre-
implantation development mediating the first lineage specification which came from genetic 
and biochemical studies. Our biochemical data confirmed inhibition of the respective 
pathways in cells cultured in EPSCM. Single chemical addition and removal experiments 
confirmed the necessity of each individual component although; the magnitude of effect was 
greatest for inhibitors of WNT and SFK signalling. Furthermore, EPSCs that were re-cultured 
in conventional ESC media rapidly lost their expanded potential differentiation capacity 
indicating that EPSCM was essential for maintaining the observed phenotype. 
 
If a cell has totipotent-like potential, then, by definition, it has pluripotent potential. Indeed, 
mouse EPSCs readily contributed to the three somatic germ layers in embryoid body assays in 
vitro and formed mature teratomas in vivo. Spectral karyotyping confirmed genetic stability 
and EPSCs were able to contribute to the germline fulfilling the requirements for assigning 
pluripotent potential. 
 
7.1.3 In vivo chimeric contribution confirms the expanded fate potential of EPSCs 
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mCherry expressing EPSCs were injected to morula, eight-cell and blastocyst stage embryos 
and the E14.5 embryo was subsequently assessed for donor cell contribution. As expected, 
2i/LIF ESCs contributed extensively to the embryo proper but donor cell contribution was not 
detected in the extra-embryonic compartment. Incredibly, EPSC contribution was detected in 
the embryo proper, yolk sac and placenta. As the placenta and yolk sac have contribution 
from both the embryonic (extra-embryonic mesoderm) and extra-embryonic lineage, multiple 
assays were performed to confirm the nature of the EPSC contribution in both compartments 
(Rossant and Cross, 2001). Definitive trophoblast or extra-embryonic contribution was 
confirmed by detecting mCherry positive donor cells in the trophoblast giant cell 
compartment and histologically with the identification of donor cells lining the maternal 
vascular sinusoids. Furthermore, gene expression analysis of a random population of donor 
cells from the placenta confirmed a comparable trophoblast lineage gene expression profile to 
a random sample of wild type placental cells (Rossant and Cross, 2001). Yolk sac sectioning 
and high resolution microscopy similarly confirmed the presence of EPSC donor cells in the 
extra-embryonic endoderm, a true extra-embryonic cell type and the extra-embryonic 
mesoderm, the epiblast derivative which will form the allantois. This data provided strong 
evidence to support the claim that EPSCs possessed bona fide totipotent-like potential in vivo.  
 
7.1.4 Single cell chimeras confirmed that EPSCM maintains a homogenous population of 
cells that possess expanded fate potential 
It was possible that the observed contribution in EPSCM may have been secondary to the 
presence of subpopulations within the culture that possessed unipotent potential such as a 
trophoblast stem cell-like cell, an ES cell and XEN cell which could in theory give rise to all 
three lineages in contribution assays. This was considered unlikely but in order to refute such 
claims, a single EPSC was injected into eight-cell embryos for chimera production. 
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Remarkably, a single EPSC could contribute extensively to both the embryonic and extra-
embryonic compartments as previously described. Furthermore, when contribution was 
observed, it was always present in both compartments confirming that EPSCM maintains a 
homogenous population of totipotent-like cells in culture, the first ever demonstration of this 
possibility. 
 
7.1.5 EPSCs have a unique transcriptome and possess a gene expression signature with 
some features of eight-cell stage pre-implantation blastomeres 
Independent of their derivation origins, EPSCs were demonstrated to be functionally similar. 
Not surprisingly, EPSCs were also found to be molecularly similar with their transcriptomes 
clustering together regardless of their derivation origin. Consistent with the experimental 
results, EPSCs shared a pluripotency foundation with mouse ESCs and possessed many 
transcriptional features known to be associated with ground-state pluripotency including 
homogenous expression of key pluripotency related factors and low expression of lineage 
specifiers (Marks et al., 2012). Interestingly, in contrast to ground-state ESCs which were 
enriched in gene ontology terms related to metabolism, EPSCs were enriched in terms related 
to placental development (Marks et al., 2012). Single cell RNA sequencing demonstrated 
molecular homogeneity supporting the functional homogeneity observed in the single cell 
chimera experiments. Intriguingly, EPSCs were enriched with the molecular signatures of 
cleavage-stage embryos, particularly the four to eight-cell embryo which may provide a 
molecular basis for their expanded potential. Importantly, the EPSC transcriptome was found 
to cluster independently of the recently reported 2C-like cells, Hex1 positive ESCs and in vivo 
reprogrammed iPSCs all of which were shown to have some degree of expanded potential in 
vivo, further supporting the claim that EPSCs represent a unique cell state (Abad et al., 2013; 




7.1.6 A dynamic methylome and bivalent domains in EPSCs may be further support for a 
pre-implantation signature 
Epiblast and  ground-state mouse ESCs which are the derived from the former represent a 
‘tabula-rasa’ or ‘blank-slate’, a site of global DNA hypomethylation prior to the initiation of 
somatic lineage commitment  (Leitch et al., 2013). This effect is mediated through elevated 
levels of Prdm14 which in turn down-regulates the de novo methyltransferases Dnmt3a/3b 
(Leitch et al., 2013). This ground-state possesses minimal repressive histone marks such as 
H3K27me3 and very few bivalent domains (Marks et al., 2012).  Bivalent domains refer to 
the co-localisation of repressive (H3K27me3) and activator (H3K4me3) histone marks at a 
promoter. This occurrence, which is prevalent in serum cultured ESCs, is thought to represent 
a site with poised transcription prior to the onset of somatic differentiation (Marks et al., 
2012).  In support of this reported data, I presented the same findings from serum and 2i 
cultured mouse ESCs in this thesis. 
 
 In contrast, EPSCs possess a unique epigenetic signature. Firstly, multiple bivalent domains 
were detected at the promoters of key developmental loci including at those of the extra-
embryonic lineage. As EPSCs have minimal expression of lineage specifiers, similar to 2i 
cultured ESCs and a homogenous expression of pluripotency genes, this bivalency is unlikely 
to represent so called ‘promiscuous transcription’ (Marks et al., 2012).   Serum cultured ESCs 
are poised to differentiate to the somatic lineage in response to appropriate environmental 
cues which is thought to be reflective of the bivalent domains it possesses which allows rapid 
activation or repression of a specific lineage determinant. It is reasonable; therefore, to 
speculate that if mouse EPSCs have some features of an eight-cell stage of development at the 
cusp of the first fate decision, the presence of bivalent domains at key trophoblast and ICM 
determinant loci would allow the cell to react quickly to developmental cues, a necessity in 




A second unique feature of mouse EPSCs is that enzymes for DNA methylation and active 
DNA demethylation are both active. This is corroborated by elevated levels of 5-
methylcytosine (mC) and 5 hydroxy-methylcytosine (5hmC) in EPSCs. Our knowledge of 
pre-implantation development describes a process of rapid and progressive DNA 
demethylation leading to the blank state that constitutes the epiblast (Guo et al., 2014; Leitch 
et al., 2013; Reik et al., 2001). The global expression of Tet1 and Tet2 mRNAs and 5hmC 
abundance is less in the trophectoderm than in the ICM (Ito et al., 2010; Senner et al., 2012).  
Furthermore 5hmC levels may have a functional role in dictating the first cell fate 
specification as loss of Tet1 expression and 5 hmC in one of the blastomeres in the two-cell 
stage embryo biases that blastomere to a TE fate (Ito et al., 2010). The co-existence of DNA 
methylation and demethylation activity in EPSCs may explain the plenipotent potential of 
EPSCs. Speculatively, based on the loss of function experiments on Tet1 in the two-cell 
embryo, an imbalance in 5mC or 5hmC in EPSCs would produce TE or ICM, respectively. 
Although further analyses are needed to confirm, such as interrogating the spatiotemporal 
methylation / demethylation pattern of individual blastomeres, the dynamic methylome in 
EPSCs may be additional evidence to support the claim that, these cells possess a pre-
implantation signature corresponding to the eight-cell stage blastomere. 
 
7.1.7 EPSCM permits the establishment and maintenance of a novel stem cell state in 
human which has biological, transcriptional and functional similarity with mouse 
EPSCs 
Experiments on human pre-implantation development are limited due to a scarcity of 
available material to study; however, transcriptional data suggests that many of the signalling 
pathways involved in the first lineage specification are shared between mouse and human 
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(Adjaye et al., 2005; Senner and Hemberger, 2010). Therefore, if these pathways are 
conserved, I speculated that it may be possible to establish a human stem cell state that has 
similarities with mouse EPSCs. Similar to mouse, we chose human ESCs as the platform for 
initial testing. Excitingly, human ESCs were capable of being converted and maintained in 
EPSCM although; there was variable success with marked line to line variation. Tentatively, 
lines that possessed properties more akin to mouse ESCs such as activity of the distal 
enhancer of OCT4, as was identified in H1 ESCs were successfully converted in comparison 
to more primed lines such as H9 ESCs which could not be converted. This is entirely 
speculative based on the mouse conversion experiments and further validation is required in 
human. I also successfully converted human iPSC lines and generated de novo iPSC lines in 
EPSCM.  
 
Following conversion, similar to mouse, human EPSCs possessed a core pluripotency 
network with high expression of pluripotency related genes and minimal expression of lineage 
specifiers. Preferential expression of genes such as KLF4, UTF1 and TFCP2L1 raised the 
possibility that the cells were adopting some transcriptional features known to be associated 
with the mouse ground-state. Beyond signalling, the cells behaved more closely to mouse 
ESCs than human ESCs with a shortened cell cycle, single cell subcloning and demonstrated 
efficient gene targeting with generation of single and dual reporter lines including OCT4, 
NANOG and dual OCT4 / SOX2 reporter lines which may be a useful biological resource for 
future studies on pluripotency and / or differentiation.  
 
Human EPSCs retained the core functional characteristics of a pluripotent cell being easily 
differentiated to three germ layers in vitro and produced mature teratomas in vivo. 
Furthermore, the cells could be selectively differentiated to functional pancreatic and 




Transcriptionally, as in mouse, EPSCM cultured human cells clustered together regardless of 
their derivation origin and possessed a unique transcriptome independent of conventional 
FGF cultured human ESCs and all published human naïve cells (Chan et al., 2013; Gafni et 
al., 2013; Takashima et al., 2014; Theunissen et al., 2014; Ware et al., 2014). Assessment of 
totipotent-like properties is difficult in human due to ethical constraints. Therefore, I sought to 
evaluate for the presence of a pre-implantation signature using surrogate assays, specifically, 
gene set enrichment analysis and epigenetic profiling of the status of X chromosome 
inactivation in human EPSCs. Intriguingly, although a crude assay, gene set enrichment 
analysis suggested that EPSCs possessed a signature that had similarity with the eight-cell 
stage of development.  
 
In pre-implantation development, zygotic gene activation coincides with the initiation of XCI. 
In humans, this corresponds to the eight-cell stage of development when XIST first becomes 
detectable (Okamoto et al., 2011; Telford et al., 1990; Van den Berg et al., 2009). Therefore, 
if human EPSCs were in fact representative of the eight-cell stage or pre-XCI phase of 
development, two active X-chromosomes and no XIST should be detectable (Van den Berg et 
al., 2009). Incredibly, > 75% of human EPSCs possessed this pattern which was further 
confirmed by the detection of biallelic gene expression and pan X-chromosome reactivation 
on RNA sequencing. However, it is known that spurious X-chromosome reactivation can 
occur in cultured cells, which is thought to be partly explained by the erosure of XIST which 
is not reversible during differentiation (Mekhoubad et al., 2012; Vallot et al., 2015). 
Amazingly, following differentiation of early passage human EPSCs, XIST reappeared, X-
linked gene expression became mono-allelic and pan X-chromosome dosage compensation 
was detected confirming that epigenetic status of the X-chromosome in EPSCs was not an 
artefact of the culture condition. This is the first demonstration that a stably cultured line can 
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maintain X-chromosome activation and retain the capacity to undergo normal dosage 
compensation during differentiation. Such a cell type may be a useful resource for 
investigating the process of random and imprinted XCI in humans and for modelling X-linked 
disease which has been hampered up until now by the lack of a cell line with the epigenetic 
characteristics described herein (Mekhoubad et al., 2012). 
 
Finally, as a proof of concept of expanded potential, trophoblast differentiation was 
performed. Human ESCs are often claimed to have a capacity to form trophoblast in vitro 
following treatment with BMP4 (Amita et al., 2013; Xu et al., 2002). Multiple debates 
suggest that this process may not reflect bona fide trophoblast induction but, is likely more 
indicative of extra-embryonic mesoderm differentiation, the somatic contribution to the 
placenta (Roberts et al., 2014).  Evidence for this statement comes from experiments which 
demonstrate failure to reactivate the endogenous ELF5 locus during BMP4-mediated 
differentiation. ELF5 is a key transcription factor in the trophoblast self-renewal network and 
is highly expressed in first trimester villous trophoblast (Hemberger et al., 2010). Remarkably 
following trophoblast induction, as compared to human ESCs, human EPSCs showed rapid 
and marked up-regulation of key trophoblast lineage determinants including ELF5 and 
critically, differentiated EPSCs rapidly became de-methylated at the ELF5 locus suggesting 
that EPSCs were differentiating to bona fide extra-embryonic trophoblast, the first ever 




This study demonstrates for the first time that substantially homogenous, genetically stable 
stem cell lines with expanded fate potential to both the embryonic and extra-embryonic 
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lineage can be derived from individual blastomeres of mouse pre-implantation embryos and 
from reprogramming mouse ESCs or somatic cells in a novel chemically defined media called 
EPSCM. EPSCM and EPSCs may provide a useful resource to study the first lineage 
specification in vitro.  
 
The establishment of EPSCs lends support to my original hypothesis that stem cell states with 
blastomere-like potential may be isolated in vitro through the selective modulation of 
pathways known to be involved in pre-implantation development. Therefore, modulation of 
additional pre-implantation signalling pathways may permit establishment of cell states that 
possess some features of the two-cell or zygote stage embryo and ultimately, the acquisition 




I have also demonstrated for the first time, that a stem cell state with features associated with 
pre-implantation blastomeres can be maintained in human using the same chemical 
formulation, EPSCM. Human EPSCs which are similar to mouse EPSCs may provide a useful 
biological resource due to their distinct biological properties including robust culture, genetic 
stability and ease of genetic modification which should accelerate disease modelling and 
ultimately cell based therapy. Moreover, the X-reactivation in early passage human EPSCs 
may facilitate studies on the mechanisms involved in the initiation and maintenance of 
random and imprinted human XCI. Finally and perhaps the most significant finding, is that 
human EPSCs can be differentiated to apparent bona fide trophoblast, the first ever 




7.2.3 Clinical relevance 
The placenta is a critical organ at the maternal-fetal interface that supports the fetus 
throughout pregnancy being involved in gas and nutrient exchange, excretion, hormone 
secretion and immunotolerance. In humans, miscarriage, intra-uterine growth restriction and 
pre-eclampsia to name but a few, are disorders of placentation. The mechanisms involved in 
pre-eclampsia for instance have remained unknown due to the inability to model human 
trophoblast development in vitro. Although additional studies are required, the present data 
suggests that human EPSCs can be differentiated to bona fide trophoblast in vitro as 
evidenced by ELF5 promoter demethylation, a key epigenetic regulator of lineage restriction 
and a tropohoblast specific determinant. Therefore, human EPSCs may permit insights to be 
obtained into disorders of human placentation which may hasten the path to its future 
prevention.  
 
7.3 Future Experiments 
With any scientific study, the obtained results are not absolute and as was described 
throughout my thesis, many areas require additional investigation to confirm or refute the 
made observation. Beyond these experiments, the major areas that will be interrogated in 
immediate future experiments focus on firstly, trying to prove that EPSCs represent a 
conserved state across multiple species by attempting to derive EPSCs from species such as 
pig, dog and monkey. Gain and loss of function studies will be performed in an attempt to 
provide mechanistic insight into which component(s) and / or signalling pathway(s) in 
EPSCM are causal for the expanded fate potential phenotype. It is possible that an optimised 
medium which contains fewer inhibitors or compounds that modulate alternative pathways 
known to be active in pre-implantation development may similarly allow maintenance of an 
expanded potential stem cell state. In addition, continuing with the original hypothesis of this 
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thesis, additional chemicals will be tested in an attempt to capture an even earlier stage of 
development in vitro.  
 
At present, a major effort is being placed on optimizing the process of mouse and human 
trophoblast induction from EPSCs, characterization of differentiated trophoblast cell types 
and attempting to isolate a self-renewing trophoblast stem cell population,  
 
An interesting platform which I am planning to use to further evaluate the developmental 
capacity of mouse EPSCs is somatic cell nuclear transfer (SCNT). The nucleus of a 
differentiated cell type once transferred into an enucleated oocyte will be successfully 
reprogrammed to a totipotent state which has the capacity to form an entire developing 
organism de novo (Gurdon, 1962). ‘Dolly’ the sheep was the first example of successful 
mammalian cloning (Wilmut et al., 1997).  
However, although at first glance, an apparent panacea, SCNT is an inefficient process with 
very few of the cloned embryos being able to develop into the adult organism (Blelloch et al., 
2006). This inefficiency is influenced by the differentiation and methylation status of the 
donor nucleus (Blelloch et al., 2006). Embryonic stem cells are the most efficient choice of 
donor nucleus for successful SCNT with a progressive reduction in efficiency as somatic 
differentiation progresses (Blelloch et al., 2006; Wakayama et al., 1999). Therefore, if EPSCs 
have features in common with a pre-implantation stage of development and represent an 
earlier temporal location in the developmental timeline, they should be an even more efficient 
donor nucleus for SCNT than conventional embryonic stem cells.  
In mouse, in addition to conversion of conventional ESCs, de novo EPSCs were derived by 
culturing pre-implantation embryos and single blastomeres in EPSCM. The human EPSCs 
presented in this thesis were generated through conversion of conventional human ESCs and 
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human iPSCs only. Therefore, the next set of experiments will focus on attempting to derive a 
human EPSC line directly from the pre-implantation human embryo. 
 
Mouse EPSCs possess a unique epigenetic signature with multiple bivalent domains detected 
at the promoters of key developmental loci including at those of the extra-embryonic lineage. 
Secondly, the enzymes for DNA methylation and active DNA demethylation are both active. 
Single cell epigenomics including DNA methylation and Chip seq analysis at each stage of 
mouse pre-implantation development are planned which will allow interrogation of the 
spatiotemporal epigenetic signature of individual blastomeres. This data will allow EPSCs to 
be chronologically positioned in the pre-implantation timeline. The gene set enrichment 
analysis and functional data presented in this thesis suggests that EPSCs have features in 
common with the eight-cell stage blastomere.  
 
The mechanism involved in the derivation of EPSCs from the pre-implantation embryo is at 
present unknown. As discussed in Chapter 3, the derivation process appears to be a complex 
reprogramming process that involves embryo cell proliferation and apoptosis. Speculatively, I 
argued that the transient loss of OCT4 and CDX2 expression in the “filled” blastocysts and 
the re-emergence of OCT4 positive or CDX2 positive cells may resemble the normal dynamic 
expression observed in the four to eight-cell embryo. In an attempt to reconcile my 
observations, in vivo single cell tracking and live embryo imaging experiments are being 
designed so as to observe the derivation process in EPSCM in real time. 
 
X-chromosome reactivation status, in vitro trophoblast induction and gene set enrichment 
analysis were the surrogate assays used in this thesis to assess for expanded differentiation 
potential in human EPSCs. In human, in vitro assays are traditionally used as in vivo 
assessment of such potential is not ethically permissible. However, with the recent 
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demonstration that the early stages of post-implantation human development can be 
successfully modelled in vitro it is conceivable, pending ethical approval, that the 
differentiation capacity of human EPSCs may be testable in a chimeric assay using this model 
system (Deglincerti et al., 2016; Shahbazi et al., 2016). 
 
7.4 Conclusion 
This thesis has shown for the first time that through chemical modulation of pathways 
implicated to be involved in pre-implantation development, a novel homogenous stem cell 
state that possesses a pre-implantation transcriptional signature and functional expanded fate 
potential to both the embryonic and extra-embryonic lineage can be established and 
maintained in vitro in both the mouse and human, suggesting a possible interspecies 
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